

# CURRICULUM VITAE

Date Prepared: 13 January 2023

1. Name: **ERIC ANDREW FINKELSTEIN, PH.D, M.H.A.**
2. **Summary of career highlights:** Dr. Finkelstein is Professor of Health Services and Systems Research at the Duke-NUS Medical School, Singapore and the Executive Director of the Lien Centre for Palliative Care. He also holds appointments at NUS School of Public Health and Duke University Global Health Institute. His research focuses on the economic causes and consequences of health behaviors, with a primary emphasis on the use of traditional and behavioral economic incentives to influence behaviors in ways to improve the public's health. Recent research also focuses on studies to better understand the complicated decisions that revolve around end of life care. He has published over 300 manuscripts and 2 books in these areas, and also successfully commercialized an Obesity Cost Calculator for employers and insurers. Based on google scholar, he has an h-index of 71, i10-index of 216 and his publications have been cited over 100,000 times, including in the landmark Supreme Court decision upholding the U.S. Affordable Care Act (aka Obamacare). He was included in the list of the World's Most Highly Cited Researchers in 2015, 2016 and 2017 by Thomson Reuters and Clarivate Analytics and among the Top 2% of scientists worldwide in a study by Stanford University in 2021.
3. Institution of primary appointment: **Duke-NUS Medical School**
4. Secondary appointment(s), if any (include clinical faculty appointment with NUS if applicable):
  - Duke University, Global Health Institute;
  - National University of Singapore, Saw Swee Hock School of Public Health.
5. Present rank(s) and title(s):
  - Executive Director, Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore;
  - Professor in Signature Research Programme in Health Services and Systems Research, Duke-NUS Medical School, Singapore;
  - Director of Research, NUS Institute for Health in Asia (NIHA);
  - Professor, Saw Swee Hock School of Public Health, National University of Singapore;
  - Research Professor, Global Health Institute, Duke University;
  - Deputy Head of Research, SingHealth Duke-NUS Supportive and Palliative Care Centre
6. Medical Licensure: **NA**
7. Specialty certification(s) and dates: **NA**
8. Education

<u>Major</u>	<u>Institution</u>	<u>Date (Year)</u>	<u>Degree</u>
Math/Economics	U. of Michigan, Ann Arbor, MI	1991	B.A.
Economics	U. of Washington, Seattle, WA	1996	M.A.
Economics	U. of Washington, Seattle, WA	1998	Ph.D.
Health Admin.	U. of Washington, Seattle, WA	1999	M.H.A.

9. Professional Society Memberships:
  - International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Singapore
  - The Obesity Society, USA
  - Society for Medical Decision Making (SMDM)

10. Professional training and academic career:

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
University of Washington, Seattle	Lead Teaching Assistant (TA), Micro & Macroeconomics	1995 - 1996
University of Washington, Seattle	Lead Teaching Assistant (TA)	1996 - 1998

University of Washington, Seattle	Instructor, Advanced Microeconomics	1998
RTI International	Senior Health Economist	1999 - 2006
RTI International	Director, Public Health Economics Program	2006 - 2007
Duke University	Visiting Instructor, Health Economics	2000 - 2007
University of North Carolina, Center for Health Promotion and Disease Prevention	Research Fellow	2008 - 2012
Duke-NUS Medical School	Deputy Director	2009 - 2012
Duke-NUS Medical School	Associate Professor	2009 - 2013
Duke University, Global Health Institute	Associate Professor of Research	2009 - 2013
National University of Singapore Saw Swee Hock School of Public Health	Associate Professor	2012 - 2013
National University of Singapore Initiative to Improve Health in Asia (NIHA)	Director of Research	2012 - Date
Lien Centre for Palliative Care	Executive Director	2012 - Date
Duke-NUS Medical School	Professor	2013 - Date
National University of Singapore Saw Swee Hock School of Public Health	Professor	2013 - Date
Duke University, Global Health Institute	Professor of Research	2013 - Date
World Bank Group	Consultant	2018 - Date
SingHealth Duke-NUS Supportive and Palliative Care Centre	Deputy Head of Research	2020 - Date

**Publications in Peer Reviewed Journals (google scholar: citations 100,000+; h-index 71; i10-index 216):**

1. Kinra S., Mallinson P., ..., **Finkelstein, E.A.**, Deo S, (2023), Impact of a financial incentive scheme on purchase of fruits and vegetables from unorganised retailers in rural India: a cluster-randomised controlled trial, *Lancet Regional Health S.E.A.*, February 01, 2023.
2. Lam, B. C. C., Lim, A., Ling, C.S., Yum, M., Koh, N., **Finkelstein, E.A.** (2023), The Impact of Obesity: A Narrative Review, *Singapore Medical Journal (forthcoming)*.
3. Chodavia, P., Teo, I., Poremski, D., Fung, D.S.S., **Finkelstein, E.A.**, (2023), Prevalence and Economic Burden of Depression and Anxiety Symptoms Among Singaporean Adults: Results from a 2022 Web Panel, *BMC Psychiatry*, 2023 Feb 14;23(1):104.
4. Teo, I., Ng, S., Bundoc, P., Malhotra, C., Ozdemir, S., Steel, Jennifer., **Finkelstein, E.A.**, (2023) COMPASS Group, A Prospective Study of Psychological Distress Among Patients with Advanced Cancer and Their Family Caregivers, *Cancer Medicine (forthcoming)*.
5. Shin, S., Puri, J., **Finkelstein, E.A.**, (2023), A Randomized Trial to Evaluate the Impact of Singapore's Forthcoming Nutri-Grade Front-of-Pack Beverage Label on Food and Beverage Purchases, *International Journal of Behavioral Nutrition and Physical Activity (forthcoming)*.
6. Sung, S. C., Lim, L., Lim, S. H., **Finkelstein, E. A.**, Chin, S. L. H., Annathurai, A., Chakraborty, B., Strauman, T. J., Pollack, M. H., & Ong, M. E. H. (2022). Protocol for a multi-site randomized controlled trial of a stepped-care intervention for emergency department patients with panic-related anxiety. *BMC Psychiatry*, 22(1), 795.
7. Yeung, K. F., Lee, Y. Q., Chong, M. F. F., Gandhi, M., Lam, A. Y. R., Julianty, S., Tan, G. C. S., Ho, E. T. L., Goh, S. Y., Tan, G. S. W., Shum, E. J. W., **Finkelstein, E. A.**, Jafar, T. H., van Dam, R. M., Teoh, Y. L., Thumboo, J., & Bee, Y. M. (2022). Baseline characteristics of participants in the Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program. *BMJ OPEN Diabetes Research & Care*, 10(5), e002966.
8. Ang, F., **Finkelstein, E. A.**, & Gandhi, M. (2022). Parent-Reported Experience Measures of Care for Children With Serious Illnesses: A Scoping Review. *Pediatric Critical Care Medicine*, 23(9), e416–e423.
9. Ozdemir, S., Chaudhry, I., Ng, S., Teo, I., Malhotra, C., **Finkelstein, E. A.**, & COMPASS Study Group (2022). Prognostic awareness and its association with health outcomes in the last year of life. *Cancer Medicine*, 10.1002/cam4.5286. Advance online publication.
10. Ozdemir, S., Chaudhry, I., Tan, S. N. G., Teo, I., Malhotra, C., Malhotra, R., & **Finkelstein, E. A.** (2022). Variation in Patient-Reported Decision-Making Roles in the Last Year of Life among Patients with Metastatic Cancer: A Longitudinal Study. *Medical Decision Making*, 272989X221131305. Advance

online publication.

11. Sim, W. S., Yeo, S. H., Choi, C., Yeo, T. W., Lee, J. J., Huynh, V. A., **Finkelstein, E. A.**, & Ozdemir, S. (2022). Preferences for a non-invasive prenatal test as first-line screening for Down Syndrome: A discrete choice experiment. *Prenatal Diagnosis*, 42(11), 1368–1376.
12. Junxing, C., Huynh, V. A., Lamoureux, E., Tham, K. W., & **Finkelstein, E. A.** (2022). Economic burden of excess weight among older adults in Singapore: a cross-sectional study. *BMJ Open*, 12(9), e064357.
13. Ozdemir, S., Ng, S., Chaudhry, I., Teo, I., Malhotra, C., **Finkelstein, E. A.**, & COMPASS Study Group (2023). Caregiver-Reported Roles in Treatment Decision Making in Advanced Cancer and Associated Caregiving Burden and Psychological Distress: A Longitudinal Study. *Medical Decision Making: an international journal of the Society for Medical Decision Making*, 43(2), 191–202.
14. Tan Soo, J.S., **Finkelstein, E.A.**, Pattanayak, S.K., Qin, P., Zhang, X.B., Jeuland, M. (2022) Air quality valuation using online surveys in three Asian megacities. *Resources, Environment and Sustainability*, 2022 Dec 1;10:100090
15. Ozdemir, S., **Finkelstein, E.A.**, Lee, J. J., Too, I. H. K., Teo, K. Y. C., Tan, A. C. S., Wong, T. Y., & Cheung, G. C. M. (2022). Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. *PLoS one*, 17(8), e0272301.
16. Jafar, T. H., Tan, N. C., Shirore, R. M., Allen, J. C., **Finkelstein, E. A.**, Hwang, S. W., Koong, A. Y. L., Moey, P. K. S., Kang, G. C., Goh, C. W. T., Subramanian, R. C., Thiagarajah, A. G., Ramakrishnan, C., Lim, C. W., Liu, J., & for SingHypertension Study Group (2022). Integration of a multicomponent intervention for hypertension into primary healthcare services in Singapore-A cluster randomized controlled trial. *PLoS medicine*, 19(6), e1004026.
17. Ozdemir, S., Lee, J. J., Yang, G. M., Malhotra, C., Teo, I., Pham, N. T., Manalo, M. F., Hapuarachchi, T., Mariam, L., Rahman, R., & **Finkelstein, E.A.** (2022). Awareness and Utilization of Palliative Care Among Advanced Cancer Patients in Asia. *Journal of Pain and Symptom Management*, 64(4), e195–e201.
18. Balasubramanian, I., **Finkelstein, E.A.**, Malhotra, R., Ozdemir, S., Malhotra, C., & COMPASS Study Team (2022). Healthcare Cost Trajectories in the Last 2 Years of Life Among Patients With a Solid Metastatic Cancer: A Prospective Cohort Study. *Journal of the National Comprehensive Cancer Network : JNCCN*, 20(9), 997–1004.e3.
19. Ozdemir, S., Yeo, S.W.J., Lee, J.J., Bhaskar, A., **Finkelstein, E.A.**, Tong, L. (2022) Patient Medication Preferences for Managing Dry Eye Disease: The Importance of Medication Side Effects. *The Patient – Patient-Centered Outcomes Research*, 2022 Jun 14;1-12.
20. Malhotra, C., Bundoc, F., Chaudhry, I., Teo, I., Ozdemir, S., **Finkelstein, E.A.** (2022) A prospective cohort study assessing aggressive interventions at the end-of-life among patients with solid metastatic cancer. *BMC Palliative Care*, 2022 May 16;21(1):73.
21. Ozdemir, S., Chen, T., Tan, C.W., Wong, W.H.W., Tan, H.S., **Finkelstein, E.A.**, Sng, B.L. (2022) Parturients' stated preferences for labor analgesia: a discrete choice experiment. *Patient Preference and Adherence*, 2022 Apr 8;16:983-994 .
22. Malkin, J.D., Baid, D., Reem, A., Alghaith, T., Alluhidan M., Alabdulkarim, H., Altowaijri, A., Almalki, Z.S., Herbst, C.H., **Finkelstein, E.A.**, El-Saharty, S., Alazemi, N. (2022) The Economic Burden of Overweight and Obesity in Saudi Arabia. *PLoS One*, 2022 Mar 8;17(3):e0264993.
23. Sallnow, L., Smith, R., Ahmedzai, S.H., **Finkelstein, E.A.**, ..., Wyatt, K. (2022) Report of the Lancet Commission on the Value of Death: Bringing Death Back Into Life. *The Lancet*, 2022 Feb 26; 399(10327):837-884.
24. Krukowski R.A., Harvey J., Naud S., **Finkelstein E.A.**, West D.S. (2022) Perspectives on the Form, Magnitude, Certainty, and Target of Financial Incentives in a Weight Loss Program. *American Journal of Health Promotion*, 2022 Jul;36(6):996-1004 .
25. Teo, I., Bhaskar, A., Ozdemir, S., Malhotra, C., Hapuarachchi, T., Joad, A. K., Manalo, M. F., Mariam, L., Ning, X., Palat, G., Rahman, R., Tuong, P. N., **Finkelstein, E. A.**, & APPROACH study group (2022). Perceived stigma and its correlates among Asian patients with advanced cancer: A multi-country APPROACH study. *Psycho-oncology*, 31(6), 938–949.
26. **Finkelstein, E.A.**, Albert S Khouri (2022). Letter to the Editor: Cost Analysis of Surgical Intraocular Pressure Management in Glaucoma, *Journal of Glaucoma*, 2022 Mar 1;31(3):e10-e11.
27. Shin, S., Chakraborty. B., Yan. X., Van Dam, R.M., **Finkelstein E.A.** (2022) Evaluations of Combinations of Nudging, Pricing, and Labelling Strategies to Improve Diet Quality: A Virtual Grocery Store

- Experiment Employing a Multiphase Optimization Strategy. *Annals of Behavioral Medicine*, 2022 Feb 23;kaab115.
28. West, D.S., Krukowski, R.A., Monroe, C.M., Stansbury, M.L., Carpenter, C.A., **Finkelstein, E.A.**, Naud, S., Ogden, D., Harvey, J.R. (2022). Randomized Controlled Trial of Financial Incentives During Weight Loss Induction and Maintenance in Online Group Weight Control. *Obesity (Silver Spring)*, 2022 Jan;30(1):106-116.
  29. **Finkelstein, E.A.**, Cheung, Y.B., Schweitzer, M.E., Lee, L.H., Kanesvaran, R., Baid, D. (2022). Accuracy Incentives and Framing Effects to Minimize the Influence of Cognitive Bias Among Advanced Cancer Patients. *Journal of Health Psychology*, 2022 Aug;27(9):2227-2235.
  30. **Finkelstein, E. A.**, Bhadelia, A., Goh, C., Baid, D., Singh, R., Bhatnagar, S., & Connor, S. R. (2022). Cross Country Comparison of Expert Assessments of the Quality of Death and Dying 2021. *Journal of Pain and Symptom Management*, 63(4), e419–e429. <https://doi.org/10.1016/j.jpainsymman.2021.12.015>
  31. Sepulveda, J., Baid, D., Johnson, F. R., & **Finkelstein, E. A.** (2022). What is a Good Death? A Choice Experiment on Care Indicators for Patients at End of Life. *Journal of Pain and Symptom Management*, 63(4), 457–467.
  32. Bhadelia, A., Oldfield, L. E., Cruz, J. L., Singh, R., & **Finkelstein, E. A.** (2022). Identifying Core Domains to Assess the "Quality of Death": A Scoping Review. *Journal of Pain and Symptom Management*, 63(4), e365–e386.
  33. Ozdemir, S., Ng, S., Wen, Y., Chaudhry, I., **Finkelstein, E.A.** (2022). Adoption of Preventive Behaviour Strategies and Public Perceptions about Covid-19 in Singapore. *International Journal of Health Policy and Management*, 2022 May 1;11(5):579-591.
  34. Ozdemir, S., Ng, S., Wong, W. H. M., Teo, I., Malhotra, C., Mathews, J. J., Joad, A. S. K., Hapuarachchi, T., Palat, G., Tuong, P. N., Bhatnagar, S., Ning, X., & **Finkelstein, E. A.** (2022). Advanced Cancer Patients' Prognostic Awareness and Its Association With Anxiety, Depression and Spiritual Well-Being: A Multi-Country Study in Asia. *Clinical oncology (Royal College of Radiologists (Great Britain))*, 34(6), 368–375.
  35. Ozdemir, S., Malhotra, C., Teo, I., Tan, S. N. G., Wong, W. H. M., Joad, A. S. K., Hapuarachchi, T., Palat, G., Tuong, P. N., Bhatnagar, S., Rahman, R., Mariam, L., Ning, X., & **Finkelstein, E. A.** (2021). Patient-Reported Roles in Decision-Making Among Asian Patients With Advanced Cancer: A Multicountry Study. *MDM Policy & Practice*, 6(2), 23814683211061398.
  36. Chay, J.X., Fenner, B.J., **Finkelstein, E.A.**, Teo, K.Y.C., Cheung, C.M.G. (2021) Real-world Cost-Effectiveness of Anti-VEGF Monotherapy and Combination Therapy for the Treatment of Polypoidal Choroidal Vasculopathy. *Eye*, 1-6. doi: 10.1038/s41433-021-01856-9.
  37. Malkin, J.D., **Finkelstein, E.A.**, Baid, D., Alqunaibet, A.M., Almudarra, S., Herbst, C.H., Dong, D., Alsukait, R., El-Saharty, S., Algwaizini, A. (2021) The Impact Of Non Communicable Diseases On Direct Medical Costs And Worker Productivity In Saudi Arabia. *Eastern Mediterranean Health Journal*, 2020;26(4):468–476. <https://doi.org/10.26719/emhj.19.049>.
  38. Hapuarachchi, T., Fernando, G., Weerasingha, S., Ozdemir, S., Teo, I., Vishwanath, P., Priyanthi, A., **Finkelstein, E.A.**, Malhotra, C. (2022). Disparities in end-of-life outcomes among advanced cancer patients in Sri Lanka: Results from the APPROACH study. *Palliative and Supportive Care*, 20(6), 832-838.
  39. Ozdemir, S., Lee, J.J., Malhotra, C., Teo, I., Yeo, K.K., Than, A., Sim, D.K.L., **Finkelstein, E.A.** (2021). Associations between Prognostic Awareness, Acceptance of Illness and Psychological and Spiritual Well-Being among Patients with Heart Failure. *Journal of Cardiac Failure*, 2021 Oct 13;S1071-9164(21)00398-5. doi: 10.1016/j.cardfail.2021.08.026.
  40. Ozdemir, S., Choong, L. H. L., Gan, S. W. S., Lim, L. W., Malhotra, C., Jafar, T. H., Yee, A. C. P., Vishwanath, P., Tan, S. N. G., & **Finkelstein, E. A.** (2021). Patient Decision Aid Development for Older Adults With End-Stage Kidney Disease in Singapore. *Kidney international reports*, 6(11), 2885–2896.
  41. Chew, C.S.E., Davis, C., Lim, J.K.E., Lim, C.M.M., Tan, Y.Z.H., Oh, J.Y. , Rajasegaran, K., Chia, Y.H.M., **Finkelstein, E.A.** (2021). Use of a mobile lifestyle intervention application as an early intervention for adolescents with obesity: a single cohort pilot study. *Journal of Medical Internet Research*, 2021;23(9):e20520. doi: 10.2196/20520.
  42. Satija, A., Bhatnagar, S., Ozdemir, S., **Finkelstein, E.A.**, Maholtra, C., Teo, I., Yang, G.M.J. (2021). Patients' Awareness of Advanced Disease Status, Psychological Distress and Quality of Life among

- Patients with Advanced Cancer – Results from the APPROACH study, India. *American Journal of Hospice and Palliative Medicine*, 2021 Sep 3:10499091211042837.
43. Pham, N.T.; Lee, J.J.; Pham, N.H., Phan, T.D.Q., Tran, K., Dang, H.B., Teo, I., Malhotra, C., **Finkelstein, E.A.**, Ozdemir, S. (2021). The prevalence of perceived stigma and self-blame and their associations with depression, emotional well-being and social well-being among advanced cancer patients: Evidence from the APPROACH cross-sectional study in Vietnam. *BMC Palliative Care*, 2021 Jul 7;20(1):104.
  44. **Finkelstein, E.A.**, Malkin, J.D., Baid, D., ..., Alqahtani, S., El-Saharty, S., Herbst, C.H. (2021). The impact of seven major noncommunicable diseases on direct medical costs, absenteeism, and presenteeism in Gulf Cooperation Council countries. *Journal of Medical Economics*, Jan-Dec 2021;24(1):828-834.
  45. Low, Y.L., **Finkelstein, E.A.** (2021). Cost Effective Analysis of Dual-Energy Computer Tomography for the Diagnosis of Occult Hip Fractures Among the Elderly. *Value in Health*, 2021 Aug 5.
  46. Ozdemir, S., Ng, S., Malhotra, C., Teo, I., **Finkelstein, E.A.**, COMPASS Study Group. (2021). Patient-Caregiver Treatment Preference Discordance and its Association with Caregiving Burden and Esteem. *Innovation in Aging*, 2021 Jun 14;5(3):igab020. doi: 10.1093/geroni/igab020. PMID: 34316519; PMCID: PMC8306724.
  47. Li, W., **Finkelstein, E.A.**, Zhen, C. (2021). Intended and Unintended Consequences of Salient Nutrition Labels. *American Journal of Agricultural Economics*, 27 May 2021.
  48. Fenwick, E.K., ..., **Finkelstein, E.A.**, ..., Lamoureux, E.L., (2021). Association of glaucoma on utility using the glaucoma utility instrument (Glau-U) developed with a discrete choice experiment. *JAMA Ophthalmology*, 2021 Jun 24;e211874.
  49. Bilger, M., Koong, A.Y.L., Phoon, I.K.Y., Tan, N.C., Bahadin, J., Bairavi, J., Batcagan-Abueg, A.P.M., **Finkelstein, E.A.** (2021). A Wireless Home Blood Pressure Monitoring System with Automatic Outcome-based feedback and Financial Incentives to improve Blood Pressure outcomes in people with Hypertension: Protocol for a Randomized Controlled Trial. *Journal of Medical Internet Research Protocols*, 2021 Jun 9;10(6):e27496.
  50. **Finkelstein, E.A.**, Baid, D., Cheung, Y.B., Schweitzer, M.E., Malhotra, C., Volpp, K.G., Kanesvaran, R., Lee, L.H., and SHAPE Study Team. (2021). Hope, Bias and Survival Expectations of Advanced Cancer Patients: A cross-sectional study. *Psycho-Oncology*, 2021 May;30(5):780-788. doi: 10.1002/pon.5675. Epub 2021 Apr 1. PMID: 33739561.
  51. Vedanthan, R., Kamano, J.H., ..., **Finkelstein, E.A.** ... Fuster, V. (2021). Group Medical Visits and Microfinance for Patients with Diabetes or Hypertension in Kenya: BIGPIC Trial. *Journal of the American College of Cardiology*, 2021 Apr 27;77(16):2007-2018.
  52. Baid, D., Hayles, E., **Finkelstein, E.A.** (2021). Return on Investment for Workplace Wellness Programs for Chronic Disease Prevention A Systematic Review. *American Journal of Preventive Medicine*, 2021 May 5:S0749-3797(21)00161-6.
  53. **Finkelstein, E.A.**, Lau, E., Doble, B., Ong, B., Koh M.S. (2021). The Economic Burden of Asthma in Singapore. *BMJ Open Respiratory Research*, 2021;8:e000654.
  54. Doble, B., Wong, M.H.M., **Finkelstein, E.A.** (2021). End-Of-Life Cost Trajectories and the Trade-off between Treatment Costs and Life-Extension: Findings from the Cost and Medical Care of Patients with Advanced Serious Illness (COMPASS) Cohort Study. *Palliative Medicine*, 2021 Mar 17:0269216321999576.
  55. Agrawal, S., Wojtanowski, A.C., Tringali, L., Foster G.D., **Finkelstein, E.A.** (2021). Financial implications of New York City's weight management initiative. *PLOS ONE*, 2021 Feb 11;16(2):e0246621.
  56. Malhotra, C., Malhotra, R., Bundoc, F., Teo, I., Ozdemir, S., Chan, N., **Finkelstein, E.A.** (2021). Trajectories of suffering in the last year of life among patients with a solid metastatic cancer. *Journal of the National Comprehensive Cancer Network*, 2021 Sep 7:1-8. doi: 10.6004/jnccn.2021.7014. Epub ahead of print. PMID: 34492633.
  57. **Finkelstein, E.A.**, Krishnan, A., Naheed, A., Jehan, I., de Silva, A., Gandhi, M., Lim, C.W., Chakma, N., Ediriweera, D.S., Khan, J., Kasturiratne, A., Hirani, S., Solayman, A.K.M., Jafar, T.H., COBRA Study Group (2021). Budget Impact and Cost-Effectiveness of the Multi-Component Hypertension Management Program, COBRA-BPS, in Rural Communities in Bangladesh, Pakistan, and Sri Lanka. *Lancet Global Health*, 2021 March 19, ;9(5):e660-e667.
  58. Ozdemir, S., Tan, S.N.G., Chaudhry, I., Malhotra, C., **Finkelstein, E.A.** (2021). Public Preferences for Government Response Policies on Outbreak Control. *The Patient – Patient-Centred Outcomes*

- Research*, 2021 May;14(3):347-358.
59. Malhotra, C., Bundoc, F., Ang, F.J.L., Ozdemir, S., Teo, I., Sim, D., Jaufeerally, F.R., Aung, T., **Finkelstein, E.A.** (2021). Financial difficulties and patient-reported outcomes among patients with advanced heart failure. *Quality of Life Research*, 2021 May;30(5):1379-1387.
  60. Bilger, M., Shah, M., Tan, N.C., Yan, L.T., Bundoc, F., Bairavi, J., **Finkelstein, E.A.** (2021). Process and outcome-based financial incentives to improve self-management and glycemic control in people with Type 2 diabetes in Singapore: A randomized controlled trial. *The Patient – Patient-Centred Outcomes Research*, 2021 Sep;14(5):555-567. doi: 10.1007/s40271-020-00491-y. Epub 2021 Jan 25. PMID: 33491116; PMCID: PMC8357673.
  61. Ozdemir, S., Tian, Y., Malhotra, C., Harding, R., Koh, G., Kumarakulasinghe, N.B., Lee, L.H., Mon, S.W., **Finkelstein, E.A.**, COMPASS Study Group. (2021). Discordance between advanced cancer patients' perceived and preferred roles in decision making and its association with psychological distress and perceived quality of care. *The Patient – Patient-Centred Outcomes Research*, 2021 Sep;14(5):581-589. doi: 10.1007/s40271-020-00480-1. Epub 2021 Feb 11. PMID: 33569723.
  62. Malhotra, C, Koh, L.E., Teo, I., Ozdemir, S., Chaudhry, I., **Finkelstein, E.A.**, Compass study team. (2020). A prospective cohort study of stability in preferred place of death among patients with Stage IV cancer in Singapore. *Journal of the National Comprehensive Cancer Network*, (2020): e24148-e24148.
  63. Doble, B., Lau, E., Malhotra, C., Ozdemir, S., Teo, I., **Finkelstein, E.A.** on behalf of the APPROACH study group. (2020). The association of self-blame with treatment preferences in a multi-country cohort of advanced cancer patients from the APPROACH study. *Journal of Psychosomatic Research*, 2020 Dec;139:110284. doi: 10.1016/j.jpsychores.2020.110284.
  64. **Finkelstein, E.A.**, Doble, B., Ang, F.J.L., Wong, W.H.M., Van Dam, R.M. (2020). A Randomized Controlled Trial Testing the Effects of A Positive Front-of-Pack Label With or Without a Physical Activity Equivalent Label on Food Purchases. *Appetite*, 2021 Mar 1;158:104997. doi: 10.1016/j.appet.2020.104997. Epub 2020 Oct 13. PMID: 33065191.
  65. Shaffer, K. M., **Finkelstein, E.A.**, Camacho, F., Ingersoll, K., Thorndike, F., Ritterband, L.M. (2020). Effects of an Internet-based cognitive behavioral therapy for insomnia program on work productivity: A secondary analysis. *Annals of Behavioral Medicine*, 2021 Jun 2;55(6):592-599. doi: 10.1093/abm/kaaa085. PMID: 33057694; PMCID: PMC8171799.
  66. Malhotra, C., Chaudhry, I., Ozdemir, S., **Finkelstein, E.A.** (2020). Reduced healthcare utilization among people with chronic medical conditions during COVID-19. *Proceedings of Singapore Healthcare*, 2020 Oct 7. doi: 10.1177.
  67. **Finkelstein, E.A.**, Lim, R., Ward, D., Evenson, K.R., (2020). Leveraging Family Dynamics to Increase the Effectiveness of Incentives for Physical Activity: The FIT-FAM Randomized Controlled Trial. *International Journal of Behavioral Nutrition and Physical Activity*, 2020 Sep 10;17(1):113.
  68. Malhotra, C., Krishnan, A, ..., Ssu, W.M., **Finkelstein, E.A.** (2020). Socio-economic inequalities in suffering at the end of life among advanced cancer patients: Results from the APPROACH study in five Asian countries. *International Journal for Equity in Health*, 2020 Sep 10;19(1):158. doi: 10.1186.
  69. Ozdemir, S., Teo, I., Bundoc, F.C., Malhotra, C., Yeo, K.K., Sim, D.K.L., **Finkelstein, E.A.** (2020). Role in Decision Making among Congestive Heart Failure Patients and its Association with Patient Outcomes: A Baseline Analysis of the SCOPAH study. *Patient Education and Counseling*, 2020 Aug 29:S0738-3991(20)30464-X. doi: 10.1016.
  70. Shin, S., Van Dam, R., **Finkelstein, E.A.** (2020). The Effect of Dynamic Food Labels with Real-time Feedback on Diet Quality: Results from a Randomized Controlled Trial. *Nutrients*, 2020 Jul 20;12(7):2158.
  71. Mon, S.W., Myint, Z., Myint M., Win, H., Zin, T., Yang, G.M.J., Malhotra, C., Teo, I., **Finkelstein, E.A.**, Ozdemir, S. (2020). Awareness of and Preference for Disease Prognosis and Participation in Treatment Decisions among Advanced Cancer Patients in Myanmar: Results from the APPROACH Study. *Asia Pacific Journal of Clinical Oncology*, 2021 Feb;17(1):149-158. doi: 10.1111/ajco.13430. Epub 2020 Sep 13. PMID: 32921003.
  72. Teo, I, Tan, Y.P., **Finkelstein, E.A.**, Yang, G.M.J., Pan, F.T., Tan, E.K.W., Ong, S.Y.K., Cheung, Y.B. (2020). The Feasibility and Acceptability of a Cognitive Behavioral Therapy-based intervention for Patients with Advanced Colorectal Cancer. *Journal of Pain and Symptom Management*, 2020 Jun 20:S0885-3924(20)30530-3.

73. Ning, X., Krishnan, A., Li X, ..., Malhotra C., **Finkelstein E.A.**, Teo I. (2020). Perceived Quality of Care and its Associated Factors among Chinese Patients with Advanced Cancer: Findings from the APPROACH study in Beijing. *Supportive Care in Cancer*, 2021 Mar;29(3):1395-1401. doi: 10.1007/s00520-020-05559-x. Epub 2020 Jul 15. PMID: 32671564.
74. Bilger, M., Özdemir, S., **Finkelstein, E.A.** (2020). Demand for Cancer Screening Services: Results from Randomized Controlled Discrete Choice Experiments. *Value in Health*, 2020; 23(9):1246–1255.
75. **Finkelstein, E.A.**, Ang, F.L., Doble, B. (2020). Randomized trial evaluating the effectiveness of within versus across-category front-of-package lower-calorie labelling on food demand. *BMC Public Health*, 2020 Mar 12;20(1):312.
76. Chin, W.T., Ozdemir, S., Baid, D., Zach, S., Tan, Z., Sia, A., **Finkelstein, E.A.**, Sng, B.L. (2020). Patients' Preferences and Trade-off during Labour Epidural Analgesia: A Discrete Choice Experiment. *Journal of Clinical Anesthesia*, 2020 Nov;66:109919. doi: 10.1016/j.jclinane.2020.109919. Epub 2020 Jun 20. PMID: 32570071.
77. Malhotra, C., Bundoc, F.G., Sim, D., Jaufeerally, F.R., **Finkelstein, E.A.** (2020). Instability in preference for place of death among patients with symptoms of advanced heart failure. *Journal of the American Medical Directors Association*, 2021; 22(2): 349.e29-349.e34.
78. Mon, S.W., Ozdemir, S., Myint Zu, W.W., Win, H., Maw, M.M., Win, K.C., Thant, K.Z., Teo, I., Krishnan, A., Goh, C.R., **Finkelstein, E.A.**, Malhotra, C. (2020). End of life experiences of patients with advanced cancer in Myanmar: results from the APPROACH study. *Asia Pacific Journal of Clinical Oncology*, 2020 Dec;16(6):333-339. doi: 10.1111/ajco.13373. Epub 2020 Jun 23. PMID: 32573100.
79. West, D.S., Krukowski, R.A., **Finkelstein, E.A.**, Stansbury, M.L., Ogden, D.E., Monroe, C.M., Carpenter, C.A., Naud, S., Harvey, J., West, D., (2020). Adding Financial Incentives to Online Group-based Behavioral Weight Control: A Randomized Controlled Trial. *American Journal of Preventive Medicine*, 2020 May 21:S0749-3797(20)30158-6.
80. Malhotra, C., Vishwanath, P., Yong, J.R., Truls, O., Seow, D., Yap, P., Tan, L.L., Tham, W.Y., Vaingankar, J., Foo, J., Tan, B.Y., Tong, K.M., Ng, W.C., Allen, J.C., Malhotra, R., Tan, W.M., Wee, S.L., Ng, L.L., Goveas, R., Mok, V., Sim, A., Ng, W.F., Wong, H.K., Balasundaram, B., Tan, R.Q., Ong, P.S., Cheong, C.Y., Yee, A., Tiong, C., Hum, A., Lee, A., **Finkelstein, E.A.** (2020). A prospective longitudinal study of caregivers of community dwelling persons with severe dementia (PISCES): Study protocol. *Journal of Alzheimer's disease*, 2020;75(2):403-416.
81. Xie, Y., Nguyen, Q. D., Hamzah, H., ..., **Finkelstein, E.A.**, Ting, D.S.W., (2020). Artificial Intelligence for Teleophthalmology-based Diabetic Retinopathy Screening in a National Program: A Modelled Economic Analysis Study. *The Lancet Digital Health*, 2020 May;2(5):e240-e249. doi: 10.1016/S2589-7500(20)30060-1.
82. Sloan, R., Kim, Y., Sawada, S., Asakawa, A., Blair, S., **Finkelstein, E.A.** (2020). Is Less Sedentary Behavior, More Physical Activity, or Higher Fitness Associated with Sleep Quality?: A Cross-Sectional Study in Singapore. *International Journal of Environmental Research and Public Health* 2020 Feb 19, 17(4), 1337.
83. Malhotra, C., Meibo, H., Malhotra, R., Sim, D., Jaufeerally, F.R., Bundoc, F.G., **Finkelstein, E.A.** (2020). Instability in end-of-life care preference among heart failure patients: Secondary analysis of a randomized controlled trial in Singapore. *Journal of General Internal Medicine*, 2020 Feb 26.
84. Doble, B., Ang, F.J.L., **Finkelstein, E.A.** (2020). The Effect of Implicit and Explicit Taxes on the Purchasing of 'High-In-Calorie' Products: A Randomized Controlled Trial. *Economics and Human Biology*, Volume 37, May 2020, 100860.
85. Man, R.E.K., Gan, A. TL., Constantinou, M., Fenwick, E. K., Holloway, E. E., **Finkelstein, E.A.**, Coote, M., Jackson, J., Rees, G., Lamoureux, E. L., (2020). Effectiveness of an Innovative and Comprehensive Eye Care Model for Individuals in Residential Care Facilities: Results of the Residential Ocular Care (ROC) Multi-Centered Randomized Controlled Trial. *British Journal of Ophthalmology*, February 2020.
86. Wei, Y., Pek, P.P., Doble, B., **Finkelstein, E.A.**, Ong, MEH., (2020). Strategies to Improve Survival Outcomes of Out-Of-Hospital Cardiac Arrest (OHCA) Given a Fixed Budget: A Simulation Study. *Resuscitation*, 2020 Feb 3. pii: S0300-9572(20)30050-2.
87. Ong, J.J.Y., Patnaik, D., Chan, Y.C., Simon, O., **Finkelstein, E.A.** (2020). Economic Burden of Migraine in Singapore. *Cephalagia Reports*, February 26, 2020.
88. Doble, B., **Finkelstein, E.A.**, Tian, Y., Saxena, N., Patil, S., Wong, T.Y., Cheung, C.M.G., (2020). Cost-Effectiveness of Intravitreal Ranibizumab with Verteporfin Photodynamic Therapy compared to

- Ranibizumab Monotherapy for Patients with Polypoidal Choroidal Vasculopathy: An EVEREST II Post-Hoc Study. *JAMA Ophthalmology*, 2020 Jan 9, 138(3), 251-259.
89. Jafar, T.H., Gandhi, H., de Silva, H.A., Jehan, I., Naheed, A., **Finkelstein, E.A.**, Turner, E.L., Morisky, A., Kasturiratne, A., Khan, A.H., Clemens, J.D., Ebrahim, S., Assam, P.N., Feng, L., COBRA-BPS Study Group, (2020). A Community-based Intervention for Managing Hypertension in Rural South Asia. *New England Journal of Medicine*, 2020 Feb 20; 382:717-726.
  90. Malhotra, C., Sim, D., Jaufeerally, F.R., Hu, M., Nadkarni, N., Ng, C.S.H., Wong, G., Tan, B.C., Lim, J.F., Chuang, C.Y.T., **Finkelstein, E.A.** (2020). Impact of a formal advance care planning program on end-of-life care for patients with heart failure: Results from a randomized controlled trial. *Journal of Cardiac Failure*, 2020 Jan 25. pii: S1071-9164(19)31494-0.
  91. Teo, I., Vilardaga, J.P., Tan, Y.P., Winger, J., Cheung, Y.B., Yang, G.M.J., **Finkelstein, E.A.**, Shelby, R.A., Kamal, A.H., Kimmick, G., Somers, T.J., (2020). A feasible and acceptable multicultural psychosocial intervention targeting symptom management in the context of advanced breast cancer. *Psychooncology*. 2020 Feb;29(2):389-397.
  92. Malhotra, C., Harding, R., Teo, I., Ozdemir, S., Koh, G.C.H., Neo, P., Lai, H.L., Kanesvaran, R., **Finkelstein, E.A.** (2019). Financial difficulties are associated with greater total pain and suffering among patients with advanced cancer: Results from the COMPASS study. *Supportive Care in Cancer*, 2019 Dec 12.
  93. Teo, I., Baid, D., Ozdemir, S., Malhotra, C., Singh, R., Harding, R., **Finkelstein, E.A.**, COMPASS Study group, (2019). Family caregivers of advanced cancer patients: self-perceived competency and meaning-making. *BMJ Supportive and Palliative Care*, 2019 Dec 5. pii: bmjcare-2019-001979.
  94. Lim, R.S.M., Gardner, D.S.L., Bee, Y.M., Cheung, Y.B., Bairavi, J., Gandhi, M., Goh, S.Y., Ho, E.T.L., Lin, X., Tan, N.C., Tay, T.L., **Finkelstein, E.A.** (2019). TRIal to slow the Progression Of Diabetes (TRIPOD): study protocol for a randomized controlled trial using wireless technology and incentives. *Trials*, 2019 Nov 28; 20(1):650.
  95. **Finkelstein, E.A.**, Ang, F.J.L., Doble, B., Wong, W.H.M., Martinus van Dam, R. (2019). A Randomized Controlled Trial Evaluating the Relative Effectiveness of the Multiple Traffic Light and Nutri-Score Front of Package Nutrition Labels. *Nutrients*, 2019 Sep 17;11(9). pii: E2236.
  96. Jacob, J., Palat, G., Verghese, N.R., Kumari, P., Rapelli, V., Kumari, S., Malhotra, C., Teo, I., **Finkelstein, E.A.**, Ozdemir, S. (2019). Health-related Quality of Life and its Socio-economic and Cultural Predictors among Advanced Cancer Patients: Evidence from a Cross-sectional Survey in India. *BMC Palliative Care*, 2020 Jan 23;19(1):11.
  97. Ang, G.S., Fenwick, E.K., Constantinou, M., Gan, A., Man, R., Casson, R., **Finkelstein, E.A.**, Crowston, J., Lamoureux, E.L. (2019). Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial. *British Journal of Ophthalmology*, pii: bjophthalmol-2018-313396.
  98. Mercer, T., Njuguna, B., Bloomfield, G.S., Dick, J., **Finkelstein, E.A.**, Kamano, J., Mwangi, A., Naanyu, V., Pastakia, S.D., Valente, T.W., Vedanthan, R., Akwanalo, C. (2019). Strengthening Referral Networks for Management of Hypertension Across the Health System (STRENGTHS) in western Kenya: a study protocol of a cluster randomized trial. *Trials*, (2019) 20:554.
  99. Ozdemir, S., Malhotra, C., Teo, I., Yang, G.M., Kanesvaran, R., Yee, A.C.P., **Finkelstein, E.A.** (2019). Palliative Care Awareness among Advances Cancer Patients and Their Family Caregivers in Singapore. *Ann Acad Med Singapore*, 2019; 48:241-6.
  100. Vedanthan, R., Kamano, J., **Finkelstein, E.A.**, Fuster, V. (2019). Community Health Workers to Improve Linkage to Hypertension Care in Western Kenya. *Journal of the American College of Cardiology*, 2019 Aug 8. pii: S0735-1097(19)36191-1.
  101. Han, E., Shiraz, F., Haldane, V., Koh, J.J.K., Quek, R.Y.C., Ozdemir, S., **Finkelstein, E.A.**, Jafar, T.H., Choong, H.L., Gan, S., Lim, L., Legido-Quigley, H. (2019). Biopsychosocial experiences and coping strategies of elderly ESRD patients: A qualitative study to inform the development of more holistic and person-centred health services in Singapore. *BMC Public Health*, 2019 Aug 14;19(1):1107.
  102. Han, E., Haldane, V., Koh, J.J.K., Quek, R.Y.C., Ozdemir, S., **Finkelstein, E.A.**, Jafar, T.H., Choong, H.L., Gan, S., Lim, L.W.W., Shiraz, F., Legido-Quigley, H. (2019). Perspectives on decision-making amongst older end-stage renal disease patients and caregivers in Singapore: A qualitative study. *Health Expectations*, 2019 Oct, 22(5):1100-1110. doi: 10.1111/hex.12943. Epub 2019 Aug 16. PMID: 31418984; PMCID: PMC6803400.
  103. Krishnan, A., **Finkelstein, E.A.**, Kallestrup, P., Karki, A., Olsen, M., Neupane, D. (2019). Cost-



- effectiveness and Budget Impact of a Community Health Worker led Lifestyle Intervention for Blood Pressure Reduction. *The Lancet Global Health*, 2019 Oct.
104. Bilger, M., Wong, T., Lee, J., Howard, K., Bundoc, F., Lamoureux, E., **Finkelstein, E.A.** (2019). Using Adherence-contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial. *Applied Health Economics and Health Policy*, 2019 Jul 18.
  105. **Finkelstein, E.A.**, Krishnan, A., Doble, B. (2019). Beyond cost-effectiveness: A five-step framework for appraising the value of health technologies in Asia-Pacific. *International Journal of Health Planning and Management*, 2019 Jul 9.
  106. **Finkelstein, E.A.**, Bilger, M., Baid, D. (2019). Effectiveness and Cost-Effectiveness of Incentives as a Tool for Prevention of Non-communicable Diseases: A Systematic Review. *Social Science & Medicine*. 2019 Jul; 232:340-350.
  107. Koot, D., Goh, P.S.C., Lim, R.S.M., Tian, Y., Yau, T.Y., Tan, N.C., **Finkelstein, E.A.** (2019). A Mobile Lifestyle Management Program (GlycoLeap) for People With Type 2 Diabetes: Single-Arm Feasibility Study. *Journal of Medical Internet Research Mhealth Uhealth*. 2019 May 24; 7(5):e12965.
  108. Berger, M.B., Steinberg, D.M., Askew, S., Gallis, J.A., Treadway, C.C., Egger, J.R., Kay, M.C., Batch, B.C., **Finkelstein, E.A.**, DeVries, A., Brewer, A., Bennett, G.G. (2019). The Balance protocol: a pragmatic weight gain prevention randomized controlled trial for medically vulnerable patients within primary care. *BMC Public Health*. 2019 May 17; 19(1):596.
  109. Verghese, N., Barrenetxea, J., Bhargava, Y., Agarwal, S., **Finkelstein, E.A.** (2019). Government Pharmaceutical pricing strategy in the Asia-Pacific region: an overview. *Journal of Market Access and Health Policy*. 2019 Apr 11;7(1):1601060. doi: 10.1080/20016689.2019.1601060. PMID: 31007877; PMCID: PMC6461095.
  110. Krishnan, A., **Finkelstein, E.A.**, Levine, E., Foley, P., Askew, S., Steinberg, D., Bennett, G.G. (2019). A Digital Behavioral Weight Gain Prevention Intervention in Primary Care Practice: Cost and Cost-effectiveness Analysis. *Journal of Medical Internet Research*. 2019 May 17;21(5):e12201. doi: 10.2196/12201. PMID: 31102373; PMCID: PMC6543798.
  111. **Finkelstein, E.A.**, Verghese, N.R. (2019). Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies. *Clinical Obesity*. 2019 Apr; 9(2):e12294.
  112. Ozdemir, S., Jafar, T.H., Choong, L.H.L., **Finkelstein, E.A.** (2019). Family dynamics in a multi-ethnic Asian society: comparison of elderly CKD patients and their family caregivers experience with medical decision making for managing end stage kidney disease. *BMC Nephrology*, 2019 Mar; 20(1):73.
  113. Zhen, C., **Finkelstein, E.A.**, Karns, S.A., Leibtag, E., Zhang, C. (2019). Scanner Data-Based Panel Price Indexes. *American Journal of Agricultural Economics*. 2019 Jan; 101(1):311-329.
  114. Ang, F.L.J., Agarwal, S., **Finkelstein, E.A.** (2019). Pilot randomized controlled trial testing the influence of front-of-pack sugar warning labels on food demand. *BMC Public Health* 2019 Feb 7; 19(1):164.
  115. Tham, E., **Finkelstein, E.A.**, Shek, L. (2019). Early childcare enrolment is a risk factor for transient early wheeze and persistent wheeze but not late onset wheeze. *Pediatric Allergy and Immunology*. 2019 Feb; 30(1):122.
  116. Perlman, A., Forgerite, S.G., ..., **Finkelstein, E.A.**, ... (2018). Efficacy and Safety of Massage for Osteoarthritis of the Knee: a Randomized Clinical Trial. *Journal of General Internal Medicine*. 2019 Mar;34(3):379-386. doi: 10.1007/s11606-018-4763-5. Epub 2018 Dec 12. PMID: 30543021; PMCID: PMC6420526.
  117. Tyagi, S., Koh, G.C., Nan, L., Tan, K.B., Hoenig, H., Matchar, D.B., Yoong, J., **Finkelstein, E.A.** (2018) Healthcare Utilization and cost trajectories post-stroke: role of caregiver and stroke factors. *BMC Health Services Research*. 2018 Nov 22; 18(1):188.
  118. Malhotra, C., Sim, D., Jaufeerally, F.R., **Finkelstein, E.A.** (2018). Associations between understanding of current treatment intent, communication with health care providers, preferences for invasive life-sustaining interventions and decisional conflict: Results from a survey of patients with advanced heart failure in Singapore. *BMJ Open*. 2018 Sep 19; 8 (9):e021688.
  119. Holloway, E.E., Constantinou, M., Xie, J., Fenwick, E.K., **Finkelstein, E.A.**, Man, R.E.K., Coote, M., Jackson, J., Rees, G., Lamoureux, E.L. (2018). Improving eye care in residential aged care facilities using the Residential Ocular Care (ROC) model: study protocol for a multicentered, prospective, customized, and cluster randomized controlled trial in Australia. *Trials*, 2018 Nov 26;19(1):650.

120. Ozdemir, S. & **Finkelstein, E.A.** (2018). Cognitive Bias: The Downside of Shared Decision Making. *JCO Clinical Cancer Informatics*. 2018 Nov; 2:1-10.
121. Malhotra, C., Foo, R., Singh, R., Ozdemir, S., Teo, I., Sim, D., Jaufeerally, F.R., Aung, T., Yeo, K.K., Nadkarni, N., **Finkelstein, E.A.** (2018). Study protocol for a cohort study of patients with advanced heart failure in Singapore. *BMJ Open*. 2018 Sep 17; 8(9):e022248.
122. Tyagi, S., Koh, G.C., Luo, N., Tan, K.B., Hoeing, H., Matcher, D.B., Yoong, J., **Finkelstein, E.A.**, Lee, K.E., Venketasubramanian, N., Menon, E., Chan, K.M., De Silva, D.A., Yap, P., Tan, B.Y., Chew, E., Young, S.H., Ng, Y.S., Tu, T.M., Ang, Y.H., Kong, K.H., Singh, R., Merchant, R.A., Chang, H.M., Yeo, T.T., Ning, C., Cheong, A., Ng, Y.L., Tan, C.S. (2018) Can caregivers report their care recipients' post-stroke hospitalization and outpatient visits accurately? Findings of an Asian prospective stroke cohort. *BMC Health Services Research*. 2018 Oct 25; 18(1):817.
123. Seah, S.S.Y., Rebello, S.A., Tai, B.C., Tay, Z., **Finkelstein, E.A.**, van Dam, R.M. (2018). Impact of tax and subsidy framed messages on high- and lower-sugar beverages sold in vending machines: a randomized crossover trial. *International Journal of Behavioral Nutrition and Physical Activity*. 2018 Aug 13; 15(1):76.
124. Palmer, K., Saha, C., Phillips, E., Krishnan, A., Foster, G., **Finkelstein, E.A.**, Wojtanowski, A., Marrero, D. (2018). The Two-Year Outcomes and Cost Effectiveness of a Commercial Weight Loss Program for the Prevention of Type 2 Diabetes among People with Prediabetes. *Endocrinology, Diabetes and Obesity*. 2018, 1(1):6.
125. **Finkelstein, E.A.**, Ozdemir, S., Malhotra, C., Jafar, T.H., Choong H.L.L., Gan, S.W.S. (2018). Understanding Factors That Influence the Demand for Dialysis among Elderly in a Multi-Ethnic Asian Society. *Health Policy*. 2018 Jun 27. pii: S0168-8510(18)30189-1.
126. Zhen C., **Finkelstein, E.A.**, Karns, S.A., Leibtag, E.S., Zhang, C. (2018). Scanner Data-based panel price indexes. *American Journal of Agricultural Economics*. 0(0): 1–19.
127. Tan, E.G.F., Teo, I., **Finkelstein, E.A.**, Chan, C.M. (2018). Determinants of Regret in Elderly Dialysis Patients. *Nephrology*. 2018 May 7.
128. Teo, I., Singh, R., Malhotra, C., Ozdemir, S., Dent, R.A., Kumarakulasinghe, N.B., Yeo, W.L., Cheung, Y.B., Malhotra, R., Kanesvaran, R., Yee, A.C.P., Chan, N., Wu, H.Y., Chin, S.M., Allyn, H.Y.M., Yang, G.M., Neo, P.S.H., Nadkarni, N.V., Harding, R., **Finkelstein, E.A.** (2018). Cost of Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS): prospective cohort study protocol. *BMC Cancer*. Apr 23;18(1):459.
129. **Finkelstein, E.A.**, Li, W., M, G., Strombotne, K., Zhen, C. (2018). Identifying The Effect of Shelf Nutrition Labels on Consumer Purchases, Results of a Natural Experiment and Consumer Survey. *American Journal of Clinical Nutrition*. 107(4):647-651.
130. Sloan, R.A., Kim, Y., Sahasranaman, A., Müller-Riemenschneider, F., Biddle, S., **Finkelstein, E.A.**, (2018). The influence of a consumer-wearable activity tracker on sedentary time and prolonged sedentary bouts: secondary analysis of a randomized controlled trial. *BMC Research Notes*. 11(1):189.
131. Jafar, T.H., Tan, N.C., Allen, J.C., **Finkelstein, E.A.**, Goh, P., Moey, P., Quah, J.H.M., Hwang, S.W., Bahadin, J., Thiagarajah, A.G., Chan, J., Kang, G., Koong, A., (2018). Management of hypertension and multiple risk factors to enhance cardiovascular health in Singapore: The SingHypertension cluster randomized trial. *Trials*. 2018 Mar 14;19(1):180.
132. Cook, A.R., Zhao, X., Chen, M.I.C., **Finkelstein, E.A.** (2018). Public preferences for interventions to prevent emerging infectious disease threats: A discrete choice experiment. *BMJ Open*. 8(2):e017355.
133. Ting, D.S.W., Cheung, C.Y.L., **Finkelstein, E.A.**, Wong, T. Y., (2017). Development and Validation of a Deep Learning System for Diabetic Retinopathy and related Eye Diseases using Retinal Images from Multi-ethnic Populations with Diabetes, *JAMA*. 318(22):2211-2223.
134. Chia, Y.M.F., Teng, T.K., Tan, E.S.J., Tay, W.T., Richards, A.M., Chin, C.W.L., Shimizu, W., Park, S.W., Hung, C.L., Ling, L.H., Ngarmukos, T., Omar, R., Siswanto, B.B., Narasimhan, C., Reyes, E.B., Yu, C.M., Anand, I., MacDonald, M.R., Yap, J., Zhang, S., Finkelstein, E.A., Lam, C.S.P. (2017). Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. *Circ Cardiovasc Qual Outcomes*, 2017 Nov;10(11).
135. Bilger, M., Shah, M., Tan, N.C., Howard, K.L., Xu, H.Y., Lamoureux, E.L., **Finkelstein, E.A.** (2017). Trial to Incentivise Adherence for Diabetes (TRIAD): study protocol for a randomised controlled trial. *Trials*, 18(1):551.
136. Ozdemir, S., Wu, H.K., **Finkelstein, E.A.**, Wong, T.T. (2017). Parents' Views on their Children's Use of

- Eye Drops and Willingness to Accept a New Sustained-Release Subconjunctival Injection. *Clinical Ophthalmology*, 1903-1909.
137. **Finkelstein, E.A.** (2017). Cost effectiveness of obesity interventions: Will we know it when we see it? *Pediatrics*, 140(3). pii: e20171916.
  138. Nguyen, H.V., **Finkelstein, E.A.**, Mital, S., Gardner, D.S. (2017). Incremental Cost-Effectiveness of Algorithm-Driven Genetic Testing Versus no Testing for Maturity Onset Diabetes of the Young (Mody) in Singapore. *Journal of Medical Genetics*, 54(11):747-753.
  139. Butte, N. F., Hoelscher, D. M., Barlow, S.E., Pont, S., **Finkelstein E.A.**, Gonzalez, A. (2017). Efficacy of a community-versus primary care-centered program for childhood obesity: TX CORD RCT. *Obesity*, 25(9):1584-1593.
  140. Jafar, T.H., Jehan, I., de Silva, H.A., Naheed, A., Gandhi, M., Assam, P., **Finkelstein, E.A.**, Quigley, H.L., Bilger, M., Khan, A.H., Clemens, J.D. (2017). Multicomponent intervention versus usual care for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: study protocol for a cluster randomized controlled trial. *Trials*, 18(1):272. PMID: PMC5469065.
  141. Nguyen, H.V., Bose, S., Mital, S., **Finkelstein, E.A.**, Koh, M.S. (2017). Is bronchial thermoplasty cost-effective as treatment for problematic asthma patients? Singapore's perspective on a global model. *Respirology*, 22(6):1102-1109. **Won Fukuchi Award for best original research paper published in the journal in 2017.**
  142. **Finkelstein, E.A.**, Tham, K.W., Haaland, B.A., Sahasranaman, A. (2017). Applying economic incentives to increase effectiveness of an outpatient weight loss program (TRIO) - A randomized controlled trial. *Social Science & Medicine*, 185, 63-70.
  143. Ozdemir, S., Wong, T.T., Allingham, R.R., **Finkelstein, E.A.** (2017). Predicted patient demand for a new delivery system for glaucoma medicine. *Medicine*, 96(15). PMID: PMC5403112.
  144. Ozdemir, S., Bilger, M., **Finkelstein, E.A.** (2017). Stated uptake of physical activity rewards programmes among active and insufficiently active full time employees. *Applied Health Economics and Health Policy*, 647-656. PMID: 28434180.
  145. Vedanthan, R., Kamano, J.H., Lee, H., Andama, B., Bloomfield, G.S., DeLong, A.K., Edelman, D., **Finkelstein, E.A.**, Hogan, J.W., Horowitz, C.R., Manyara, S. (2017). Bridging Income Generation with Group Integrated Care for cardiovascular risk reduction: Rationale and design of the BIGPIC study. *American Heart Journal*, 188:175-185.
  146. **Finkelstein, E.A.**, Ozdemir, S., Malhotra, C., Jafar, T.H., Choong, H.L., Suhardjono, J. (2017). Identifying factors that influence physicians' recommendations for dialysis and conservative management in Indonesia. *Kidney International Reports*, 2(2):212-218.
  147. Malhotra, C., Xiang, L., Ozdemir, S., Kanesvaran, R., Chan, N., **Finkelstein, E.A.** (2016). A comparison of attitudes toward length and quality of life between community dwelling older adults and patients with advanced cancer. *Psycho-Oncology*, 26(10):1611-1617.
  148. Bilger, M., Kruger, E.J., **Finkelstein, E.A.** (2016). Measuring Socioeconomic Inequality in Obesity: Looking Beyond the Obesity Threshold. *Health Econ*, 26(8):1052-1066. PMID: PMC5516143.
  149. **Finkelstein, E.A.**, Haaland, B., Bilger, M., Sahasranaman, A., Sloan, R.A., Nang, E.E.K., Evenson, K.R. (2016). Effectiveness of activity trackers with and without incentives to increase physical activity (TRIPPA): a randomized controlled trial. *The Lancet Diabetes & Endocrinology*, 4(12):983-995.
  150. Nguyen, H.V., Tan, G.S., Tapp, R.J., Mital, S., Ting, D., Wong, T.H., Tan, C., Laude, A., Shyong, T.E., Tan, N.C., **Finkelstein, E.A.**, Wong, T.Y., Lamoureux, E.L. (2016). Cost Effectiveness of A National Telemedicine Diabetic Retinopathy Screening Program in Singapore. *Ophthalmology*, 123(12):2571-2580.
  151. Bilger, M., Wong, T.T., Howard, K.L., Lee, J.Y., Toh, A.N., John, G., Lamoureux, E.L., **Finkelstein, E.A.** (2016). Study on Incentives for Glaucoma Medication Adherence (SIGMA). A Randomized controlled trial to increase glaucoma medication adherence using value pricing: study protocol for a randomized controlled trial. *Trials*, 17(1):316. PMID: PMC4947326.
  152. Tobe, W.S., **Finkelstein, E.A.**, (One of 115 listed collaborators) Global Alliance for Chronic Diseases Hypertension Research Teams with the World Hypertension League (2016). The Global Alliance for Chronic Diseases Supports 15 Major Studies in Hypertension Prevention and Control in Low-and Middle-Income Countries. *J Clin Hypertens, Greenwich*. 18(7):600-605.
  153. Malhotra, C., Bilger, M., Liu, J., **Finkelstein, E.A.** (2016). Barriers to breast and cervical cancer screening in Singapore: A mixed methods analysis. *Asia Pacific Journal of Cancer Prevention*. 17(8):3887-3895.

154. Malhotra, C., Sim, D.K., Jaufeerally, F., Vikas, N.N., Sim, G.W., Tan, B.C., Ng, C.S., Tho, P.L., Lim, J., Chuang, C.Y, Fong, F.H, Liu, J., **Finkelstein, E.A.** (2016). Impact of advance care planning on care of patients with heart failure: Study protocol for a randomized controlled trial. *Trials*, 17(1):285. PMID: PMC4902978.
155. Jafar, T.H., de Silva A., Naheed, A., Jehan, I., Liang, F., Assam, P.N., Legido-Quigley, H., **Finkelstein, E.A.**, Ebrahim, S., Hameed, A., COBRA-BPS Study Group (2016). Control of Blood Pressure and Risk Attenuation - A Public Health Intervention in rural Bangladesh, Pakistan, and Sri Lanka: Feasibility Trial Results. *Journal of Hypertension*, 34(9):1872-1881.
156. Malhotra, C., Wong, G.C.S., Tan, B.C., Ng, C.S.H., Lee, N.C., Lau, C.S.L., Sim, D.K.L., **Finkelstein, E.A.** (2016). Living with heart failure: Perspectives of patients from an Asian setting. *Proceedings of Singapore Healthcare*, 25(2):92-97.
157. Ding, D., Lawson, K.D., Kolbe-Alexander, T., **Finkelstein, E.A.**, Katzmarzyk, P.T., Mechelen, W., Pratt, M., Lancet Physical Activity Series 2 Executive Committee (2016). The Economic Burden of Physical Inactivity: A Global Analysis of Major Non-Communicable Diseases. *The Lancet*, 388(10051):1311-1324.
158. Nguyen, H.V., Tan, G.S., Tapp, R.J., Mital, S., Ting, D., Wong, T.H., Tan, C., Laude, A., Shyong, T.E., Tan, N.C., **Finkelstein, E.A.**, Wong, T.Y., Lamoureux, E.L. (2016). Cost Effectiveness of A National Telemedicine Diabetic Retinopathy Screening Program in Singapore. *Ophthalmology*, 123(12):2571-2580.
159. Nguyen, V.H., Bose, S., **Finkelstein, E.A.** (2016). Incremental Cost-Utility of Sevelamer Relative to Calcium Carbonate for Treatment of Hyperphosphatemia among Pre-Dialysis Chronic Kidney Disease Patients. *BMC Nephrology*, 17(1):45. PMID: PMC4848865.
160. Dong, D., Ozdemir, S., Bee, Y.M., Toh, S.A., Bilger, M., **Finkelstein, E.A.** (2016). Measuring High-risk Patients' Preferences for Pharmacogenetic Testing to Reduce Severe Adverse Drug Reaction: A Discrete Choice Experiment. *Value in Health*, 19(6):767-775.
161. **Finkelstein, E.A.**, Malhotra, C., Chay, J., Chopra, A., Kanesvaran, R., Ozdemir, S. (2016). Impact of treatment subsidies and cash pay-outs on treatment choices at the end of life. *Value in Health*, 19(6):788-794.
162. **Finkelstein, E.A.**, Mansfield, C., Wood, D., Rowe, B., Chay, J., Ozdemir, S. (2016). Tradeoffs between Civil Liberties and National Security: A Discrete Choice Experiment. *Contemporary Economic Policy*, 35(2): 292-311.
163. Yong, K.L., Nguyen, H.V., Cajucom-Uy, H.Y., Foo, V., Tan, D., **Finkelstein, E.A.**, Mehta, J.S. (2016). Cost Minimization Analysis of Precut Cornea Grafts in Descemet's Stripping Automated Endothelial Keratoplasty. *Medicine*, 95(8):e2887. PMID: PMC4779024.
164. Luo, N., Wang, X., Ang, M., **Finkelstein, E.A.**, Aung, T., Wong, T.Y., Lamoureux, E. (2015). A Vision "Bolt-On" Item Could Increase the discriminatory Power of the EQ-5D Index Score. *Value Health*, 18(8):1037-1042.
165. Corso, P., **Finkelstein, E.A.**, Miller, T., Fiebelkorn, I., Zaloshnja, E. (2015). Incidence and lifetime costs of injuries in the United States. *Injury Prevention*, 21(6):434-440.
166. Flynn, T.N., Bilger, M., Malhotra, C., **Finkelstein, E.A.** (2015). Are Efficient Designs Used In Discrete Choice Experiments Too Difficult For Some Respondents? A Case Study Eliciting Preferences for End-Of-Life Care. *Pharmacoeconomics*, 34(3):273-284.
167. Malhotra, C., Chan, N., Zhou, J., Dalager, H.B., **Finkelstein, E.A.** (2015). Variation in physician recommendations, knowledge and perceived roles regarding provision of end-of-life care. *BMC Palliative Care*, 14(1):52. PMID: PMC4623295.
168. Chen, P.Y., **Finkelstein, E.A.**, Ng, M.J., Yap, F., Yeo, S.H., Rajadurai, V.S., Chong, Y.S., Gluckman, P.D., Saw, S.M., Kwek, Y.C., Tan, K.H. (2015). Incremental Cost-effectiveness Analysis of Gestational Diabetes Mellitus Screening Strategies in Singapore. *Asia-Pacific Journal of Public Health*, 28(1):15-25.
169. Epstein, L.H., **Finkelstein, E.A.**, Katz, D., Jankowiak, N., Pudlewski, C., Paluch, R.A. (2015). Effects of nutrient profiling and price changes based on NuVal® scores on food purchasing in an on-line experimental supermarket. *Public Health Nutrition*, 19(12):2157-2164.
170. Dong, D., Tan-Koi, W.C., Teng, G.G., **Finkelstein, E.A.**, Sung, C. (2015). Cost-effectiveness analysis of genotyping for HLA-B\*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. *Pharmacogenomics*, 16(16):1781-1793.

171. Dong, D., Bilger, M., Dam, R.M.V., **Finkelstein, E.A.** (2015). Consumption of Specific Foods and Beverages and Excess Weight Gain Among Children And Adolescents. *Health Affairs*, 34(11):1940-1948.
172. **Finkelstein, E.A.**, Bilger, M., Flynn, T., Malhotra, C. (2015). Preferences for end-of-life care among community-dwelling older adults and patients with advanced cancer: A discrete choice experiment. *Health Policy*, 119(11):1482-1489.
173. Lamoureux, E., Mcintosh, R., Constantinou, M., Fenwick, E., Xie, J., Casson, R., **Finkelstein, E.A.**, Goldberg, I., Healey, P., Thomas, R., Ang, G.S., Pesudovs, K., Crowston, J. (2015). The Glaucoma Initial Treatment Study: Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment: study protocol for a randomized controlled trial. *Trials*, 16:406. PMID: PMC4567808.
174. Epstein, L.H., **Finkelstein, E.A.**, Raynor, H., Nederkoorn, C., Fletcher, K.D., Jankowiak, N., Paluch, R.A. (2015). Experimental analysis of the effect of taxes and subsidies on calories purchased in an on-line supermarket. *Appetite*, 95:245-251.
175. Boh, C., Li, H.H., **Finkelstein, E.A.**, Haaland, B.A., Xin, X.H., Yap, S., Pasupathi, Y., Ong, M.E. (2015). Factors Contributing to Inappropriate Visits of Frequent Attenders at the Emergency Department of a Tertiary Hospital. *Academic Emergency Medicine*, 22(9):1025-1033.
176. Malhotra, C., Farooqui, M.A., Kanesvaran, R., Bilger, M., **Finkelstein, E.A.** (2015). Comparison of preferences for end-of-life care among patients with advanced cancer and their caregivers: A discrete choice experiment. *Palliative Medicine*, 29(9):842-850.
177. Goodwin, N.J., O'Farrell, S.E., Jagoe, K., Rouse, J., Roma, E., Biran, A., **Finkelstein, E.A.** (2015). The Use of Behaviour Change Techniques in Clean Cooking Interventions to Achieve Health, Economic and Environmental Impact. A review of the evidence and scorecard of effectiveness. *Journal of Health Communication*, 20 (sup1):43-54.
178. **Finkelstein, E.A.**, Sahasranaman, A., John, G., Haaland, B.A., Bilger, M., Sloan, R.A., Khaing, N.E., Evenson, K.R. (2015). Design and baseline characteristics of participants in the Trial of Economic Incentives to Promote Physical Activity (TRIPPA): A randomized controlled trial of a six month pedometer program with financial incentives. *Contemp Clin Trials*, 41:238-247.
179. Lai, H., Choong, C.V., Fook-Chong, S., Ng, Y.Y., **Finkelstein, E.A.**, Haaland, B., Goh, E.S., Leong, B.S., Gan, H.N., Foo, D., Tham, L.P., Charles, R., Ong, M.E, PAROS study group (2015). Interventional strategies associated with improvements in survival for out-of-hospital cardiac arrests in Singapore over 10 years. *Resuscitation*, 89:155-161.
180. Tan, T.E., Peh, G.S.L., **Finkelstein, E.A.**, Mehta, J.S. (2015). A practical model for economic evaluation of tissue-engineered therapies. *WIREs Systems Biology and Medicine*, 7(2):91-100.
181. Ang, M., Nguyen, H.V., Sieh, Y.K., Shu, C., Chee, S.P., **Finkelstein, E.A.** (2015). Cost-Effectiveness of Alternative Strategies for Interferon-gamma Release Assays and Tuberculin Skin Test in Tuberculous Uveitis. *British Journal of Ophthalmology*, 99(7):984-989.
182. Hoelscher, D.M., Butte, N.F., Vandewater, E.A., Sharma, S.V., Huang, T., **Finkelstein, E.A.**, Pont, S., Sacher, P., Byrd-Williams, C., Oluyomi, A., Durand, C., Li, L.L., Kelder, S.H. (2015). Incorporating Primary and Secondary Prevention Approaches to Address Childhood Obesity Prevention and Treatment in a Low-Income, Ethnically Diverse Population: Study Design and Demographic Data from the Texas Child Obesity Research Demonstration (TX CORD) Study. *Childhood Obesity*, 11(1):71-91. PMID: PMC4696423.
183. **Finkelstein, E.A.**, Strombotne, K.L., Zhen, C., Epstein, L.H. (2014). Food prices and obesity: A review. *Advances in Nutrition*, Nov 14;5 (6):818-821.
184. **Finkelstein, E.A.**, Kruger, E. (2014). Meta- and Cost-Effectiveness Analysis (CEA) of Commercial Weight Loss Strategies. *Obesity*, 22(9):1942-1951.
185. **Finkelstein, E.A.** (2014). How big of a problem is obesity? *Surg Obes Relat Dis*, 10(4):569-570.
186. Tan, T.E., Peh, S.L., George, B.L., Cajucom-Uy, H.Y., Dong, D., **Finkelstein, E.A.**, Mehta, J.S. (2014). A Cost-Minimization Analysis of Tissue-Engineered Constructs for Corneal Endothelium Transplantation. *PLOS ONE*, 9(6):e100563. PMID: PMC4065108.
187. **Finkelstein, E.A.**, Kruger, E., Karnawat, S. (2014). Cost-effectiveness Analysis of Qsymia for Weight Loss. *Pharmacoeconomics*, 33(7):699-706.
188. **Finkelstein, E.A.**, Chay, J.X., Bajpai, S. (2014). The economic burden of self-reported and undiagnosed cardiovascular diseases and diabetes on Indonesian households. *PLOS ONE*, 9(6):e99572. PMID: PMC4051736.

189. Keyserling, T.C, Sheridan, S.L., Draeger, L.B., **Finkelstein, E.A.**, Gizlice, Z., Kruger, E., Johnston, L.F., Sloane, P.D., Samuel-Hodge, C., Evenson, K.R., Gross, M.D., Donahue, K.E., Pignone, M.P., Vu, M.B., Steinbacher, E.A., Weiner, B.J., Bangdiwala, S.I., Ammerman, A.S. (2014). A Comparison of Live Counseling With a Web-Based Lifestyle and Medication Intervention to Reduce Coronary Heart Disease Risk: A Randomized Clinical Trial. *JAMA Internal Medicine*, 174(7):1144-1157.
190. Vedanthan, R., Kamano, J.H., Naanyu, V., Delong, A.K., Were, M.C., **Finkelstein, E.A.**, Menya, D., Akwanalo, C.O., Bloomfield, G.S., Binanay, C.A., Velazquez, E.J., Hogan, J.W., Horowitz, C.R., Inui, T.S., Kimaiyo, S., Fuster, V. (2014). Optimizing Linkage and Retention to Hypertension Care in Rural Kenya (LARK Hypertension Study): study protocol for a randomized controlled trial. *Trials*, 15(1):143. PMID: PMC4113229.
191. Epstein, L.H., Paluch, R.A., Wrotniak, B.H., Daniel, T.O., Kilanowski, C., Wilfley, D., **Finkelstein, E.A.** (2014). Cost-effectiveness of family-based group treatment for child and parental obesity. *Child Obes*, 10(2):114-121.
192. Farooqui, M.A., Tan, Y.T., Bilger, M., **Finkelstein, E.A.** (2014). Effects of financial incentives on motivating physical activity among older adults: results from a discrete choice experiment. *BMC Public Health*, 14(1):141. PMID: PMC3933254.
193. **Finkelstein, E.A.**, Graham, W.C., Malhotra, R. (2014). Lifetime Direct Medical Costs of Childhood Obesity. *Pediatrics*, 133(5):854-862.
194. Zhen, C., **Finkelstein, E.A.**, Nonnemaker, J.M., Karns, S.A., Todd, J.E. (2014). Predicting the Effects of Sugar-Sweetened Beverage Taxes on Food and Beverage Demand in a Large Demand System. *American Journal of Agricultural Economics*, 96(1):1-25. PMID: PMC4022288.
195. **Finkelstein, E.A.**, Malhotra, C., Yee, A.C. (2014). Improving the End-of-Life Experience in Singapore: Building Capacity in Palliative Care Research and Education. *Annals Academy of Medicine Singapore*, 43(1) Editorial.
196. Dong, D., Tan, A., Mehta, J.S., Tan, D., **Finkelstein, E.A.** (2014). Cost-effectiveness of Osteo-odonto Keratoprosthesis in Singapore. *American Journal of Ophthalmology*, 157(1):78-84.
197. Dixon, J.B., Egger, G., **Finkelstein, E.A.**, Kral, J., Lambert, G.W. (2013). "Obesity Paradox" misunderstands the biology of optimal weight throughout the life cycle. *International Journal of Obesity*, 39(1):82-84.
198. Ngo, C.S., Pan, C.W., **Finkelstein, E.A.**, Lee, C.F., Wong, B.Y., Ong, J., Ang, M., Wong, T.Y., Saw, S.M. (2013). A cluster randomized controlled trial evaluating an incentive-based outdoor physical activity program to increase outdoor time and prevent myopia in children. *Ophthalmic and Physiological Optics*, 34(3):362-368.
199. Epstein, L.H., Jankowiak, N., Fletcher, K.D., Carr, K.A., Nederkoorn, C., Raynor, H., **Finkelstein, E.A.** (2013). Women who are motivated to eat and discount the future are more obese. *Obesity*, 22(6):1394-1399.
200. Zheng, Y.F., Chen, W.P., Chay, J.X., Wong, T.Y., **Finkelstein, E.A.**, Saw, S.M. (2013). The Economic Cost of Myopia in Adults Aged over 40 Years in Singapore. *IOVS*, 54(12):7532-7537.
201. Hanoch, Y., **Finkelstein, E.A.** (2013). Health psychology meets behavioral economics: Introduction to special issue. *Health Psychology*, 32(9):929-931.
202. Dreyer, N.A., Dixon, J.B., Okerson, T., **Finkelstein, E.A.**, Globe, D. (2013). Prevalence of Comorbidities and Baseline Characteristics of LAP-BAND AP® Subjects in the Helping Evaluate Reduction in Obesity (HERO) Study. *PLOS ONE*, 2013 Nov 15;8(11):e78971. doi: 10.1371/journal.pone.0078971. PMID: 24260140; PMID: PMC3829819.
203. **Finkelstein, E.A.**, Allaire, B.T., Globe, D., Dixon, J.B. (2013). The Business Case for Bariatric Surgery Revisited: A Non-Randomized Case-Control Study. *PLOS ONE*, 2013 Sep 19;8(9):e75498. doi: 10.1371/journal.pone.0075498. PMID: 24069423; PMID: PMC3777948.
204. Sheridan, S.L., Draeger, L.B., Pignone, M.P., Sloane, P.D., Samuel-Hodge, C., **Finkelstein, E.A.**, Gizlice, Z., Vu, M., Gitterman, D.P., Bangdiwala, S.I., Donahue, K.E., Evenson, K., Ammerman, A.S., Keyserling, T.C. (2013). Designing and Implementing a Comparative Effectiveness Study of Two Strategies for Delivering High Quality CHD Prevention: Methods and Participant Characteristics for the Heart to Health Study. *Contemporary Clinical Trials*, 36(2):394-405.
205. Dharani, R., Lee, C.F., **Finkelstein, E.A.**, Saw, S.M. (2013). Response to Mahroo et al., *Eye (Lond)*, 27(8):991.

206. Drury, V.B., Saw, S.M., **Finkelstein, E.A.**, Wong, T.Y., Tay, K.C. (2013). A new community-based outdoor intervention to prevent myopia and increase physical activity in Singapore children: findings from focus groups. *Annals Academy of Medicine Singapore*, 42(5):225-231.
207. Chan, S.L., Low, J.W., Lim, Y.W., **Finkelstein, E.A.**, Farooqui, M.A., Chia, K.S., Wee, H.L. (2013). Willingness-to-pay and preferences for warfarin pharmacogenetic testing in Chinese warfarin patients and general public. *Personalized Medicine*, 10(2):127-137.
208. **Finkelstein, E.A.**, Tan, Y.T., Malhotra, R., Lee, C.F., Goh, S.S., Saw, S.M. (2013). A Cluster Randomized Controlled Trial of an Incentive-Based Outdoor Physical Activity Program, *The Journal of Pediatrics*, 163(1):167-172.
209. Rees, G., Holloway, E.E., Mellor, D., Sturrock, B.A., Hegel, M.T., Casten, R., Xie, J., **Finkelstein, E.A.**, Keefe, J.E. (2013). Integrated depression management: a trial of a new model of care in a low vision rehabilitation setting. *Ophthalmic Epidemiology*, 20(5):321-329.
210. Bilger, M., **Finkelstein, E.A.**, Kruger, E., Linnan, L.A., Tate, D.F. (2013). The Effect of Weight Loss on Health, Productivity and Medical Expenditures among Overweight Employees. *Medical Care*, 51(6):471-477.
211. Malhotra, R., Ostbye, T., Riley, C.M., **Finkelstein, E.A.** (2013). Young adult weight trajectories through midlife by body mass category. *Obesity*, 21(9):1923-1934.
212. **Finkelstein, E.A.**, Zhen, C., Bilger, M., Nonnemaker, J., Farooqui, M.A., Todd, J.E. (2013). Implications of a sugar-sweetened beverage (SSB) tax when substitutions to non-beverage items are considered. *Journal of Health Economics*, 32(1):219-239.
213. Bose, S., Ang, M., Mehta, J.S., Tan, D.T., **Finkelstein, E.A.** (2013). Cost-Effectiveness of Descemet's Stripping Endothelial Keratoplasty Versus Penetrating Keratoplasty. *Ophthalmology*, 120(3):464-470.
214. Rahman, A.K.M., Bose, S., Linnan, M., Rahman, A., Mashreky, S., Haaland, B., **Finkelstein, E.A.** (2012). Cost-effectiveness of an injury and drowning prevention program in low-and-middle-income countries. *Pediatrics*, 130(6):1621-1628.
215. Jakicic, J.M., Tate, D.F., Lang, W., Davis, K.K., Polzien, K., Rickman, A.D., Erickson, K., Neiberg, R.H., **Finkelstein, E.A.** (2012). Effect of a Stepped-Care intervention approach on weight loss in adults: a randomized clinical trial. *Journal of the American Medical Association*, 307(24), 2617-2626.
216. Dong, D., Sung, C., **Finkelstein, E.A.** (2012). Cost-effectiveness of HLA-B\*1502 genotyping newly diagnosed adult epilepsy patients in Singapore. *Neurology*, 79(12): 1259-1267.
217. Dharani, R., Lee, C.F., Theng, Z.X., Drury, V.B., Ngo, C., Sandar, M., Wong, T.Y., **Finkelstein, E.A.**, Saw, S.M. (2012). Comparison of measurements of time outdoors and light levels as risk factors for myopia in young Singapore children. *Eye*, 2012 Jul;26(7):911-8. doi: 10.1038/eye.2012.49. Epub 2012 May 4. PMID: 22562184; PMCID: PMC3396160.
218. Crane, M.M., Tate, D.F., **Finkelstein, E.A.**, Linnan, L.A. (2012). Motivation for participating in a weight loss program and financial incentives: An analysis from a randomized trial. *Journal of Obesity*, PMCID: PMC3345232.
219. Do, Y.K., **Finkelstein, E.A.** (2012). Youth employment, income and smoking initiation: Results from Korean Panel Data. *Journal of Adolescent Health*, 51(3), 226-232.
220. **Finkelstein, E.A.**, Bilger, M. (2012). Hard truths and a new strategy for addressing childhood obesity. *Childhood Obesity*, 8(2):106-109.
221. Epstein, L.H., Jankowiak, N., Nederkoorn, C., Raynor, H.A., French, S.A., **Finkelstein, E.A.** (2012). Experimental research on the relationship between food price changes and food purchasing patterns: A targeted review. *American Journal of Clinical Nutrition*, 95(4):789-809. PMCID: PMC3302358.
222. Linnan, L.A., Tate, D.F., Harrington, C., Brooks, A., **Finkelstein, E.A.**, Bangdiwala, S.I., Britt, A. (2012). Organizational- and employee-level recruitment into a worksite-based weight loss study. *Journal of Clinical Trials*, 9(2), 215-225.
223. **Finkelstein, E.A.**, Khavjou, O.A., Thompson, H., Trogdon, J.G., Pan, L.P., Sherry, B., Dietz, W.H. (2012). Obesity and severe obesity forecasts through 2030. *American Journal of Preventive Medicine*, 42(6), 563-570.
224. **Finkelstein, E.A.**, Ostbye, T., Malhotra, R. (2013). Body mass trajectories through mid-life among Class I obese adults. *Surgery for Obesity and Related Disorders*, 9(4):547-553.
225. Dixon, J.B., Murphy, D.K., Segel, J.E., **Finkelstein, E.A.** (2012). *Impact of laparoscopic adjustable gastric banding on Type 2 diabetes. Obesity Reviews*, 13(1), 57-67.

226. Lopes, G.L., Segel, J.E., Tan, D.S., Do, Y.K., Mok, T., **Finkelstein, E.A.** (2012). Cost effectiveness of epidermal growth factor receptor mutation testing and first line treatment with Gefitinib for patients with advanced adenocarcinoma of the lung. *Cancer*, 118(4), 1032-1039.
227. Trogdon, J.G., Cohen, J.W., Feagan, C.W., **Finkelstein, E.A.** (2012). State and payer specific estimates of annual medical expenditures attributable to obesity. *Obesity (Silver Spring)*, 20(1), 214-220.
228. Zheng, Y.F., Lamoureux, E., **Finkelstein, E.A.**, Wu, R.Y., Raghavan, L., Chua, D., Wong, T.Y. (2011). Independent impact of area-level socioeconomic measures on visual impairment. *Investigative Ophthalmology & Visual Science*, 52(12), 8799-8805.
229. Ferdinand, K.C., Orenstein, D., Hong, Y., Journigan, J.G., Trogdon, J.G., Bowman, J., Zohrabian, A., Kilgore, M., White, A., Mokdad, A., Pechacek, T.F., Goetzel, R.Z., Labarthe, D.R., Puckrein, G.A., **Finkelstein, E.A.**, Wang, G., French, M.E., Vaccarino, V. (2011). Health economics of cardiovascular disease: Defining the research agenda. *CVD Prevention and Control*, Vol.6, no.3, 91-100.
230. Anderson, W.L., Armour, B.K., Wiener, J.M. , **Finkelstein, E.A.** (2011). Estimates of national health care expenditures associated with disability. *Journal of Disability Policy Studies*, 21(4), 230-240.
231. **Finkelstein, E.A.**, Allaire, B.T., DiBonaventura, M., Burgess, S.M. (2011). Incorporating indirect costs into a cost-benefit analysis of laparoscopic adjustable gastric banding (LAGB). *Value in Health*, 15(2), 299-304.
232. Do, Y.K., **Finkelstein, E.A.** (2011). Adolescent weight status and self-reported school performance in South Korea. *Journal of Obesity*, PMID: PMC3249351.
233. **Finkelstein, E.A.**, Allaire, B.T., DiBonaventura, M., Burgess, S.M. (2011). Direct and indirect costs and potential cost savings of laparoscopic adjustable gastric banding among obese patients with diabetes. *Journal of Occupational and Environmental Medicine*, 53(9), 1025-1029.
234. Li, J., Linnan, L.A., **Finkelstein, E.A.**, Tate, D.F., Naseer, C., Evenson, K.R. (2011). Knowledge and perceptions of overweight employees about lifestyle-related health benefit changes. *North Carolina Medical Journal*, 72(3),183-190.
235. Koo, T.S., **Finkelstein, E.A.**, Tan, D., Mehta, J.S. (2011). Incremental cost-utility analysis of deep anterior lamellar keratoplasty compared to penetrating keratoplasty for the treatment of keratoconus. *American Journal of Ophthalmology*, 152(1), 40-47.
236. Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., Butler, J., Dracup, K., Ezekowitz, M.D., **Finkelstein, E.A.**, Hong, Y., Johnston, S.C., Khera, A., Lloyd-Jones, D.M., Nelson, S.A., Nichol, G., Orenstein, D., Wilson, P.W., Woo, Y.J. (2011). Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. *Circulation*, 123(8), 933-944.
237. **Finkelstein, E.A.**, Strombotne, K.L., Chan, N.L., Krieger, J. (2011). The impact of mandatory menu labeling in one fast food chain in King County, Washington. *American Journal of Preventive Medicine*, 40(2), 122-127.
238. **Finkelstein, E.A.**, Allaire, B.T., Burgess, S.M., Hale, B.C. (2011). Financial implications of coverage for laparoscopic adjustable gastric banding. *Surgery for Obesity and Related Diseases*, 7(3), 295-303.
239. **Finkelstein, E.A.**, Strombotne, K.L., Popkin, B.M. (2010). The costs of obesity and implications for policymakers. *Choices*, 25(3).
240. Houtven, V.G., Reed, W.R., Biddle, E.A., Volkwein, J.C., Clayton, L., **Finkelstein, E.A.** (2010). Rates and costs of respiratory illness in coal mining: A cross-industry comparative analysis. *The Journal of Occupational and Environmental Medicine*, 52(6), 610-617.
241. **Finkelstein, E.A.**, Zhen, C., Nonnemaker, J.M., Todd, J.E. (2010). Impact of targeted beverage taxes on higher and lower income households. *Archives of Internal Medicine*, 170(22), 2028-2034.
242. **Finkelstein, E.A.**, Segel, J.E. (2010). Does cost-savings mean cost effective? *American Journal of Preventive Medicine*, 39(5), 489-490.
243. **Finkelstein, E.A.**, DiBonaventura, M., Burgess, S.M., Hale, B.C. (2010). The costs of obesity in the workplace. *Journal of Occupational and Environmental Medicine*, 52(10), 971-976.
244. Tangka, F.K., Trogdon, J.G., Richardson, L.C., Howard, D., Sabatino, S.A., **Finkelstein, E.A.** (2010). Cancer treatment cost in the United States: Has the burden shifted over time? *Cancer*, 116(14), 3477-3484.
245. **Finkelstein, E.A.**, Strombotne, K.L. (2010). The economics of obesity. *American Journal of Clinical Nutrition*, 91(5), 1520S-1524S.
246. Epstein, L.H., Dearing, K.K., Roba, L.G., **Finkelstein, E.A.** (2010). The influence of taxes and subsidies on energy purchased in an experimental purchasing study. *Psychological Science*, 21(3), 406-414.



247. Anderson, W. L., Armour, B.S., **Finkelstein, E.A.**, Wiener, J.M. (2010). Estimates of state-level health-care expenditures associated with disability. *Public Health Reports*, 125(1), 44-51. PMID: PMC2789815.
248. **Finkelstein, E.A.**, Brown, D.S, Wrage, L.A., Allaire, B.T., Hoerger, T.J. (2010). Individual and aggregate years-of-life-lost associated with overweight and obesity. *Obesity (Silver Spring)*, 18(2), 333-339.
249. **Finkelstein, E.A.**, Tangka, F.K., Trogdon, J.G., Sabatino, S.A., Richardson, L.C. (2009). The personal financial burden of cancer for the working –aged population. *American Journal of Managed Care*, 15(11), 801-806.
250. **Finkelstein, E.A.**, Linnan, L.A., Tate, D.F., Leese, P.J. (2009). A longitudinal study on the relationship between weight Loss, medical expenditures, and absenteeism among overweight employees in the WAY to Health Study. *Journal of Occupational and Environment Medicine*, 51(12), 1367-1373. PMID: PMC2813269.
251. Tate, D.F., **Finkelstein, E.A.**, Khavjou, O.A., Gustafson, A. (2009). Cost effectiveness of internet interventions: Review and recommendations. *Annals of Behavioral Medicine*, 38(1), 40-45. PMID: PMC2772952.
252. **Finkelstein, E.A.**, Trogdon, J.G, Cohen, J.W., Dietz, W.H. (2009). Annual medical spending attributable to obesity: Payer- and service-specific estimates. *Health Affairs (Millwood)*, 28(5), w822-831.
253. Nonnemaker, J.M., Morgan-Lopez, A.A., Pais, J.M., **Finkelstein, E.A.** (2009). Youth BMI trajectories: Evidence from the NLSY97. *Obesity (Silver Spring)*, 17(6), 1274-1280.
254. Trogdon, J.G., **Finkelstein, E.A.**, Reyes, M., Dietz, W.H. (2009). A return-on-investment simulation model of workplace obesity interventions. *Journal of Occupational Environmental Medicine*, 51(7), 751-758.
255. Armour, B.S., **Finkelstein, E.A.**, Fiebelkorn, I.C. (2009). State-level Medicaid expenditures attributable to smoking. *Preventing Chronic Disease*, 6(3), A84. PMID: PMC2722402.
256. Khavjou, O.A., **Finkelstein, E.A.**, Farris, R.P. & Will, J.C. (2009). Recall of three heart disease risk factor diagnoses among low-income women. *Journal of Women’s Health*, 18(5), 667-675.
257. Brown, D.S, **Finkelstein, E.A.**, Brown, D.R., Buchner, D.M, Johnson, F.R. (2009). Estimating older adults' preferences for walking programs via conjoint analysis. *American Journal of Preventive Medicine*, 36(3), 201-207.
258. McKinnon, R.A., Orleans, C.T., Kumanyika, S.K., Haire-Joshu, D., Krebs-Smith, S.M., **Finkelstein, E.A.**, Thompson, J.W. (2009). Considerations for an obesity policy research agenda. *American Journal of Preventive Medicine*, 36(4), 351-357. PMID: PMC2824162.
259. Honeycutt, A.A., Segel, J.E., Hoerger, T.J., **Finkelstein, E.A.** (2009). Comparing cost-of-illness estimates from alternative approaches: An application to diabetes. *Health Services Research*, 44(1), 303-320. PMID: PMC2669634.
260. Nonnemaker, J. M., **Finkelstein, E.A.**, Engelen, M.A., Hoerger, T. J., Farrelly, M.C. (2009). Have efforts to reduce smoking really contributed to the obesity epidemic? *Economic Inquiry*, 47(2), 366-376
261. **Finkelstein, E.A.**, Brown, D.S. (2008). Return on investment for bariatric surgery. *The American Journal of Managed Care*, 14(9), 561-562.
262. Trogdon, J.G., **Finkelstein, E.A.**, Hoerger, T.J. (2008). Use of econometric models to estimate expenditure shares. *Health Services Research*, 43(4), 1442-1452. PMID: PMC2517274.
263. Trogdon, J.G., **Finkelstein, E.A.**, Hylands, T., Dellea, P.S., Kamal-Bahl, S.J. (2008). Indirect costs of obesity: A review of the current literature. *Obesity Reviews*, 9(5), 489-500.
264. **Finkelstein, E.A.**, Trogdon, J.G., Brown, D.S., Allaire, B.T., Dellea, P.S., Kamal-Bahl, S.J. (2008). The lifetime medical cost burden of overweight and obesity: Implications for obesity prevention. *Obesity (Silver Spring)*, 16(8), 1843-1848.
265. **Finkelstein, E.A.**, Brown, D.S., Brown, D.R., Buchner, D.M. (2008). A randomized study of financial incentives to increase physical activity among sedentary older adults. *Preventive Medicine*, 47(2), 182-187.
266. Allison, D.B., Downey, M., Atkinson, R.L., Billington, C.J., Bray, G.A., Eckel, R.H., **Finkelstein, E.A.**, Jensen, M.D., Tremblay, A. (2008). Obesity as a disease: A white paper on evidence and arguments commissioned by the Council of the Obesity Society. *Obesity (Silver Spring)*, 16(6), 1161-1177.
267. Arterburn, D., Westbrook, E.O., Wiese, C.J., Ludman, E.J., Grossman, D.C., Fishman, P.A., **Finkelstein, E.A.**, Jeffery, R.W., Drewnowski, A. (2008). Insurance coverage and incentives for weight loss among adults with metabolic syndrome. *Obesity(Silver Spring)*, 16(1), 70–76.

268. Brown, D.S., **Finkelstein, E.A.**, Mercy, J.A. (2008). Methods for estimating medical expenditures attributable to intimate partner violence. *Journal of Interpersonal Violence*, 23(12), 1747–1766.
269. **Finkelstein, E.A.**, Trogdon, J.G. (2008). Public health interventions for addressing childhood overweight: Analysis of the business case. *American Journal of Public Health*, 98(3), 411–415. PMID: PMC2253570.
270. **Finkelstein, E.A.**, Brown, D. S., Evans, W.D. (2008). Do obese persons comprehend their personal health risks? *American Journal of Health Behavior*, 32(5), 508–516.
271. Corso, P.S., Mercy, J.A., Simon, T.R., **Finkelstein, E.A.**, Miller, T.R. (2007). Medical costs and productivity losses due to interpersonal and self-directed violence in the United States. *American Journal of Preventive Medicine*, 32(6), 474–482.
272. Farris, R.P., Will, J.C., Khavjou, O.A., **Finkelstein, E.A.**, (2007). Beyond effectiveness: Evaluating the public health impact of the WISEWOMAN program. *American Journal of Public Health*, 97(4), 641–647. PMID: PMC1829343.
273. **Finkelstein, E.A.**, Brown, D.S., Trogdon, J.G., Ben-Joseph, R., Segel, J. E. (2007). Age-specific impact of obesity on disease prevalence and medical costs overall and for precursors to metabolic syndrome. *Value in Health*, 10(S1), S45–S51.
274. **Finkelstein, E.A.**, Chen, H., Prabhu, M., Trogdon, J.G., Corso, P.S. (2007). The relationship between obesity and injuries among U.S. adults. *American Journal of Health Promotion*, 21(5), 460–468.
275. **Finkelstein, E.A.**, Linnan, L.A., Tate, D.F., Birken, B.E. (2007). A pilot study testing the effect of different levels of financial incentives on weight loss among overweight employees. *The Journal of Occupational and Environmental Medicine*, 49(9), 981–989.
276. **Finkelstein, E.A.**, Prabhu, M., Chen, H. (2007). Increased prevalence of falls among elderly individuals with mental health and substance abuse conditions. *American Journal of Geriatric Psychiatry*, 15(7), 611–619.
277. Khavjou, O.A., **Finkelstein, E.A.**, Will, J.C. (2007). The impact of medication use in a multi-component intervention: Results from the WISEWOMAN program. *American Journal of Health Promotion*, 21(4), 267–273.
278. Trogdon, J. G., **Finkelstein, E.A.**, Nwaise, I.A., Tangka, F.K., Orenstein, D. (2007). The economic burden of chronic cardiovascular disease for major insurers. *Health Promotion Practice*, 8(3), 234–242.
279. Will, J.C., Khavjou, O.A., **Finkelstein, E.A.**, Loo, R.K., Gregory, M. K. (2007). One-year changes in glucose and other heart disease risk factors among participants of WISEWOMAN, a patient-centered intervention program for low-income women. *European Diabetes Nursing*, 4(2), 57–63.
280. Corso, P.S., **Finkelstein, E.A.**, Miller, T.R., Fiebelkorn, I.C., Zaloshnja, E. (2006). Incidence and lifetime costs of injuries in the United States. *Injury Prevention*, 12(4), 212–218.
281. Evans, W.D., Renaud, J.M., **Finkelstein, E.A.**, Kamerow, D.B., Brown, D.S. (2006). Changing perceptions of the childhood obesity epidemic. *American Journal of Health Behavior*, 30(2), 167–176.
282. Mobley, L.R., Root, E.D., **Finkelstein, E.A.**, Khavjou, O.A., Farris, R.P., Will, J.C. (2006). Environment, obesity, and cardiovascular disease risk in low-income women. *American Journal of Preventive Medicine*, 30(4), 327–332.
283. **Finkelstein, E.A.**, Brown, D.S. (2006). Why does the private sector under invest in obesity prevention and treatment? *North Carolina Medical Journal*, 67(4), 310–312.
284. **Finkelstein, E.A.**, Khavjou, O.A., Will, J.C. (2006). Cost-effectiveness of WISEWOMAN, a program aimed at reducing heart disease risk among low-income women. *Journal of Women's Health*, 15(4), 379–389.
285. **Finkelstein, E.A.**, Khavjou, O. A., Will, J.C., Farris, R.P., Prabhu, M. (2006). Assessing the ability of cardiovascular disease risk calculators to evaluate effectiveness of trials and interventions. *Expert Review of Pharmacoeconomics & Outcomes Research*, 6(4), 417–424.
286. Stevens, J.A., Corso, P.S., **Finkelstein, E.A.**, Miller, T.R. (2006). The costs of fatal and non-fatal falls among older adults. *Injury Prevention*, 12(5), 290–295. PMID: PMC2563445.
287. **Finkelstein, E.A.**, Ruhm, C.J., Kosa, K.M. (2005). Economic causes and consequences of obesity. *Annual review of Public Health*, 26, 239–257. Palo Alto, CA: Annual Reviews.
288. Evans, W.D., **Finkelstein, E.A.**, Kamerow, D.B., Renaud, J.M. (2005). Public perceptions of childhood obesity. *American Journal of Preventive Medicine*, 28(1), 26–32.

289. **Finkelstein, E.A.**, Brown, D.S. (2005). A cost-benefit simulation model of coverage for bariatric surgery among full-time employees. *The American Journal of Managed Care*, 11(10), 641–646.
290. **Finkelstein, E.A.**, Fiebelkorn, I.C., Wang, G. (2005). The costs of obesity among full-time employees. *American Journal of Health Promotion*, 20(1), 45–51.
291. **Finkelstein, E.A.**, Brown, D.S., Avidor, Y., Takeuchi, A.H. (2005). The role of price, sociodemographic factors, and health in the demand for bariatric surgery. *The American Journal of Managed Care*, 11(10), 630–637.
292. **Finkelstein, E.A.**, Chen, H., Miller, T.R., Corso, P.S., Stevens, J.A. (2005). A comparison of the case-control and case-crossover designs for estimating medical costs of non-fatal fall-related injuries among older Americans. *Medical Care*, 43(11), 1087–1091.
293. **Finkelstein, E.A.**, French, S., Variyam, J.N., Haines, P.S. (2004). Pros and cons of proposed interventions to promote healthy eating. *American journal of preventive medicine*. 27(3), 163-171
294. Corso, P.S., Grosse, S., **Finkelstein, E.A.** (2004). The skinny on COI analysis: Letter to the Editor. *Obesity Research*, 12(7), 1189.
295. **Finkelstein, E.A.**, Fiebelkorn, I.C., Wang, G. (2004). State-level estimates of annual medical expenditures attributable to obesity. *Obesity Research*, 12(1), 18–24.
296. **Finkelstein, E.A.**, Fiebelkorn, I.C., Corso, P. S., Binder, S.C. (2004). Medical expenditures attributable to injuries in the United States, 2000. *Journal of the American Medical Association*, 291, 817–818; *Morbidity and Mortality Weekly Report*. 53(1), 1–4.
297. **Finkelstein, E.A.**, French, S., Variyam, J., Haines, P. (2004). An economic analysis of nutrition interventions to reduce obesity. *American Journal of Preventive Medicine*, 27(3), 163–171.
298. **Finkelstein, E.A.**, Khavjou, O.A., Mobley, L.R., Haney, D.M., Will, J.C., (2004). Racial/ethnic disparities in coronary heart disease risk factors among WISEWOMAN enrollees. *Journal of Women's Health*, 13(5), 503–518.
299. **Finkelstein, E.A.**, Wittenborn, J.S., Farris, R.P. (2004). Evaluation of public health demonstration programs: The effectiveness and cost-effectiveness of WISEWOMAN. *Journal of Women's Health and Gender Based Medicine*, 13(5), 625–633.
300. Max, W., Rice, D.P., **Finkelstein, E.A.**, Bardwell, R.A., Leadbetter, S. (2004). The economic toll of intimate partner violence against women in the United States. *Violence and Victims*, 19(3), 259–272.
301. Mobley, L.R., **Finkelstein, E.A.**, Khavjou, O.A., Will, J.C. (2004). Spatial analysis of body mass index and smoking behavior among WISEWOMAN participants. *Journal of Women's Health*, 13(5), 519–528.
302. Saver, B. G., Ritzwoller, D.P., Maciosek, M., Goodman, M. J., Conrad, D.A., **Finkelstein, E.A.**, Cain, K.C. (2004). Does payment drive procedures? Payment for specialty services and procedure rate variations in three HMOs. *American Journal of Managed Care*, 10(3), 229–237.
303. Will, J.C., Farris, R.P., Sanders, C.G., Stockmyer, C.K., **Finkelstein, E.A.** (2004). Health promotion interventions for financially disadvantaged women: An overview of the WISEWOMAN projects. *Journal of Women's Health*, 13(5), 484–502.
304. **Finkelstein, E.A.**, Bray, J.W., Chen, H., Larson, M.J., Miller, K., Tompkins, C., Manderscheid, R. (2003). Prevalence and costs of major depression among elderly claimants with diabetes. *Diabetes Care*, 26(2), 415–420.
305. **Finkelstein, E.A.**, Corso, P.S. (2003). Cost-of-illness analyses for policy making: A cautionary tale of use and misuse. *Expert Review of Pharmacoeconomics and Outcomes Research*, 3(4), 367–369.
306. **Finkelstein, E.A.**, Fiebelkorn, I.C., Wang, G. (2003). National medical expenditures attributable to overweight and obesity: How much and who's paying? *Health Affairs* (Web exclusive), W3–219–226.
307. **Finkelstein, E.A.**, Kosa, K. M., Brown, D.R. (2003). Use of incentives to motivate health behaviors among employees. *Gender Issues*, 21(3), 50–59.
308. **Finkelstein, E.A.**, Troped, P.J., Will, J.C., Palombo, R. (2002). Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: The Massachusetts WISEWOMAN project. *Journal of Women's Health*, 11(6), 519–526.
309. Hoerger, T. J., **Finkelstein, E.A.**, Bernard, S.L. (2001). Medicare beneficiary satisfaction with durable medical equipment suppliers. *Health Care Financing Review*, 23(1), 123–136.

#### **Publications in Non-Peer Reviewed Outlets:**

1. **Finkelstein, E.A.**, COMPASS Study Team (2021). *End of Life Utilization and Costs and the Role of Palliative Care in Treating Patients with Advanced Cancer*, Lien Centre for Palliative Care Policy Brief 2, November 2021.
2. Ada Alqunaibet, Christopher H. Herbst, Sameh El-Saharty, and Abdullah Algwaizini, **Finkelstein, E.A.** (2021). *Noncommunicable Diseases in Saudi Arabia: Toward Effective Interventions for Prevention*, 41-100, 125-168, World Bank Group, June 2021.
3. Miller, T., **Finkelstein, E.A.**, Zaloshnja, E., Hendrie, D. (2012). The Cost of Child and Adolescent Injuries and The Savings from Prevention, in K. Liller (Ed.), *Injury Prevention for Children and Adolescents: Research, Practice, and Advocacy, Second Edition*, Washington DC: American Public Health Association, 21-81, 2012.
4. **Finkelstein, E.A.**, Yang, H.K. (2011). Obesity and Medical Costs, in *The Oxford Handbook of Social Science of Obesity*, by Cawley J., Oxford University Press, April, 2011.
5. **Finkelstein, E.A.**, Hoerger, T.H. (2010). *Can Fiscal Approaches Help to Reduce Obesity Risk*, in *Obesity Epidemiology From Aetiology to Public Health*, Edited by Crawford D., Jeffery R., Ball K. and Brug J., Oxford University Press, London, November, 2010.
6. IOM (including **Finkelstein, E.A.**). *Local Government Actions to Prevent Childhood Obesity*. Washington, DC: The National Academies Press, 2009.
7. Miller, T., **Finkelstein, E.A.**, Zaloshnja, E., Hendrie, D. (2006). The cost of child and adolescent injuries and the savings from prevention, in K. Liller (Ed.), *Injury prevention for children and adolescents: Research, practice, and advocacy*. Washington, DC: American Public Health Association.
8. **Finkelstein, E.A.**, Bray, J.W., Larson, M. J., Miller, K., Tompkins, C., Keme, A., Manderscheid, R. (2003). Prevalence of and payments for mental health and substance abuse conditions in public and private sector health plans. In R. Manderscheid and M. Henderson (Eds.), *Mental health, United States, 2002*. Washington, DC: U.S. Government Printing Office.

#### **Authored Books:**

1. **Finkelstein, E.A.**, & Zuckerman, L. (2008). *The Fattening of America*. NJ: John Wiley & Sons, Inc.
2. **Finkelstein, E.A.**, Corso, P.S., Miller, T.R. (2006). *The incidence and economic burden of Injuries in the United States*. Oxford University Press.

#### **Editorials, Commentaries, and Interviews:**

1. **Finkelstein, E.A.** (Oct 4, 2022) *Obese and overweight in Singapore cause \$261m in annual medical, absenteeism costs*. Lianhe Zaobao and Yahoo news.
2. **Finkelstein, E.A.** (June 22, 2022) *End-of-Life Care*. CNA website (In Focus).
3. **Finkelstein, E.A.** (Feb 8, 2022) *THE LANCET: Experts warn of the increasing overmedicalisation of death, call for radical rethink of how society cares for people dying*. CNA938 Live Radio Interview (Health Matters programme on CNA938)
4. **Finkelstein, E.A.** (Jan 27, 2022) *Few countries offer a good place to die*. CNA938 Live Radio Interview (Money Mind on CNA938).
5. **Finkelstein, E.A.** and Drishti Baid (May 07, 2021) *COVID-19 unlikely to become a thing of the past anytime soon*. Central News Asia, Singapore Edition.
6. **Finkelstein, E.A.** (Nov 30, 2020) *Healthy food labels that work and don't work*. CNA938 Live Radio Interview (Eat, Drink, Singapore).
7. **Finkelstein, E.A.** Semra Ozdemir and Drishti Baid (Oct 24, 2020) *Covid vaccination and the quest for herd immunity in Singapore*. The Straits Times.
8. **Finkelstein, E.A.** (Oct 17, 2019) *The pros and cons of food labelling for healthy choices*. The Straits Times.
9. **Finkelstein, E.A.** (Nov 13, 2018) *Will fee benchmarks stem S'pore's rising tide of healthcare inflation?* TODAY Online.
10. **Finkelstein, E.A.** (Oct 13, 2018) *Lancet Commission on the Value of Death*.
11. **Finkelstein, E.A.** (July 31, 2018). *When doctors and caregivers do not help patients make the best decisions*. TODAY.

12. **Finkelstein, E.A.** (March 31, 2016). *How much would you pay to extend your life by a year?* The Straits Times.
13. **Finkelstein, E.A.** (November 18, 2013). *Lessons from Obamacare for Singapore.* TODAY.
14. **Finkelstein, E.A.** (April 24, 2013). *A better way to spend on healthcare.* TODAY.
15. **Finkelstein, E.A.** (May 18, 2012). *Don't discard 3M health model.* The Straits Times.

**Presentations** (from 2016 to current, most recent first):

1. **Finkelstein E.A.** (2023 Jan). World Bank MENA Innovation Series: Countdown to 2030: *The challenge of NCDs in Saudi Arabia*, virtual webinar.
2. **Finkelstein E.A.** (2022 Oct). *Palliative Care development in the region (Closer look at Quality of Death and Dying)*; at Mandarin Hospice Summit 2022, virtual webinar.
3. **Finkelstein, E.A.** (2022 Oct). *Scaling-up Low-Cost Solutions To Improve Hypertension Care Globally*; at SGH ASM Symposium 4, Singapore.
4. **Finkelstein, E.A.** (2022 Oct). *Musings on the 'Value of Death'*; at Lien Centre for Palliative Care Conference 2022, Singapore.
5. **Finkelstein, E.A.** (2022 Aug). *Cross Country Comparison of Expert Assessments of the Quality of Death and Dying 2021*; at 7<sup>th</sup> International African Palliative Care Conference, virtual webinar, Uganda.
6. **Finkelstein, E.A.** (2022 Aug). *A Cross Country Comparison of the Quality of Death Dying*; at All India Institute of Medical Science (AIIMS); India
7. **Finkelstein, E.A.** (2022 Aug). *A Cross Country Comparison of the Quality of Death Dying*; at Tohoku University; Tokyo, Japan.
8. **Finkelstein, E.A.** (2022 Aug). *The Burden of Obesity in Singapore: A health economic perspective*; at Obesity Policy Engagement Network in Singapore (OPEN SG), virtual webinar, Singapore
9. **Finkelstein, E.A.** (2022 May). *Measuring Health Preferences of Multiple Stakeholders: Issues & Challenges*; at ISPOR 2022, Washington, USA.
10. **Finkelstein, E.A.** (2022 May). *A Cross-Country Comparison of the Quality of Death and Dying*; at Canadian Society of Palliative care Physician: Advanced Learning in Palliative Care (ALPM) conference, virtual webinar.
11. **Finkelstein, E.A.** (2022 April). *A Cross Country Comparison Expert Assessments of the Quality of Death and Dying, 2021*; at Lien Collaborative CTC Palliative Care Training, virtual webinar
12. **Finkelstein, E.A.** (2022 April). *A Cross Country Comparison Expert Assessments of the Quality of Death and Dying, 2021*; at Cicely Saunders Institute of Palliative Care open seminar series 2022, virtual webinar.
13. **Finkelstein, E.A.** (2022 April). *A Cross Country Comparison of the Quality of Death Dying*; at Singhealth's SDSPCC Research Meeting, Singapore, virtual webinar.
14. **Finkelstein, E.A.** (2022 March). *A Cross Country Comparison of the Quality of Death Dying*; at Weill Cornell Medicine Geriatrics & Palliative Medicine meeting session, USA.
15. **Finkelstein, E.A.** (2022 March). *A Cross Country Comparison of the Quality of Death Dying*; at Rutgers University School of Public Health, USA.
16. **Finkelstein, E.A.** (2022 March). *The Economics of Dying* at British Royal Society of Medicine, The Lancet Commission on the value of death virtual webinar.
17. **Finkelstein, E.A.** (2022 February). *Behavioural Economics as a Tool for Chronic Disease Prevention and Treatment? Theory and Evidence* for Singapore-ETH Centre, virtual webinar.
18. **Finkelstein, E.A.** (2021 December). *Hope, Bias, and Survival Expectations of advanced cancer patients*; at 7th Singapore Palliative Care Conference (SPCC 2021) session: Patient and caregiver perspectives – research and clinical implications, virtual webinar.
19. **Finkelstein, E.A.** (2021 November). *Behavioural Economics as a Tool for Chronic Disease Prevention and Treatment? Theory and Evidence*; at University of Virginia, USA.
20. **Finkelstein, E.A.** (2021 October). *Public preferences for subsidizing moderately life-extending treatments for patients with advanced illnesses*; at SMDM Virtual Annual Meeting, USA
21. **Finkelstein, E.A.** (2021 July). *Behavioural Economics as a Tool for Chronic Disease Prevention and Treatment? Theory and Evidence*; Remote presentation to Brain, Behavior, and Cancer Seminar Series by The Biobehavioral Cancer Control Program at University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, virtual webinar, USA.

22. **Finkelstein, E.A.** (2021 June). *Quality of Death and Dying*; at Jockey Club End-of-Life Community Care (JCECC) Project's International Conference 2021: Community End-of-Life Care: Sustainable Development and New Frontier, virtual webinar, Hong Kong.
23. **Finkelstein, E.A.** (2021 June). *Economics of Obesity*; at Saudi Health Council Seminar Series, virtual webinar, Saudi Arabia
24. **Finkelstein, E.A.** (2021 January). *Budget Impact and Cost Effectiveness of the Multi-Component Hypertension Management Program, COBRA-BPS, in Rural Communities in Bangladesh, Pakistan and Sri Lanka*; at Innovations in Clinical Development South Asia Forum 2021, virtual webinar.
25. **Finkelstein, E.A.** (2021 January). *The Causes and Consequences of Overtreatment at the End-of-Life*, at Palliative Care, Culture & the Clinic Symposium virtual seminar.
26. **Finkelstein, E.A.** (2020 December). *The Association of Self-blame with Treatment Preferences*, from "Learnings from 'Asian Patient Perspectives regarding Oncology Awareness, Care and Health' (APPROACH)", at APHN virtual seminar.
27. **Finkelstein, E.A.** (2020 December). *The Use of Technology and Incentives for NCD Prevention: What does the evidence say?*, at Human Capital in the COVID-19 Era, virtual course by The International Monetary Fund's Middle East Center for Economics and Finance Kuwait & The World Bank.
28. **Finkelstein, E.A.** (2020 November). *Using NUSMart, an Online Experimental Grocery Store, To Improve Diet Quality in Kingdom of Saudi Arabia (KSA)*, at Saudi Arabia Centre for Disease Control (SCDC) virtual meeting.
29. **Finkelstein, E.A.** (2020 October). *The Association of Self-blame with Treatment Preferences & Prognostic awareness and its association with health outcomes*, from "Learnings from 'Asian Patient Perspectives regarding Oncology Awareness, Care and Health' (APPROACH)", at APHN virtual seminar
30. **Finkelstein, E.A.** (2020 October). *Principles of the End-of-Life Care Framework*, at OECD Expert Workshop On End-Of-Life Care, virtual webinar
31. **Finkelstein, E.A.** (2020 September). *The Association of Self-blame with Treatment Preferences*, from "Learnings from 'Asian Patient Perspectives regarding Oncology Awareness, Care and Health' (APPROACH)", at Singapore Duke Global Health Institute Global Health virtual seminar
32. **Finkelstein, E.A.** (2020 September). *Economic Burden of Migraine in Singapore*, at PATHw Regional Roundtable Webinar "Re-imagining Healthy Workplaces In Asia", virtual webinar.
33. **Finkelstein, E.A.** (2020 August). *Healthcare costs at End-of-life*, from "Learnings from the COMPASS cohort study of advanced cancer patients", LCPC virtual webinar.
34. **Finkelstein, E.A.** (2020 July). *A Brief Summary of COMPASS & SHAPE Research Projects*, virtual presentation to Temasek Foundation.
35. **Finkelstein, E.A.** (2019 December). *Hope, Bias, and Survival Expectations and Among Cancer Patients*. Presented at Palliative Care Department, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam.
36. **Finkelstein, E.A.** (2019 December). *Hope, Bias, and Survival Expectations and Among Cancer Patients*. Presented at MOI University, Eldoret, Kenya.
37. **Finkelstein, E.A.** (2019 December). *An Introduction to Health Economics Methods*. Presented at MOI University, Eldoret, Kenya.
38. **Finkelstein, E.A.** (2019 December). *Behavioral Economics as a Tool for Chronic Disease Prevention*. Presented at MOI University, Eldoret, Kenya.
39. **Finkelstein, E.A.** (2019 November). *Global Modeling approaches on the Economic Impact of Obesity and High Impact Interventions. What type of modeling could work for KSA?* Presented at Saudi Health Council/ World Bank Group Obesity Week, Riyadh, Saudi Arabia.
40. **Finkelstein, E.A.** (2019 November). *A Brief Introduction to Cost Effectiveness of Interventions: Relative Effectiveness, Economics of Treatment*. Presented at Saudi Health Council/ World Bank Group Obesity Week, Riyadh, Saudi Arabia.
41. **Finkelstein, E.A.** (2019 November). *Beyond cost-effectiveness: A five-step framework for appraising the value of health technologies*. Presented at J&J SMU Hospital Management Programme 2019, Singapore.
42. **Finkelstein, E.A.** (2019 October). *Hope, Bias and Survival Expectations of Advanced Cancer Patients*. Presented at Brown Bag Seminar at University of Georgia, Atlanta, USA.
43. **Finkelstein, E.A.** (2019 October). *Economic and Psychological Nudges to Improve Diet Quality: What Can Policy Makers Learn From Observational and Experimental Studies?* Presented at University of

South Carolina, Columbia, USA.

44. **Finkelstein, E.A.** (2019 October). *Hope, Bias and Survival Expectations of Advanced Cancer Patients in Singapore*. Presented at 14th Singapore Public Health & Occupational Medicine (PHOM), Singapore.
45. **Finkelstein, E.A.** Doble, B.M. (2019 October). *Overview of Lancet Commission on "Value of Death"*. Presented at Lien Centre for Palliative Care's 10th Year Anniversary Conference, Singapore.
46. **Finkelstein, E.A.** (2019 October). *Results from "COMPASS: Costs and Medical Care of Patients with Advanced Serious Illness in Singapore" Study*. Presented at Lien Centre for Palliative Care's 10th Year Anniversary Conference, Singapore.
47. **Finkelstein, E.A.** (2019 October). *Cognitive Biases and Disentangling Hope from Beliefs about Prognosis and Findings from "COMPASS: Costs and Medical Care of Patients with Advanced Serious Illness in Singapore" and "SHAPE: Survival Expectations and Hope Among Cancer Patients at End-of-Life" on Prognosis*. Presented at Lien Centre for Palliative Care's 10th Year Anniversary Conference, Duke-NUS Medical School, Singapore.
48. **Finkelstein, E.A.** (2019 October). *Moving from Quality to Value: How Do We Get There?*. Presented at HSRI Research Forum Oct 2019, Duke-NUS Medical School, Singapore.
49. **Finkelstein, E.A.** (2019 September). *Using Observational and Experimental Research to Improve Diet Quality*. Presented at Columbia University, Mailman School of Public Health, New York, USA.
50. **Finkelstein, E.A.** (2019 September). *Using Observational and Experimental Research to Improve Diet Quality*. Presented at London School of Health and Tropical Medicine, London, United Kingdom.
51. **Finkelstein, E.A.** (2019 September). *Prognostic Beliefs among Patients with Advanced Cancer*. Presented at Cicely Saunders Institute, Kings College London, United Kingdom.
52. **Finkelstein, E.A.** (2019 August). *What is value in quality improvement?* Presented at National Palliative Care QI Conference, Singapore.
53. **Finkelstein, E.A.** (2019 August). *Heart failure patients' stated preference for aggressive end-of-life care: Does it change over time?* Presented at APHC 2019, Surabaya, Indonesia.
54. **Finkelstein, E.A.** (2019 July). *Randomized Controlled Trial Evaluating the Effect of Implicit and Explicit Taxes on the Purchasing of 'High-in Calories' Products*. Presented at iHEA World Congress, Basel, Switzerland.
55. **Finkelstein, E.A.** (2019 June). *A Randomized Controlled Trial Evaluating the Relative Effectiveness of Two Front-of-Pack Nutrition Labels*. Presented at ISBNPA Conference, Prague, Czech Republic.
56. **Finkelstein, E.A.** (2019 June). *Randomized Controlled Trial Evaluating the Effect of Implicit & Explicit Taxes on the Purchasing of 'High-In-Calorie' Products (IMPEX)*. Presented at ISBNPA Conference, Prague, Czech Republic.
57. **Finkelstein, E.A.** (2019 May). *Why Good Deaths Are Hard To Find*. Presented at University of Pennsylvania, Pennsylvania, USA.
58. **Finkelstein, E.A.** (2019 May). *Disentangling Hope from Beliefs about Prognosis Among Advanced Cancer Patients in Singapore*. Poster presented at EAPC Conference, Berlin, Germany.
59. **Finkelstein, E.A.** (2019, April) *Value-Based Care in an Academic Institution (Beyond Quality to Value)*, Presented at SGH 23rd Annual Scientific Meeting, Singapore.
60. **Finkelstein, E.A.** (2019, April) *Randomized Control Trial Evaluating the Effects of the Implicit Taxes on the Purchasing of the High-Calories' Products*, Presented at SGH 23rd Annual Scientific Meeting, Singapore.
61. **Finkelstein, E.A.** (2019, April) *Using the NUSMart Web-Based Grocery Store to Improve Diet Quality Among Singaporean*, Presented at NMRC Awards Ceremony and Research Symposium 2019, Singapore.
62. **Finkelstein, E.A.** (2019, March) *Using Observational and Experimental Studies to Improve Diet Quality: A Research Agenda*, Presented at Duke Global Health Institute, Durham, North Carolina.
63. **Finkelstein, E.A.** (2018 December) *5 Steps to Develop a Value Proposition for a New Health Innovation*, Presented at ETH, Zurich, Switzerland.
64. **Finkelstein, E.A.** (2018 December) *Female Community Health Volunteer Led Lifestyle Intervention is a Highly Cost-Effective, Low-Cost and Scalable Solution for Blood Pressure Control in Nepal*, Lifestyle 2019 Scientific Session, Katmandu, Nepal.
65. **Finkelstein, E.A.** (2018 December). *Building the Business Case for Health Innovations: Examples and Best Practices*. Presented at Medtronic Asia Pacific Health Economics and Reimbursement Summit, Singapore.
66. **Finkelstein, E.A.** (2018 December). *Why Good Deaths Are Hard To Find*. Presented at Cipto

Mangunkusumo Hospital RSCM, Jakarta, Indonesia.

67. **Finkelstein, E.A.** (November 2018). *Key Consideration in Health Technology Assessment*. Presented at Asia Pacific Health Technology Assessment Workshop Stand-Alone Scientific Symposium, Singapore.
68. **Finkelstein, E.A.** (2018 October). *The cost of medicalised Death*. Presented at the Value of Death meeting Lancet Commission, Bristol, UK.
69. **Finkelstein, E.A.** (2018 October). *Why Good Deaths Are Hard To Find*. Presented at the National Library Singapore for Singapore Hospice Council.
70. **Finkelstein, E.A.** (2018 October). *Six Month Results of a Randomized Controlled Trial of an Incentive-based Physical Activity Program Targeting Both Children and Adults (FIT-FAM)*. Presented at the 13<sup>th</sup> Singapore Public Health & Occupational Medicine Conference in Singapore.
71. **Finkelstein, E.A.** (2018 September). *On Value Based Health Care Delivery and Pricing*. Presented at the Hospital Management Asia 2018 Conference, Bangkok, Thailand.
72. **Finkelstein, E.A.** (2018 September). *HTA Success stories from Singapore: Maximizing the value of Health services Research*. Presented at the Health Intervention and Technology Assessment Program (HITAP), Bangkok, Thailand.
73. **Finkelstein, E.A.** (2018 September). *Behavioural Economics as a Tool for Chronic Disease Prevention: Theory and Evidence*. Presented at the Health Intervention and Technology Assessment Program (HITAP), Bangkok, Thailand.
74. **Finkelstein, E.A.** (2018 June). *Health Technology Assessment and Pharmacoeconomics*, Presented at Centro Hospitalar Conde de S. Januário (CHCSJ), Macau.
75. **Finkelstein, E.A.** (2018 June). *A Single-arm Feasibility Study of GlycoLeap, a Mobile Lifestyle Management Program for People with Type 2 Diabetes*. (Poster) Presented at the 17<sup>th</sup> International Society of Behavioral Nutrition and Physical Activity (ISBNPA 2018) Annual Meeting in Hong Kong.
76. **Finkelstein, E.A.** (2018 June). *Encouraging Healthy Nutrition in Purchases in an Online Grocery Setting using Experimental Economics (NUSMart)*. (Poster) Presented at the 17<sup>th</sup> International Society of Behavioral Nutrition and Physical Activity (ISBNPA 2018) Annual Meeting in Hong Kong.
77. **Finkelstein, E.A.** (2018 June). *Randomized Controlled Trial of an Incentive-based Physical Activity Program targeting both Children and Adults (FIT-FAM)*. (Poster) Presented at the 17<sup>th</sup> International Society of Behavioral Nutrition and Physical Activity (ISBNPA 2018) Annual Meeting in Hong Kong.
78. **Finkelstein, E.A.** (2018 March). *Economic causes and consequences of health behaviors*. Presented at the Tianfu International Clinical Nutrition Conference, Chengdu, China.
79. **Finkelstein, E.A.** (2018 March). *Behavioral Economics as a Tool for Chronic Disease Prevention: Theory and Evidence*. Presented at Department of Population Health Science and Policy Grand Rounds, Icahn School of Medicine at Mount Sinai, New York, USA.
80. **Finkelstein, E.A.** (2018 February). *Behavioural Economics and Biases in Decision Making: Ethical Considerations and Practical Recommendations*. Presented at the 25th Annual Conference of Indian Association of Palliative Care (IAPCON 2018) in New Delhi, India.
81. **Finkelstein, E.A.** (2018 February). *Prognostic awareness and expected survival among advanced cancer patients in Singapore: Results from COMPASS Cohort Study*. Presented at the 25th Annual Conference of Indian Association of Palliative Care (IAPCON 2018) in New Delhi, India.
82. **Finkelstein, E.A.** (2018 January). *Exploring the Complicated Decisions around End of Life Care: Research at the Lien Centre for Palliative Care, Singapore*. Presented at the Singapore Hospice Council/Lien Centre for Palliative Care Multi-disciplinary Forum in Singapore.
83. **Finkelstein, E.A.** (2017 November). *Nudges for Chronic Disease Prevention*. Presented at the Future Trends Forum in Taipei, Taiwan.
84. **Finkelstein, E.A.** (2017 October). *Nudges for Weight Management*. Presented at The Obesity, Bariatric and Endocrine Societies (OBES) Symposium 2017 in Singapore.
85. **Finkelstein, E.A.** (2017 October). *Using Behavioral Economics to Transform Measurement Tools into Intervention Tools*. Presented at Duke Kunshan Conference on Digital Health Science and Innovation: Partnerships between Academia and Industry in Kunshan, Jiangsu Province, China.
86. **Finkelstein, E.A.** (2017 October). *Exploring the Complicated Decisions around End of Life Care: Research at the Lien Centre for Palliative Care, Singapore*. Presented at Cicely Saunders Institute, Department of Palliative Care, Policy and Rehabilitation London, United Kingdom
87. **Finkelstein, E.A.** (2017 September). *Applying Behavioral Economic Principles to Design Health Interventions*. Presented at 6<sup>th</sup> Asia Pacific Primary Care Research Conference (APPCRC), Singapore.



88. **Finkelstein, E.A.** (2017 September). *Nudges For Healthy Living*. Presented at 6<sup>th</sup> Asia Pacific Primary Care Research Conference (APPCRC), Singapore.
89. **Finkelstein, E.A.** (2017 September). *Developing a Value Message for Health Care Innovation*. Presented at Apollo Endosurgery Inc., Austin, Texas, USA.
90. **Finkelstein, E.A.** (2017 September). *Exploring the Complicated Decisions around End of Life Care*. Presented at University of Tennessee in Memphis, USA.
91. **Finkelstein, E.A.** (2017 September). *Behavioral Economics as a Tool for Chronic Disease Prevention: Theory & Evidence*. Presented at University of Tennessee in Memphis, USA.
92. **Finkelstein, E.A.** (2017 September). *An Introduction to Research and Education at the Duke-NUS Lien Centre for Palliative Care*. Presented at Duke University in Durham, USA.
93. **Finkelstein, E.A.** (2017 September). *RWE in best practice – What Types of Evidence for what purpose. Building a Business Case for Healthcare Innovations using RWE*. Presented at APAC Real World Data Summit, Bangkok.
94. **Finkelstein, E.A.** (2017 September). *The Emergence of RWE and Harnessing it to Support Value-Based Models*. Presented at APAC Real World Data Summit 2017, Bangkok.
95. **Finkelstein, E.A.** (2017 July). *The Value of Integration - A Health Service Perspective: The Differential Costs of Living and Dying: Embracing Multiple Perspectives*. Presented at 12<sup>th</sup> Asia Pacific Hospice Conference (APHC 2017) – Greater Than the Sum of Its Parts, Singapore.
96. **Finkelstein, E.A.** (2017 July). *Revolutions in the Economics of Health Systems: Understanding Factors That Influence the Demand for Marginally Life Extending Treatments: The Case of Dialysis Among Elderly Singaporeans*. Presented at 12th World Congress of the International Health Economics Association, Boston, USA.
97. **Finkelstein, E.A.** (2017 April). *Health Technology Assessment (HTA): Budget Impact Analysis in National Essential Drug List Selection*. Presented at 6th HTAsia link MOH Workshop in Hanoi, Viet Nam.
98. **Finkelstein, E.A.** (2017 April). *New Device Interventions & Health Technology Assessment: Predicted Patient Demand for a New Delivery System for Glaucoma Medicine*. Presented at SGH 22nd Annual Scientific Meeting, Singapore.
99. **Finkelstein, E.A.** (2017 March). *Affordable Cancer Care in Asia: Funding spotlight - Access to palliative care*. Presented at War on Cancer session 2017 by *The Economist*, Singapore.
100. **Finkelstein, E.A.** (2017 March). *Stated Uptake of Incentive-Based Physical Activity Rewards Programmes Among Active and Insufficiently Active Full Time Employees*. Presented at NMRC Awards Ceremony and Research Symposium 2017, Singapore.
101. **Finkelstein, E.A.** (2016 December). *How can health care systems better support families, care-givers and community members in caring for people of all ages for who death is near?* Presented at Salzburg Global Seminar Session 562 Rethinking Care toward the End of Life in Salzburg, Austria.
102. **Finkelstein, E.A.** (2016 November). *Behavioral Economics – Evidence for Chronic Disease Prevention?* Presented at 6<sup>th</sup> ISPAH Congress in Bangkok, Thailand.
103. **Finkelstein, E.A.** (2016 October). *Comparing Health Systems*. Presented at 9th Healthcare Policy and Governance Programme in Singapore.
104. **Finkelstein, E.A.** (2016 October). *Impact of treatment subsidies and cash payouts on treatment choices at the end of life*. Presented at 21<sup>st</sup> International Congress on Palliative Care in Montreal, Canada.
105. **Finkelstein, E.A.** (2016 September). *Applications in Behavioural Economics to Reduce Risk Factors for Chronic Diseases*. Presented at Singapore International Public Health Conference in Singapore.
106. **Finkelstein, E.A.** (2016 September). *Success Stories of Health Economics in Singapore*. Presented at Singapore International Public Health Conference in Singapore.
107. **Finkelstein, E.A.** (2016 September). *Old Habits Die Hard - Behavioural Economics to the Rescue*. Presented at Singapore Health & Biomedical Congress in Singapore.
108. **Finkelstein, E.A.** (2016 September). *Using Behavioral Economics to Improve Diabetes Prevention and Treatment*. Presented at Singhealth Duke-NUS Scientific Congress 2016 in Singapore.
109. **Finkelstein, E.A.** (2016 September). *Incremental Cost-Effectiveness of Algorithm-Driven Genetic Testing versus No Testing for Maturity Onset Diabetes of the Young (MODY) in Singapore*. Presented at ISPOR 7<sup>th</sup> Asia-Pacific Conference in Singapore.
110. **Finkelstein, E.A.** (2016 August). *Cost-Utility of Sevelamer vs. Calcium Carbonate for Treatment of Hyperphosphatemia among Pre-Dialysis CKD Patients*. Presented at Sanofi-Aventis lecture in

Singapore.

111. **Finkelstein, E.A.** (2016 August). *Economic aspects of providing cancer care in a public health system in Singapore*. Presented at National Cancer Centre COE program in Singapore.
112. **Finkelstein, E.A.** (2016 June). *Introduction to Behavioural Economics and Use of Incentives for Chronic Disease Prevention and Treatment*. Presented at Moi University Hospital Grand Rounds in Eldoret, Kenya.
113. **Finkelstein, E.A.** (2016 June). *Making the Business Case for Health Innovations*. Presented at Moi University Hospital Grand Rounds in Eldoret, Kenya.
114. **Finkelstein, E.A.** (2016 May). *Applying health economics in Asia*. Presented at FT Asia Healthcare & Life Sciences Summit Forging Frontiers for Pharmaceuticals in Singapore.
115. **Finkelstein, E.A.** (2016 February). *Success stories of local cost-effectiveness analyses*. Presented at NMRC Awards Ceremony and Research Symposium 2016 in Singapore.
116. **Finkelstein, E.A.** (2016 January). *Impact of treatment subsidies and cash payouts on treatment choices at the end of life*. Presented at SMDM 2<sup>nd</sup> Biennial Asia-Pacific Conference in Hong Kong.

**Professional Awards and Special Recognitions:**

1. Recognized among the Top 2% of Scientists Worldwide in a study by Stanford University, 2021
2. SingHealth Duke-NUS Research Team Award, 2020
3. Dean's Excellence Awards (DEA) 2019 in Research, Duke-NUS Medical School
4. Included in list of World's Most Highly Cited Researchers in 2015, 2016, 2017 and 2018 by Thomson Reuters and Clarivate Analytics
5. One of the Most Highly Cited Articles in Journal of Health Economics from 2013 to 2016
6. *Health Affairs* most read paper 2009
7. Successfully commercialize an Obesity Cost Calculator, which generated over \$400K USD in revenue
8. RTI Highly Published Author Award, 2007
9. RTI Early Career Author Award, 2006
10. RTI Highly Published Author Award, 2006
11. Nominee (with Phaedra Corso and Ted Miller), Society for Advancement of Violence and Injury Research (SAVIR), Research! America's Garfield Award for Public Health Impact for *The Incidence and Economic Burden of Injuries in the United States*, 2006
12. RTI Outstanding Paper Award, 2005
13. RTI Highly Published Author Award, 2005
14. RTI Outstanding Paper Award, 2004
15. Langton Award for Outstanding Undergraduate Teaching, 1998
16. Fellow, Agency for Health Care Policy and Research, 1997 to 1999
17. Special Contribution Award, Department of Veterans Affairs, 1996

**Organizations and Participation: (Offices held, committee assignments, etc.):**

1. Expert Consultant, Singapore Translational Cancer Consortium (STCC) Health Technology Assessment (HTA) panel (1 October 2022 to 30 September 2025)
2. Member, National Strategy for Palliative Care (NSPC) Review Workgroup (18 May 2022 to 30 June 2023).
3. Public Health Advisor, Governance Committee of the National Epidemiology, Prognostication and Health Related Impact of CKD (NEPHRIC) Consortium (1 January 2022 to 31 December 2024).
4. Scientist, KK Women's and Children's Hospital (1 March 2021 to 28 February 2023)
5. SingHealth Family Medicine Academic Clinical Programme Research Expert Advisory Panel (October 2020 to September 2023).
6. Duke-NUS Conflict of Interest Management Committee Member (COIMC) (1 April 2020 to 31 March 2023)
7. Health Services & Systems Research (HSSR) Faculty Appointments and Promotion Committee Member (2020)

8. FY2020 TDF & MOH-ISS Research Interview Panel (13 September 2019)
9. Research Scientist, National Heart Centre Singapore (1 April 2019 to 31 March 2025)
10. Committee Member of the Lancet Commission on Global Hearing Loss (2019- present)
11. Committee Member of the Lancet Commission on the Value of Death (2019- present)
12. Invited Member, 3<sup>rd</sup> Subcommittee for the National Advisory Committee on Cancer (NACC) (2019-present)
13. Ex-Officio Member, Health Services Research Institute Management Committee (HSRIMC), (1 April 2018 to 31 March 2021)
14. SingHealth Advisory Member for Enhancing Innovation Committee (01 Dec. 2018 to present)
15. Duke-NUS Centre of Regulatory Excellence (CoRE) Internal Appointments and Promotions Committee (APC), (15 Nov 2017 to 14 Oct 2019)
16. Singapore Population Health Improvement Centre (SPHERiC), Scientific & Knowledge Translation Committee (SKTC), (1 Aug 2017 to 1 Aug 2021)
17. Ministry of Health Disease Management Workgroup, Diabetes Prevention and Care Taskforce, (19 July 2016 to present)
18. Ministry of Health Disease Management Workgroup, Cancer Prevention and Care Taskforce, (19 July 2016 to 12 June 2019) Singapore Ministry of Health
19. NUS Initiative to Improve Health in Asia (NIHA) Management Committee, (2016 to present)
20. Duke-NUS CORE Internal Appointments and Promotions Committee (APC), (2015)
21. 1st International Public Health Conference in conjunction with the 7<sup>th</sup> Public Health & Occupational Medicine Conference in (2012)
22. Singapore Hospice Council, (2012 – present)
23. Invited Member to Technical Consultation on Identifying Approaches to Control Obesity, World Health Organization, Melbourne, Australia (11-13 April 2011)
24. Invited member, Regional High-Level Meeting on Scaling up Multi-sectoral Actions for Non-communicable Disease Prevention and Control, World Health Organization, Seoul Republic of Korea (17-18 March 2011)
25. 5<sup>th</sup> Singapore Public Health & Occupational Medicine Conference, (2010)
26. ISPOR Singapore (2010 – present)
27. Graduate School Program Committee, Duke-NUS Graduate Medical School, (2010 – present)
28. Medical Student Program Committee, Duke-NUS Graduate Medical School, (2010 – present)
29. Institute of Medicine's Committee on Childhood Obesity Prevention Actions for Local Governments, (2009)

a. Reviewer

1. Singapore Ministry of Health (MOH) New Investigator Grant Review Panel (2021)
2. Ageing and Palliative Care for Temasek Foundation Innovates CLG Limited, (2017-2020)
3. UK Medical Research Council Peer Reviewer, August, 2018.
4. ARF Tier 2 Ministry of Education Grants Review - T24-1901-P06 - *Explaining the rise in healthcare expenditures: Evidence from Singapore*, (2018)
5. National Medical Research Council (NMRC) Health Services Research New Investigator Grant application – *“Understanding factors associated with returning to work after a diagnosis of a chronic disease and/or onset of a disability in Singapore”* (2017)
6. Health Services Research Institute's (HSRI) Health Services Research and Analytics Technologies for SingHealth (HEARTS) Review Committee, (FY17/18)
7. The National Medical Research Council Local Review Panel (LRP) for the Health Services Research New Investigator Grant (HSR NIG) Scheme, (2013 – 2014)
8. National Center for Injury Prevention and Control, Initial Review Group, (2008)
9. NIH Community Influences on Health Behaviors study section, (2007-2008)
10. NIH Special Emphasis Panel (Social Science and Population Studies), (June 2006)
11. National Science Foundation (2007)

b. Scientific Advisory Board Membership

1. Lifestyle Medicine Economic Research Consortium, (2018 to present)
2. Council of Directors of the True Health Coalition, GLIMMER Initiative
3. Farewell LLC, (2017)

4. Weight Watchers International Inc. (now WW), (2015 to 2022)
  5. Virgin Pulse, (2015 to 31 December 2016)
  6. Curves International Holdings Inc. and Jenny Craig Inc., (1 June 2014 to 31 January 2015)
- c. Editorial Boards
1. Health Psychology, (2010 – 2015)
  2. American Journal of Preventive Medicine, (2009 – 2016)
  3. American Journal of Health Promotion, (2012 to 2015)
  4. Guest Editor for a Special Issue on Behavioral Economic in Health for the journal Health Psychology, (2012)

**Previous and Current Teaching and Mentoring Responsibilities:**

- a. Academic Teaching at National University of Singapore – Lead Instructor
1. Health Economics (one semester annually beginning in 2010)
  2. Health Technology Assessment (one semester annually beginning in 2017)
- b. Short courses:
1. 3 Day Duke-NUS Executive Education Course Offering: 'Building the Business Case for Health Innovations' (Annually since 2014) – Course developer and Lead Facilitator
  2. Virtual 2 day Leadership Course on Health Economics at Singapore Management University (January 2022)
  3. Virtual 3-day workshop on Health Technology Assessment for Singapore-ETH Centre (20, 21, 27 Oct 2021)
  4. Virtual 1 day Leadership Course on Health Technology Assessment at Singapore Management University (19 May 2021)
  5. Co-led a 5 day Leadership Development Programme to regional health policy makers entitled Fostering Effective Health Systems Leadership in an Interconnected World, 3 to 8 December, 2017
  6. Modelling Obesity and Economics at University of Alabama, Birmingham in Birmingham, USA (14 May 2014)
  7. 4 hour course on Cost-Effectiveness Analysis at Xi'an Jiaotong University in Xi'an, China (21 May 2012)
  8. 20 hour course on Comparative Structure and Finance of Health Systems in the Duke-PKU Global Health Certificate Program at Peking University in Beijing, China (13-17 June 2011, 4-8 June, 2012)
- c. Mentoring Roles

Ph.D. students:

1. Hendra, NUS Faculty of Dentistry, Member of Research Thesis Committee (2022 to present)
2. Felicia Ang Jia Ler, Duke-NUS Medical School IBM. Program, Primary Supervisor (2019 to present – Primary Advisor)
3. Jamie Jay-May Lo, Saw Swee Hock School of Public Health. Member of Thesis Advisory Committee (TAC). (2020 to present)
4. Chong Jia Loon, Duke-NUS Medical School, Singapore. Member of Thesis Advisory Committee (2016-2020)
5. Kang Wan Chen, Duke-NUS Medical School, Singapore. Member of Thesis Advisory Committee (2015-2019)
6. Tan Pui San, Duke-NUS Medical School, Singapore. Member of Thesis Advisory Committee (2015-2016)
7. Dong Di, Duke-NUS Medical School, Singapore. Primary dissertation adviser (2010-2015 – Primary Advisor). *Di won the best dissertation in Social Sciences award*
8. Yanyi Guan, Saw Swee Hock School of Public Health. Member of Thesis Advisory Committee (TAC). (2014)

- Jiang Li, University of North Carolina. Member of Thesis Advisory Committee. (2009-2013)

Duke-NUS and Duke University Medical students (2011-present):

- Parth Chodavadia (Duke University, 2022)
- Kathy Dai (Duke University, 2022)
- Sophia Reyes (2021)
- Celestine Loh Jia Ling (2020)
- Koh Ling En (2019)
- Jeselin Putri Andono (2019)
- Ng Guan Yee (Co-mentor, 2018))
- Tan Gui Fang, Edlyn (Co-mentor, 2016)
- Chia May Fen, Yvonne (Co-mentor, 2016)
- Wu Hong King (2015)
- Andalib Hossain (2014)
- Chen Pin Yu, Petty (Co-Mentor, 2014)
- Wang Hao (Co-Mentor, 2012)
- Hsuan Lai (Co-Mentor, 2011)
- Connie Boh (Co-mentor, 2011)
- Saideep Bose (2010)
- Tim Khoo (Duke University, 2010)

Duke-Global Health Institute Masters students:

- Danni Zhao (2017)
- Jiayang Hong (2017)
- Junjian Gaoshan (2014)
- Weixi Jiang (2014)
- Junyang Wang (2014)
- Shu Chen\* (2014)

NUS SSHSPH:

- Irene Ooi (2020) (received Dean's medal for best practicum)
- Low Ying Liang (2019)
- Geraldine John (2014)

**Areas of research interests:** health economics, healthcare financing, behavioral economics, obesity, conjoint analysis.

**Summary of Research Support as Principal Investigator at Duke-NUS:**

Year	External funding as Principal Investigator at Duke-NUS (SGD)
2009	93,262
2010	-
2011	339,700
2012	1,299,400
2013	343,248
2014	11,270,976
2015	2,246,606
2016	1,062,604
2017	2,698,155
2018	601,668
2019	11,039,045
2020	1,099,222
2021	387,340
2022	0

<b>TOTAL</b>	<b>32,481,226</b>
--------------	-------------------

**Pending Research Grants:**

1. **(NMRC/PHRG Open Category)** SGD \$498,462 2.5 years  
**Estimating Market Demand, Cost Effectiveness and Budget Impact of a National Lung Cancer Screening Program in Singapore**

Professional groups in Singapore have recommended standardized lung cancer screening guidelines and government subvention of low-dose computed tomography (LDCT), noting that international studies have shown LDCT to be cost-effective for select high-risk groups on some countries. However, whether LDCT screening would be cost-effective for high-risk groups in Singapore, and the costs to government resulting from subsidies of a given magnitude, remain an open question. The goal of this study is to address these questions. Specifically, we propose the following two aims: (1) Using a mixed methods approach, estimate the demand for LCDT as a function of individual risk characteristics and program features, as well as estimate the extent uptake can be improved through targeted messaging and other policies. (2) Using a microsimulation model that incorporates the risk profiles of those who opt to screen, quantify the cost-effectiveness and budget impact of candidate screening strategies.

Role: Principal Investigator

2. **(HSS Seed Fund)** SGD \$40,000 1.0 years  
**A Best Worst Scaling Exercise to Determine What Recent Medical Graduates Consider as the Most Important Attributes of a High-Quality Medical Education**

The aim of this study is to develop a preference-based algorithm to help prospective students identify which medical school is most closely aligned with their preferences. We will first develop and refine a list of candidate attributes from perusing the existing published rankings and via a review of peer reviewed and grey literature using appropriate databases. In-depth qualitative interviews will then be conducted with students and faculty members to refine and generate a long list of candidate attributes. Using candidate attributes, we will develop and pilot test the Decision Support Tool using an adaptive Case 2 Best-Worst-Scaling (BWS) approach.

Role: Principal Investigator

3. **Grant: PHRG** 2.25 years  
**Singapore Ministry of Health (MOH NMRC)**  
**Total value awarded: SGD \$836,863.30**

***Randomized Trials to Evaluate Promising Front-Of-Pack Labels to Improve Diet Quality***

This effort proposes two studies to improve diet quality. In collaboration with the Health Promotion Board (HPB), a Singapore government organization committed to promoting healthy living in Singapore, the first study aims to explore optimal implementation of the upcoming Nutri-Grade labels for beverages that Singapore plans to launch in December 2022. The second study aims to explore whether overall diet quality can be further improved via personalized nutrition labels that are 1) tailored to consumer preferences and 2) applicable to both foods and beverages. This type of 'precision public health' is in direct response to the grant call that aims to 'shift away from broad-based interventions to interventions that are tailored to maximize impact.

Role: Principal Investigator

**Current Research Support as PI or Site PI (by year of award):**

**2020**

1. **Grant: 2021-ETH-0001-EF** 01/03/2020 – 28/02/2025  
**ETH Singapore SEC Ltd**

**Total Value Awarded: SGD \$352,175**

***Future Health Technologies (FHT): Module 4: Health Data Governance and Value Creation***

Health Technology Assessments (HTAs) seek to understand the value proposition for the different technologies developed in the other modules of this programme. The objectives of this project are: (1) to advise FHT Modules 1 to 3 in a consulting capacity on which types of HTA analyses are most appropriate given the goals of the technology and on when these analyses should be conducted in the product life-cycle; and (2) to take the lead role in performing the agreed upon analyses with significant input from the Module leads.

Role: Duke-NUS Principal Investigator

## 2019

1. **Grant: H-614-12-000011** 01/10/2019 – 30/09/2025

**Lien Foundation, SingHealth Foundation, and National Cancer Centre Singapore**

**Total Value Awarded:** SGD \$9,750,000

*The Lien Foundation, SingHealth Foundation, and National Cancer Centre Singapore* have provided funding to support a Centre of Excellence in Palliative Care housed within the Duke-NUS Medical School. The Lien Centre for Palliative Care (LCPC) mission focuses on developing and delivering traditional and blended learning palliative care education programs targeted physicians and allied health professionals, initiating and incubating high value research projects, and engaging with key stakeholders in Singapore and the region in efforts to enhance the end of life experience for patients and caregivers. This funding supports Phase 3 of LCPC for 6 years.

Role: Principal Investigator

2. **Grant: MOH-000263 (MOH-HSRGHP18may-0002)** 01/08/2019 – 31/01/2024

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$549,730

***Using the Multiphase Optimization Strategy to Improve Diet Quality (MOSTDQ)***

This study proposes to apply the Multiphase Optimization Strategy (MOST) framework and our fully functional web-based grocery store (NUSMart), containing over 4,000 products, to design a multicomponent intervention aimed to cost effectively improve diet quality (Aim 1). We will then conduct a 2-arm randomized controlled trial to test whether the assembled multicomponent intervention has a sustained positive effect on diet quality over repeated purchases (Aim 2).

Role: Principal Investigator

3. **Grant: NIHA-2018-002** 01/02/2019 – 31/08/2023

**NUS-Global Asia Institute NIHA Research Grant**

**Total Value Awarded:** SGD \$249,980

***Randomized Trials of Low-Cost Behavioral Economic (BE) Strategies to Address Rising Rates of Chronic Disease (TEH-C and DINE)***

The focus of this application is to conduct two randomized controlled BE trials, one focusing on physical activity (PA) and the other on food purchasing. TEH-C tests a novel hedonic rewards strategy for increasing PA that behavioral economic theory posits may work better than cash. DINE explores the effect of real-time feedback and injunctive norm-based messaging with and without financial incentives to encourage the purchase of healthy foods in an online grocery store setting. Each strategy is low cost and highly scalable with the potential for a significant public health impact in Singapore and the region if successful.

Role: Principal Investigator

## 2018

1. **Grant: 1R01DK115939-01A1** (PI: Herring) 01/09/2018 – 30/06/2023

**National Institute of Diabetes and Digestive and Kidney Diseases**

**Total Direct Costs:** USD \$485,849 (\$34,888 Duke-U. subcontract)

***Partnering with WIC to prevent excessive weight gain in pregnancy***

We propose a pragmatic trial design in which we will intervene during pregnancy in Urban (Philadelphia) and rural (Durham) WIC clinics, using WIC resources. The proposed project will constitute the first translation of a comprehensive antenatal obesity treatment program focused exclusively on low-income, ethnic minority mother, using strengths of mHealth and WIC provider counselling for intervention delivery

Role: Co-Investigator

## 2017

1. **Grant: NMRC/HSRG/0079/2017** 12/10/2017 – 30/06/2023

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$1,631,294.20

***A Randomized Trial to Slow the Progression of Diabetes (The TRIPOD study)***

We will conduct a three arm randomized controlled trial to test whether a low cost mobile diabetes

management application (DMAPP), with or without an incentive program (INCENT), can improve blood sugar levels at 12 months as measured by HbA1c levels (primary) among those with type 2 diabetes. We hypothesize that DMAPP will improve HbA1c relative to control but that the greatest improvements will occur for those exposed to both interventions (DMAPP+INCENT). Similar hypotheses will be tested for secondary outcomes, including proportion of participants progressing to treatment with insulin, weight, blood pressure, physical activity, dietary outcomes, glucose monitoring, number of medications, and medication adherence. All outcomes will be tested at baseline, 6, 12, 18, and 24 months. We will also quantify the incremental cost effectiveness of DMAPP and DMAPP+INCENT and the net cost implications of both from a third party payer's perspective.

Role: Principal Investigator

**2. Grant: GPMOHPREDIC1 (PI Bee)**

01/08/2017 – 31/03/2024

**Singapore Ministry of Health (MOH)**

**Funding Amount:** SGD \$4,245,251

***The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes Programme (The PreDICTED Programme)***

The proposed study will evaluate the effectiveness of a community-based large-scale prevention programme (PreDICTED) in reducing the rate of progression from pre-DM to DM through a large scale randomized controlled trial. This proposal study will evaluate the effectiveness and cost effectiveness of the PreDICTED intervention compared to usual care over the 3 year intervention period.

Role: Co-Investigator

**2015**

**1. Grant: 2015-SMF-0003 / LCPC-IN14-0003**

**Singapore Millennium Foundation**

24/12/2015 – 23/06/2019

**Total Value Awarded:** SGD \$749,922

**Lien Centre for Palliative Care Incubator Research Award**

18/06/2016 – 17/01/2024

**Total Value Awarded:** SGD \$579,000

***Costs and Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS)***

This is a longitudinal study which aims to prospectively capture health care utilization, cost, and quality of life indicators from 600 patients with advanced cancer using both administrative and survey data collected until patient's death. Patients and their caregivers are interviewed by the research team at baseline and subsequently at every three months until the patient's death. Additionally, the study recruits patient's treating physician. After patient's death, caregivers are asked to complete a questionnaire at 8 weeks and 6 months after patient's death assessing bereavement adjustment. This study is being conducted at National Cancer Centre, National University Hospital and Tan Tock Seng Hospital.

Role: Principal Investigator

**Completed Research Support (2006 to present):**

**2021**

**1. Grant: 2021-2464**

31/12/2021 – 30/04/2022

**Novo Nordisk Pharma (Singapore) Pte Ltd**

**Total Value Awarded:** SGD \$60,000

***Economic Burden of Obesity in Singapore***

This research aims to estimate the economic burden of excess weight in Singapore arising from increased healthcare utilisation and reduced work productivity. Based on a retrospective analysis a unique dataset, we will estimate the average per capita and total direct medical and indirect costs associated with overweight and obesity among Singaporeans aged 40 years or older, where the burden is largest. These findings will result in a publication that will be used to stimulate discussion on how best to prevent and treatment overweight and obesity in the city state.

Role: Principal Investigator

**2. Grant: 2021-2411**

27/12/2021 – 15/09/2022

**Boston Scientific**

**Total Value Awarded:** SGD \$65,000

***Cost-Effectiveness and budget impact analyses of Rezum™ for benign prostatic hyperplasia (BPH) in***



## **Singapore**

This research aims to evaluate the incremental cost-effectiveness of Rezum™ compared to pharmacotherapy (Alpha-Blockers, and 5-Alpha Reductase Inhibitors), other minimally invasive (prostatic urethral lift; PUL) and invasive surgical treatments (Transurethral Resection of the Prostate; TURP), for treating moderate-to-severe BPH in Singapore. Effectiveness will be measured in terms of quality-adjusted life years (QALYs). The cost-effectiveness analysis will be performed from the Singapore healthcare system perspective over a lifetime horizon, consistent with best practices.

Role: Principal Investigator

### **3. Grant: MOH-000784-01**

01/12/2021 – 30/04/2022

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$100,000

#### ***COVID-19 Top-up Grant for A Randomized Trial to Slow the Progression of Diabetes (The TRIPOD Study)***

The research objective of this one-year, three-arm randomized controlled trial is to test whether an evidence-based, low-cost mobile diabetes management package (DMP), with or without an incentive programme grounded in economic theory (M-POWER Rewards), can cost-effectively improve health outcomes for those with type 2 diabetes. Due to COVID, additional funding was granted to complete the study.

Role: Principal Investigator

### **4. Grant: 7202186/ 7204409**

01/09/2021 – 30/06/2022

**World Bank Group**

**Total Value Awarded:** SGD \$87,340.18

#### ***Phase 3: Evaluating A Promising Food Policy Intervention Using NUSMart: A Sin-Tax Scheme***

KSA recently introduced an excise tax on beverages in response to increasing rates of obesity and diabetes. The goal of this project is to evaluate the existing and/or new tax policies for Saudi Arabia using our NUSMart online grocery store.

Role: Principal Investigator

### **5. Grant: NMRC/HCE/2021**

01/08/2021 – 28/02/2022

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$75,000

#### ***Evaluation of Outcomes in Healthcare Research Commissioned Study: Disability-Adjusted Life Year/ Quality-Adjusted Life Year (DALY/QALY) Analysis Part 2***

This research aims to evaluate the health outcomes, in terms of adjusted life years gained, of healthcare research grants that have been awarded to Investigators in Singapore by government funding bodies. The hypothesis to be tested is that there is a 1% improvement in disability-adjusted /quality-adjusted life years resulting from potential policy changes that arose from the healthcare research conducted.

Role: Principal Investigator

## **2020**

### **1. Contract: 7197919**

15/11/2020 – 30/09/2021

**World Bank Group**

**Total Value Awarded:** SGD \$68,178

#### ***Phase 2: Evaluating Promising Food Policy Interventions Using NUSMart***

The goal of this project is to evaluate promising front-of-pack nutrition labels for Saudi Arabia using a randomized controlled trial and our NUSMart online grocery store. We conducted a three-arm hypothetical online shopping study with 656 KSA residents to estimate the effects of 1) Chilean warning label and 2) modified Nutri-Score label relative to no-label control condition.

Role: Principal Investigator

### **2. Contract: LCPCSVC-2020-002**

01/10/2020 – 31/03/2021

**Singapore Eye Research Institute (SERI)**

**Total Value Awarded:** SGD \$30,000

#### ***Quantifying the Economic Burden of Eye Diseases in Singapore***

The goal of this project is to use existing survey data provided by the Singapore Eye Research Institute to

quantify the economic burden of major eye diseases in Singapore.

Role: Principal Investigator

**3. Grant: 2020-SMF-0006**

01/09/2020 - 31/08/2022

**Temasek Foundation**

**Total Value Awarded:** SGD \$99,300

***Survival Expectations and Hope among Advanced Cancer Patients in Singapore 2.0 (SHAPE 2.0)***

With prior funding from Temasek Foundation Innovates, we showed that patients with advanced cancer are susceptible to common biases in judgement and that these biases are amplified by greater levels of hope. The goal of this effort is to extend our prior analysis by linking the survey data we previously collected to medical records and death statistics to test whether patients who report greater levels of hope are also more likely to pursue aggressive end-of-life treatments and whether pursuit of these treatments leads to any survival advantage or merely increases costs.

Role: Principal Investigator

**4. Contract: 2020-0475/ 2021-0823**

28/05/2020 – 31/03/2022

**AstraZeneca (Singapore) Pte Ltd**

**Total Value Awarded:** SGD \$70,000

***Cost-Effectiveness of Lokelma (ZS) for the management of hyperkalaemia in CKD Patients in Singapore***

The goal of this effort is to (1) customize a cost-effectiveness model of Lokelma (ZS), developed by AstraZeneca, for use in Singapore and (2) evaluate its cost-effectiveness for managing hyperkalaemia in patients with chronic kidney disease from the payer perspective.

Role: Principal Investigator

**5. Grant: 2020-0548**

01/03/2020 – 28/02/2021

**Duke Global Health Institute (DGHI)**

**Total Value Awarded:** SGD \$34,700

***African Patient Perspectives Regarding Oncology Awareness, Care, & Health (APPROACH-MTRH)***

APPROACH, which stands for Asian Patients Perspective regarding Oncology Awareness, Care and Health, to date has been fielded in 14 hospitals across 10 countries in Asia. It is a cross-sectional survey that systematically captures key dimensions of the end of life experience for patients with advanced illness, including quality of life, levels of pain and distress, use of life-extending treatments, palliative care and non-traditional medicines, treatment decision-making, and multiple dimensions of quality of care. The results provide insights into the challenges that patients with advanced illness face and help identify and advocate for areas for improvement. This study aims to expand our Asia focused APPROACH study to Africa, starting with Moi Teaching and Research Hospital (MTRH).

Role: Principal Investigator

**6. Contract: 7196065**

01/03/2020 – 30/06/2020

**World Bank Group**

**Total Value Awarded:** SGD 69,869.98

***Phase 1: Applications of Experimental Studies to Assess Policies Aimed to Improve Diet Quality in Saudi Arabia***

This project aims to provide a research plan to rigorously assess promising policies aimed to improve diet quality in Saudi Arabia. Policies to consider include both tax and labelling policies.

Role: Principal Investigator

**7. Grant: NMRC/HCE/2020**

01/02/2020 – 31/08/2020

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$75,000

***Evaluations of Healthcare Outcomes Research: Disability-Adjusted Life Year/Quality-Adjusted Life Year Analysis (DALY/QALY)***

The focus of this study is to evaluate the effectiveness and cost-effectiveness of healthcare research grants that have been provided to healthcare institutions in Singapore. The objective is to determine whether the research grants have resulted in policy changes that have brought about DALY/QALY improvements in Singapore and beyond. This will be done by analyzing existing data from a survey conducted by National

Medical Research Council that reports policy and practices changes resulting from funded research and then modelling the benefits of these changes to quantify the DALY/QALY savings.

Role: Principal Investigator

**8. Grant: LF-QODDI2020**

01/01/2020 – 31/12/2021

**Lien Foundation**

**Total Value Awarded:** SGD \$300,000

***Quality of Death & Dying Index 2020***

The focus of this project is to update prior QODDI indices to again rank countries in their ability to deliver high quality end of life care. This includes identifying core measures that determine how well a country is faring with regard to access, quality and affordability of palliative care, developing an online tool for countries to benchmark their progress against other countries and across time, presenting best practices from higher and lower income countries, discussing trends in palliative care delivery, and using the results to raise awareness of key issues likely to affect the delivery of end of life care. This effort will be completed via a literature review, qualitative interviews, a discrete choice experiment with qualified professionals to assign survey weights, and a data collection exercise to populate the QODDI tool across countries.

Role: Principal Investigator

**2019**

**1. Grant: 2019-SMF-0005**

01/11/2019 – 31/07/2022

**Temasek Foundation**

**Total Value Awarded:** SGD \$146,335

**A comparison of healthcare utilization, costs and the provision of low-value care in patients with and without evidence of cognitive impairment in the last year of life.**

Healthcare utilization, associated costs, the appropriateness of care and any differences in these outcomes between patients with and without evidence of cognitive impairment in the last year of life are poorly understood. How co-morbidities affect these outcomes/ differences is also unknown. We aim to quantify these outcomes/ differences using MOH Mediclaims utilization and cost data and linking a subset of this data to the Singapore Chinese Health Study. The findings will allow for a better understanding of end-of-life experiences, forecasting of future costs/ utilization, appropriate setting of subsidies and identification of opportunities to improve end-of-life care for patients with evidence of cognitive impaired.

Role: Principal Investigator

**2. Contract: 2018-2126**

01/06/2019 – 31/07/2020

**AstraZeneca (Singapore) Pte Ltd**

**Total Value Awarded:** SGD \$53,000

***Economic Burden of Asthma in Singapore***

The study aims to estimate the per capita and total direct healthcare and societal (e.g., costs to patients, to social services, to employers in the form of productivity losses, to family and friends via informal care as well as direct healthcare costs) burden due to asthma for Singaporean children and adult populations, stratified by disease severity.

Role: Principal Investigator

**3. Contract: 2018-2135**

29/04/2019 – 31/03/2020

**Roche Singapore Pte Ltd**

**Total Value:** SGD \$40,000

***Recurrence and Associated Direct Medical Costs in HER2-Positive Early Breast Cancer Patients in Singapore***

The study aims to (1) establish the recurrence rate over the longest follow-up possible for HER2-positive early breast cancer in Singapore, (2) establish the recurrence rate over the longest follow-up possible for HER2-positive early breast cancer in multiple sub-groups of interest, including patients with/without lymph node positive and/or hormone receptor positive/negative breast cancer, (3) compare the rate of recurrence over the longest follow-up possible for HER2-positive early breast cancer in patients receiving different anti-cancer treatment regimens in the neo-adjuvant and/or adjuvant setting, and (4) estimate the direct medical costs incurred after recurrence of breast cancer in Singapore.

Role: Principal Investigator

**4. Grant: SERI-2019**

01/03/2019 – 31/12/2020

**Singapore Eye Research Institute (SERI)**

**Total Value Awarded:** SGD \$200,000

***Health Economics Agenda and Economic Studies for Ophthalmology Research***

Duke-NUS will identify and execute five health economic studies. The studies identified are: (1) Use of a Discrete Choice Experiment (DCE) to Development a Glaucoma-Specific Health Utility Measure, (2) Incremental Cost-Effectiveness of Optical Coherence Tomography (OCT) to screen for Glaucoma among High-Risk Patients, (3) Artificial Intelligence for Teleophthalmology-Diabetic Retinopathy Screening in a National Program: A Cost Minimization Analysis, (4) A Cost Effectiveness Analysis of Artificial Intelligence for Teleophthalmology-Diabetic Retinopathy Screening in Singapore, and (5) Healthcare related Quality of Life and Economic Burden of Myopia.

Role: Principal Investigator

**2018**

**1. Grant: 2018-SMF-0004**

01/09/2018 – 31/08/2021

**Temasek Foundation Innovates**

**Total Value Awarded:** SGD \$150,928

***Survival Expectations and Hope among Cancer Patients at End-of-Life (SHAPE)***

The primary aim of this study is to discern patient's beliefs about prognosis independent of hope. Secondary Aims are to 1) identify factors that influence patient's beliefs, 2) explore whether and how patients would like to receive prognostic information and 3) the percentage who received the information the way they would have liked. We address these aims by randomizing cancer patients with a prognosis of less than one year to receive one of two versions of a survey. Version 1 includes prognosis questions similar to those used in prior studies. Version 2 includes identical questions but incorporates an incentive compatible strategy where a reward is offered for 'correct' answers, as determined by their treating physician's prediction. We hypothesize that, although many patients will continue to be overly optimistic about their prognosis, those patients responding to Version 2 will provide more accurate estimates.

Role: Principal Investigator

**2. Grant: 2018-0776**

15/07/2018 – 14/10/2019

**Novartis Singapore Pte Ltd**

**Total Value Awarded:** SGD \$40,000

***Cost-Effective Analysis of Combination Therapy (Ranibizumab + visudyne (verteporfin) photo dynamic therapy (vPDT)) vs Ranibizumab Monotherapy for PCV patients in Singapore***

Asian AMD patients have a higher proportion of PCV diagnosis compared to their western counterparts (Maruko et al., 2007). A recent publication on the use of combination therapy (ranibizumab + vPDT) vs ranibizumab monotherapy showed significant VA gain for patients in the combination therapy arm (Koh et al., 2017). This study suggests that combination therapy may be beneficial for patients with PCV. The cost effectiveness of combination treatment has not been conducted to date. The primary objective of this study is to assess the cost effectiveness of combination therapy (Ranibizumab +vPDT) compared to Ranibizumab monotherapy for PCV patients in Singapore in terms of cost per QALY gained.

Role: Principal Investigator

**3. Grant: 2018-0624**

04/07/2018 – 31/12/2019

**Weight Watchers International, Inc**

**Total Value Awarded:** USD \$30,000 (SGD \$40,142.08)

***Participation, Weight Loss, and Financial Implications to City of New York's Weight Management Initiative***

As an independent evaluator, Duke-NUS will estimate the savings generated due to weight loss to beneficiaries of Weight Watchers in NYC. Apply the estimated medical expenditure changes from the Cawley et al model (Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. *PharmacoEconomics* 2015; 33:707-722) to predict savings in medical expenditures based on baseline BMI and amount of weight loss, for participants with and without

diabetes. Complete the analysis on data pulled between June 1, 2016-August 21, 2017 (15 months). The evaluation period will be 12 months (June 1, 2016-May 31, 2017). Estimate differential savings based on members' program type (online or worksite/community meetings), members' starting BMI and members' amount of weight loss.

Role: Principal Investigator

**4. Grant: 2018-0666/2020-0760**

26/06/2018 – 30/06/2021

**Sysmex Pte Ltd**

**Total Value Awarded:** SGD \$48,150

**Cost-effectiveness analysis of Sysmex Point-of-Care diagnostic tool in Indonesia.**

To propose a health economics research agenda and conduct one cost-effectiveness analysis (CEA) in support of Sysmex lines of business. The CEA may focus on the POC diagnostic tool or other Sysmex technologies and will be finalized after a presentation of the research agenda and discussions with Sysmex leadership.

Role: Principal Investigator

**5. Grant: 2019-0750**

01/04/2018 – 28/02/2022

**KK Women's and Children's Hospital Pte Ltd**

**Total Value Awarded:** SGD \$222,528

***Cost Containment in Pharmacogenomics Testing, Identifying Obstacles to Implementation of Pharmacogenomics and Impact on Anticonvulsant Prescription Patterns***

This study aims to improve frontline adoption of pharmacogenomic testing for HLA-B\*1502 allele by improving speeds and reducing costs of point-of-care testing. In collaboration with KK Women's and Children's Hospital, NanoBio Lab, and Singapore General Hospital, we will (1) clinically validate a novel rapid HLA-B\*1502 testing system, (2) evaluate its impact on anticonvulsant prescription patterns compared to existing testing practices from a cost-effectiveness perspective, and (3) quantify user preferences for the genetic test via a discrete choice experiment survey.

Role: Principal Investigator

**6. Grant: Novartis Singapore Pte Ltd (2018-0099)**

01/03/2018 – 31/12/2019

**Total Value Awarded:** SGD \$49,920

***Migraine Project: Economic Burden of Migraine in Singapore***

Migraine, a common disabling primary headache disorder, is often misconceived as a low-impact condition, despite being ranked among the twenty most disabling illnesses worldwide. It imposes a substantial economic burden on society due to healthcare resource utilization and lost productive time. This study aims to quantify the economic burden of migraine in Singapore, and estimate the incremental costs borne by migraine-sufferers compared to migraine-free respondents, using an on-line web-panel.

Role: Principal Investigator

**7. Grant: H-614-13-000011**

01/02/2019 – 03/03/2020

**NUS-Global Asia Institute NIHA Research Grant (NIHA)**

**Total Value Awarded:** SGD \$50,000

***Digital Health as an Enabler of Healthy Ageing in Asia***

The study aims to provide a comprehensive overview of healthcare technologies that could enable healthy ageing with relevant case studies in Asia and discuss opportunities and challenges to member of the ecosystem, i.e. healthcare service providers, policy makers and regulatory professionals, and patients and caretakers.

Role: Principal Investigator

**2017**

**1. Grant: Roche Singapore Pte Ltd**

16/10/2017 – 15/04/2018

**Total Value Awarded:** SGD \$34,775

***Drug Pricing Policies in Asia-Pacific Countries***

In efforts to contain rising public sector expenditures on prescription medicines, many APAC countries

have adopted formal and informal pharmaceutical pricing strategies. This narrative review describes the most commonly used strategies, including a detailed examination of the use of International Reference Pricing (IRP) in sixteen APAC countries.

Role: Principal Investigator

**2. Grant: NMRC/HSRG/0080/2017**

12/10/2017 – 31/01/2020

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$209,492

***Tailoring Health Communication Materials to Improve Decision Making of Elderly ESRD Patients (RE-TREAT)***

The goal of this proposal is to explore and improve decision-making among older ESRD patients. Aim 1 proposes to conduct a qualitative study of ESRD patients to explore factors that were influential in their decision to choose a form of dialysis or CM, information that they would have liked to know, their treatment experiences, and whether and to what extent they may have experienced decision regret. Aim 2 uses the results of Aim 1 to develop a new set of counselling material, including printed material and a video with patient testimonials, to be used as patient decision aids, specifically for elderly ESRD patients. Aim 3 evaluates the patient decision aids from Aim 2 in a Phase II trial, using stated choice (primary) and revealed choice (secondary). If the results from Aim 3 suggest the new information is superior, they will be further tested in a longer term study that focuses on real, as opposed to stated, choices.

Role: Principal Investigator

**3. Grant: NMRC/CTGIITL/0001/2014 (PI Sng)**

12/10/2017 – 11/06/2020

**Singapore Ministry of Health (MOH)**

**Total Value of** SGD \$54,570

***Collaborative Outcomes with Labour Epidural Use (COLEUS) Study***

The objective of this collaboration is to investigate the value of epidural pumps that are developed by Dr Sng's group at KKH. We will develop a discrete choice experiment (DCE) survey to estimate women's willingness to pay for reducing chances of breakthrough pain, motor block, instrumental delivery and postpartum depression.

Role: Co-Investigator

**4. Grant: NMRC/HSRG/0060/2016**

08/02/2017 – 29/02/2020

**Singapore Ministry of Health (MOH)**

**Total Direct Costs:** SGD \$685,495.03

***Multiphase Evaluation of Healthier Choice Symbol (HCS) Logo***

In efforts to promote a healthy diet, in 2001 the Singapore Health Promotion Board (HPB) supplemented traditional nutrition labelling with the Healthier Choice Symbol (HCS), which identifies food items within a specific category of foods (e.g., Sugar-Sweetened Beverages) as healthier choices. In 2009, HPB introduced enhanced versions of the HCS, although some firms continue to use the original logo. The study aims to assess the role of the HCS logos in influencing food choice.

Role: Principal Investigator

**5. Grant: 1R01-DK109696-01A1 (PI Bennett)**

01/02/2017 – 31/01/2021

**US National Institute of Health (NIH)**

**Total Value:** USD \$445,668

***Optimizing a standalone text messaging-based weight loss intervention***

This experimental trial among 592 obese adults will include a core 6-month weight loss texting intervention that includes tailored behavior change goals, interactive self-monitoring, automated feedback, and skills training. Using a fractional factorial design, participants will be randomized to one of 16 experimental conditions that will test the text messaging components.

Role: Co-Investigator

**2016**

**1. Grant: Research Collaboration Agreement - Ref: 2016-1595 06/12/2016 – 05/06/2018**

**NUS/SingHealth Polyclinics/ KKT Technology Pte Ltd**

**Total Value Awarded:** SGD \$62,632

***A single arm feasibility study of Glyco Leap, an on-line lifestyle modification and self-management program for people with Type 2 diabetes***

This feasibility study will explore the use of Glyco Leap, a proprietary online lifestyle modification and self-management education program developed by Holmusk, Singapore for people with type 2 diabetes, as an add-on to primary care delivered through the SingHealth Polyclinic at Tampines. The goal of the study is to test whether patients with diabetes who receive care at the clinic are amenable to such an intervention, to quantify program fidelity for those who do enroll in the study, and to explore the extent to which the intervention can be used in conjunction with primary care in efforts to improve health outcomes. If results are promising, a randomized controlled trial will follow.

Role: Principal Investigator

**2. Grant: NMRC/HSRG/0053/2016**

01/10/2016 – 31/10/2019

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$999,972

***Singapore cohort of patients with advanced heart failure (SCOPAH)***

Congestive heart failure (CHF) is one of the leading causes of death in Singapore. Although anecdotal data suggests that end-of-life (EOL) care that patients with advanced CHF receive is sub-optimal, limited data is available that assesses the EOL experience of patients and that can be used to identify specific areas for improvement. Further, advance care planning, a promising intervention recently introduced in Singapore to enable patients with life limiting illnesses, including those with advanced CHF, to receive EOL treatments according to their own preferences, has not been systematically evaluated. This project thus aims to (1) enroll 250 patients with advanced CHF and follow them for a period of one year or till they die, to assess their EOL experience and to identify specific areas for improvement; and to (2) conduct a randomized controlled trial of 250 patients with advanced CHF to assess whether patients receiving ACP are more likely to receive EOL care consistent with their preferences. Results from this project will provide recommendations for ways to improve EOL care for patients with advanced CHF and test the effectiveness of ACP.

Role: Principal Investigator

**3. Grant: 5R18-DK109518-2 (PI Bennett)**

01/05/2016 – 30/04/2021

**US National Institute of Health (NIH)**

**Total Value:** USD \$435,182

***A Pragmatic Trial of a Digital Health Intervention to Prevent Weight Gain in Primary Care***

This pragmatic trial conducted in a rural community health center system will test the effectiveness of a 12-month weight gain prevention intervention consisting of self-monitoring and feedback via interactive voice response and/or text messaging, tailored skills training, and responsive coaching.

Role: Co-Investigator

**4. Grant: 1R01HL130816-01 (PI Herring)**

15/01/2016 – 31/12/2020

**US National Institute of Health (NIH)**

**Total Direct Costs:** USD \$514,775 (USD \$26,477 Duke U. subcontract)

***Community-based obesity treatment in African American women after childbirth: a randomized controlled trial of WIC mothers***

This project aims to reduce disparities in obesity by implementing and evaluating a novel community-based behavioral weight loss intervention in African American WIC participants during the first postpartum year.

Role: Co-Investigator

**2015**

**1. Grant: MR/N006178/1 (PI Tazeen)**

01/09/2015 – 31/08/2018

**UK Medical Research Council/Department for International Development**

**Total Value Awarded:** £1,992,221

***Primary Care Strategies to Reduce High Blood Pressure: A Cluster Randomized Trial in Rural Bangladesh, Pakistan and Sri Lanka (COBRA-BPS)***

This is a cluster randomized controlled trial (RCT) in 30 rural communities in Bangladesh, Pakistan and Sri Lanka aimed at reducing BP levels of individuals with hypertension (systolic BP  $\geq$ 140 mm Hg or diastolic BP

≥90 mm Hg, or on antihypertensive therapy). The RCT will enrol 2550 individuals aged 40 years or older with hypertension in these communities to evaluate the effectiveness and cost-effectiveness of a “multi-component strategy (MCI)”.

Role: Co-Investigator

**2. Grant: NMRC/HSRNIG/0013/2016** (PI Ozdemir) 07/07/2015 – 31/07/2018

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$99,920

***Randomized Controlled Trial of a Physical Activity Program for Teenagers (FIT-TEEN)***

Childhood obesity is one of the major challenges in developed countries, including Singapore. One of the main reasons behind growing childhood obesity is low levels of physical activity, and children may be patterning their levels of inactivity after their parents. Physical activity interventions that target children and parents could have a significant public health impact. Incentives for meeting activity goals can be effective in promoting sustained levels of physical activity. We propose to test two types of incentive strategies (fixed threshold versus a dynamic threshold based on peer effects). We also hypothesize that the average number of steps taken by children will be higher when families are compared to other families in terms of physical activity than when they are not compared to other families.

Role: Co-Investigator

**3. Grant: NMRC/HSRNIG/0007/2015** 07/07/2015 – 31/07/2017

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$99,745

***The Role of Risk Factors in Influencing Inpatient Utilization and Costs: Evidence from linked Singapore Chinese Cohort Data***

As the country becomes wealthier and its population ages, Singapore is facing a dual health challenge. It wants to expand access to insurance coverage and subsidy for its people, and at the same time, find ways to control healthcare costs. Thus far, the government has been proactive in responding to this dual challenge. Recent policy efforts expanded coverage to accommodate those with low incomes and the elderly. In particular, changes have been proposed for MediShield to cover the entire population. These policy changes raises the need to address a number of issues related to the costs of expanded access and more generally, to identify strategies to control costs. This research aims to quantify elderly’s inpatient costs during their aging years and at their end-of-life stage, with a focus on the cost burden associated with risk factors (such as smoking, obesity, drinking) and chronic diseases.

Role: Mentor for new investigator

**4. Grant: NMRC/HSRG/0052/2015** (PI Bilger) 20/06/2015 – 30/06/2019

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$490,285

***Randomized control trial to improve hypertension outcomes using wireless home blood pressure monitoring with automatic outcome-based feedback and financial incentives***

We propose a 6-month randomized controlled trial with 228 hypertensive patients with uncontrolled blood pressure from the Singhealth Polyclinic in Bedok, Singapore. The proposed trial will have three equal sized and parallel study arms in order to measure the incremental effectiveness and cost-effectiveness of an intervention with wireless HBPM and automatic outcome-based feedback with and without financial incentives compared to HBPM alone.

Role: Co-Investigator

**5. Grant: 2R01DK056746-14** (Harvey/West) 01/04/2015 – 31/03/2020

**US National Institute of Health (NIH)**

**Total Direct Costs:** USD \$688,924

***Internet Assisted Obesity Treatment: Enhanced by Financial Incentives***

The major goal of this randomized controlled trial is to determine whether incorporating financial incentives increases the amount and duration of weight losses achieved by Internet-delivered behavioral treatment. A secondary, exploratory aim is to quantify the incremental cost-effectiveness of each intervention strategy compared to established cost-efficacy thresholds. Overweight and obese adults at



two study sites (N=416; 27% minority) will randomized to: (1) Internet intervention; or 2) Internet intervention plus financial incentives for implementation of key self-management behaviors (daily self-weighing, self-monitoring of dietary intake and achieving step goals) (Internet+Incentives). Measures of body weight, treatment engagement (e.g., attendance, self-monitoring, website utilization, motivational factors, weight control behaviors) and treatment delivery cost will be obtained over an 18-month period.

Role: Consultant

**6. Grant: NMRC/HSRG/0048/2015**

25/02/2015 – 31/08/2018

**Singapore Ministry of Health (MOH)**

**Total Direct Costs: SGD \$540,457**

***Randomized Controlled Trial of an Incentive-based Physical Activity Program targeting both children and adults (FIT-FAM)***

There is overwhelming evidence that sustained physical activity reduces the risk of many common diseases. Yet, data reveals low levels of physical activity among working age adults and their children in Singapore. One strategy that has been successfully employed to influence behaviors of parents is to use their children as an intermediary. This strategy has a successful track record in public health, where children have helped their parents quit smoking and wear seatbelts. In this study we propose to test whether children can promote increased physical activity of a working parent at the same time that they increase their own activity level. This proposal is an extension of a prior study where we showed that modest financial incentives can increase physical activity levels among youth. We now propose to conduct a follow-on trial where the reward is tied not only to the child's own steps, but to that of their parents. Rewards will be based on step activity measured through a state-of-the-art wireless step counter. Just as children were motivated to increase their own activity levels in efforts to achieve the incentive, we hypothesize that they will also be effective advocates for increasing the activity levels of their parents.

Role: Principal Investigator

**2014**

**1. Grant: 1R01HL125487-01A1**

01/12/2014 – 30/11/2019

PI Rajesh Vedanthan, MD MPH, Mount Sinai School of Medicine (MSSM)

**US National Institute of Health (NIH)**

**Total Value Awarded: USD \$3.4M (Duke PI Finkelstein – total value of Duke sub grant – USD \$260K)**

***Bridging Income Generation with Group Integrated Care (BIGPIC)***

Cost-effective, context-specific, and culturally appropriate interventions are critical to reduce risk factors for CVD in LMICs, and both group medical visits and microfinance have the potential to achieve this. In partnership with the Government of Kenya, the Academic Model Providing Access to Healthcare Partnership has expanded its clinical scope of work in rural western Kenya to include diabetes and hypertension, and has piloted group care and microfinance initiatives with promising early results. However, the effectiveness of these strategies individually, and in combination, on improving CVD risk is not known. Thus, the overall objective of this proposal is to utilize a transdisciplinary implementation research approach to address the challenge of reducing CVD risk in low-resource settings via a group randomized controlled trial.

Role: Co-Investigator

**2. Grant: AG-2014-001**

27/11/2014 – 22/02/2019

**National University of Singapore GAI Aging Cluster**

**Total Value Awarded: SGD \$320,000**

***Encouraging Healthy Nutrition Purchases in an Online Grocery Setting using Experimental Economics (NUSMart)***

This study proposes to develop an online grocery store and enroll participants to make their typical grocery purchases through this store. Using the information gathered from the participants' purchasing behavior, this proposal will apply experimental economic methods to test the extent to which food purchasing behavior can be positively influenced through a series of nutrition information and/or incentive-based interventions. The findings from this research can be used by policymakers in efforts to improve the value of nutrition information to discourage unhealthy food consumption, and by insurers and others looking to design value-based programs that reward participant's for healthier food purchases.

Role: Principal Investigator

**3. Grant: H-614-12-000011** 01/10/2014 – 30/09/2019

**Lien Foundation, SingHealth Foundation, and National Cancer Centre Singapore**

**Total Value Awarded:** SGD \$9,750,000

*The Lien Foundation, SingHealth Foundation, and National Cancer Centre Singapore* have provided funding to support a Centre of Excellence in Palliative Care housed within the Duke-NUS Graduate Medical School. The Lien Centre for Palliative Care (LCPC) mission focuses on developing and delivering traditional and blended learning palliative care education programs targeted physicians and allied health professionals, initiating and incubating high value research projects, and engaging with key stakeholders in Singapore and the region in efforts to enhance the end of life experience for patients and caregivers. This funding supports Phase 2 of LCPC for 5 years.

Role: Principal Investigator

**4. Grant: MOH (HLTHQ0ECO14000206/1)** 21/08/2014 – 26/01/2015

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$52,000 (Duke-NUS SGD \$13,000)

***ITQ for the provision of analysis services to estimate return of investments in eye research in Singapore to Ministry of Health***

Develop a model to estimate return on investment in eye research by Singapore Ministry of Health (MOH).

Role: Principal Investigator

**5. Contract: NMRC (HLTHQ0ECO14000206/1)** 21/08/2014 – 26/01/2015

**National Medical Research Council (NMRC)**

**Total Value Awarded:** SGD \$65,000

***Estimate return on investment for eye research funding provided by Singapore to Ministry of Health***

The goal of this study is to estimate the Singapore government's return for investments in eye research.

Role: Principal Investigator

**6. Contract: Sanofi-Aventis (CL2014-006)** 19/08/2014 – 18/08/2015

**Sanofi-Aventis Singapore Pte Ltd**

**Total Value Awarded:** SGD \$28,355

***Cost Effectiveness of Sevelamer vs Calcium Carbonate in Singaporean Patients with CKD-ND***

Hyperphosphatemia is a universal problem with chronic kidney disease and is an independent risk factor for increased morbidity and mortality. Phosphate binders can lower the level of phosphate in the blood but lead to their own set of complications with prolonged use. This study will compare the cost-effectiveness of an older calcium based binder with Sevelamer, a new non-calcium based binder, using a Markov model of the Singapore chronic kidney disease population.

Role: Principal Investigator

**7. Grant: SHF/13/GMC(2)/017(US)** 01/04/2014 – 31/03/2015

**SingHealth Foundation**

**Total Value Awarded:** SGD \$154,650

***Develop a Palliative Care Online Training Portal for Healthcare Professionals***

The portal is a dynamic e-learning platform that provides relevant training and information on palliative care to 1) healthcare professionals, 2) non-professional caregivers and 3) the general public (volunteers, students etc.) who will benefit from increased knowledge in palliative care and palliative care services.

Role: Principal Investigator

**8. Grant: 2013-SMF-0002** 03/02/2014 – 02/02/2017

**Singapore Millennium Foundation**

**Total Value Awarded:** SGD \$260,480

***Knowledge and preferences for treatment of end stage renal disease among elderly patients and their family caregivers***

Understanding patient's preferences regarding treatment for end-stage renal disease (ESRD) is important to guide treatment recommendations and policies. Currently, treatment choices for ESRD are likely to be distorted

by a lack of knowledge among patients and their caregivers regarding outcomes and costs that result from a given choice. Therefore, this study proposes to assess patient and caregiver knowledge about outcomes and costs of dialysis and conservative treatment, and to quantify the extent to which select features and outcomes of dialysis influence the decision to choose it over conservative treatment, and the change in uptake that would result from a given change in one of the attribute levels (or better information on that attribute). The study involves focus groups with stated preference conjoint survey with elderly stage 4 and 5 chronic kidney disease patients.

Role: Principal Investigator

**9. Grant: SMPO201301** (PI Gardner) 01/01/2014 – 31/03/2015

**Stratified Medicine Programme Office Singapore**

**Total Value Awarded:** SGD \$520,000 (Duke-NUS SGD \$20,000)

***Translational genetic approaches for stratifying adults with young onset diabetes and diagnosing monogenic diabetes in Singapore***

This project uses a Markov model to estimate the cost-effectiveness of genetic stratifying tests for specific types of MODY in Singapore.

Role: Co-Investigator

**10. Grant: SMPO201302** (PI Tan PH) 01/01/2014 – 30/06/2015

**Stratified Medicine Programme Office Singapore**

**Total Value Awarded:** SGD \$520,000 (Duke-NUS SGD \$20,000)

***Stratification of triple negative breast cancer into clinically relevant groups***

This project evaluates the costs of treating triple breast cancers in Singapore and estimates the cost effectiveness of triple negative breast cancer stratifying tests using a Markov model.

Role: Co-Investigator

**11. Grant: R01HL119568** (PI Ward / Linnan) 01/01/2014 – 31/12/2018

**US National Institutes of Health (NIH)**

**Total Value Awarded:** USD \$489,547

***Care2BWell: A Worksite Physical Activity & Wellness Program for Child Care Staff***

Child care workers are among the lowest wage workers in the US workforce; and face a wide range of chronic health conditions. This randomized controlled trial in 104 child care settings will test the effects of a multi-level physical activity intervention on worker physical activity outcomes (primary) and other risk behaviors. We will also assess changes in the workplace environment at these centers that support health.

Role: Consultant

## **2013**

**1. Grant: NIHA-2013-1-004** 10/09/2013 – 09/09/2015

**NUS Global Asia Institute**

**Total Value Awarded:** SGD \$239,148

***A Randomized Controlled Trial to Motivate and Sustain Physical Activity using Financial Incentives (TAKSI)***

This is a randomized controlled trial of taxi drivers to test (1) the extent to which different types of financial incentives, when combined with a pedometer-based activity program, motivates and sustains physical activity; and (2) whether mental accounting exists among drivers and if so, the extent to which framing of the incentives as cash or taxi rental credits influences both primary and secondary outcomes.

Role: Principal Investigator

**2. Grant: NIHA-2013-1-005** (PI Bilger) 10/09/2013 – 09/03/2018

**National University of Singapore (NUS)**

**Total Value Awarded:** SGD \$249,880

***A Randomized Controlled Trial to Improve Diabetes Outcomes through Financial Incentives (TRIAD)***

Type II diabetes is associated with a host of adverse and costly complications, including heart attacks, strokes, blindness, kidney failure, and severe neuropathy that may result in amputations. For those with diabetes, glycemic control is essential to minimize complications but many fail at being sufficiently adherent to their treatment. We propose to test two incentive-based intervention strategies aimed at improving diabetes outcomes amongst

patients with uncontrolled glycemc levels. The incentives are tied either to processes aimed at improving blood sugar levels (glucose testing, physical activity and medication adherence) or directly to the intermediary outcome (blood glucose in the acceptable range). While process incentives are likely to provide more motivation for treatment adherence, as these goals may be comparably easier to meet, these incentives only reward intermediary outcomes and it might be more effective to reward successfully achieving a health outcome directly.  
Role: Co-Investigator

**3. Contract: CL2013-009**

14/06/2013 – 14/06/2014

**Vivus, Inc.**

**Total Value Awarded:** USD \$75,000

***Cost-Effectiveness of Treatment with Qsymia***

There are two principle aims of this project. The first aim is to quantify the cost-effectiveness of a new weight loss drug, Qsymia, compared to a placebo, in terms of quality-adjusted life years (QALYs) gained. The second aim is to quantify the cost-effectiveness of Qsymia compared to other weight loss products, including gastric banding and gastric bypass surgery, commercial weight loss programs with published clinical trial data, and other commercially available (or soon to be available) weight loss drugs.

Role: Principal Investigator

**4. Grant: 2012-SMF-0001**

01/02/2013 – 31/01/2016

**Singapore Millennium Foundation**

**Total Value Awarded:** SGD \$164,783

***Survey on Preferences for care at the end of life among cancer patients in Singapore***

This is a stated preference conjoint survey of 500 breast, colorectal and lung cancer patients in Singapore to understand their preferences and willingness to pay for care at EOL.

Role: Co-Investigator

**5. Grant: LCPC(I)/2013/0002 (N. Chan, NUH is PI)**

01/02/2013 – 31/05/2015

**National University Cancer Institute Endowment fund & NUH Cancer Fund**

**Total Value Awarded:** SGD \$15,225

***National Survey of Physicians regarding Palliative Care Provision***

The project aims to understand variation in end of life care practices among physicians dealing patients suffering from life limiting illnesses in Singapore

Role: Co-Investigator

**6. Grant: NHMRC APP10466 (Lamoreaux; U. of Melbourne is PI)**

01/01/2013 – 31/12/2016

**Australia National Health and Medical Research Council (NHMRC)**

**Total value Awarded:** AUS \$861,581.08

***Improving vision and quality of life: An innovative and comprehensive eye care model for individuals in residential care facilities***

To date, Australia does not have a comprehensive eye health service model for those living in residential care facilities. To address this gap, we have developed a novel model of eye care for people living in residential care facilities. We have pilot tested this new model and our initial results suggest that it has the potential to be an effective eye care model for managing vision impairment and improving QoL for this subset of the Australian population. In this study, we will assess the effectiveness and cost-effectiveness of this new model of eye care for older people across several residential care facilities.

Role: Co-Investigator

**2012**

**1. Grant: HSRG11NOV023**

12/12/2012 – 30/06/2015

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$159,500

***Use of Conjoint Analysis to Estimate Cost-Effective Strategies for Increasing Screening Rates for Breast and Cervical Cancer Screening Programs***

Many Singaporeans do not undertake screenings consistent with recommended guidelines. The aim of this study is to improve our understanding of key factors that guide the decision of whether or not to use cancer screening services and determine how to cost-effectively increase the reach of the programs. We

propose conducting focus groups in order to identify the key factors that drive the decision to attend a screening exam. Conjoint analysis methods will then be used to estimate the relative importance of each of these factors and the extent to which modest incentives, targeted information and other strategies identified via the focus groups are expected to increase screening uptake. We will also give a special attention to the identification of potential knowledge gaps and misconceptions about cancer screening.  
Role: Principal Investigator

**2. Contract: CL2012-026**

20/11/2012 – 05/11/2013

**Sanofi-Aventis Singapore Pte Ltd**

**Total Value Awarded:** SGD \$32,100

***Analysis of Indonesian Family Life Survey (IFLS) Analysis***

This project aims to quantify, to the extent possible, the following information for Indonesia: Prevalence of non-communicable diseases (NCDs) and related risk factors, including diabetes/high blood sugar, hypertension, heart problems and stroke; Direct and indirect costs for select NCDs; and other measures of burden for these NCDs, which may include greater levels of unemployment, higher rates for insurance, greater healthcare utilization, and greater government transfers for treating these conditions among low income and/or aged individuals, and to forecast expected burden in the future.

Role: Principal Investigator

**3. Grant: NIHA0742.001**

16/08/2012 – 14/11/2015

**NUS Global Asia Institute**

**Total Value Awarded:** SGD \$127,500

***A Randomized Incentive-Based Weight Loss Trial in Singapore***

This is a randomized controlled trial in collaboration with the Life Centre at SGH which seeks to (1) test the extent to which traditional or behavioral economic incentives, when combined with an existing evidence-based weight loss program, improve weight loss and weight loss maintenance and (2) compare the cost-effectiveness of each program.

Role: Principal Investigator

**4. Grant: R01- CA167091, (Epstein; U Buffalo is lead)**

01/04/2012 – 01/04/2015

**US National Heart, Lung and Blood Institute (NHLBI)**

**Total Value Awarded:** Duke-NUS Direct Costs: USD \$110,000

***The Influence of pricing and nutrient profiling on food purchases***

The application proposes to conduct a four-group randomized controlled trial to evaluate the influence of food price changes in the form of taxes and subsidies and nutrient profiling on food purchasing behaviors among ethnically and socioeconomically diverse individuals.

Role: Co-Investigator

**5. Grant: HSRG10NOV002**

01/01/2012 – 31/08/2015

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$980,300

***A Randomized Trial of Economic Incentives to Promote Walking Among Full Time Employees***

There is overwhelming evidence that increased physical activity confers a variety of health benefits, yet recent survey data reveal that full time employees over age 35 are among the least active subsets of the Singaporean population. Employers in Singapore are increasingly looking to economic incentives to encourage healthy behaviors among employees although the evidence base justifying the use of these programs is limited. We propose to address this gap by (1) assessing the reach and sustainability of employer-based walking programs through a stated preference conjoint analysis, (2) quantify the effectiveness of a 6 month walking program, and (3) determine the cost-effectiveness of a scalable incentive-driven employer based walking program both with and without incentives.

Role: Principal Investigator

**2011**

**1. Grant: LCPC (1)/2011/001**

01/12/2011 – 30/11/2013

**Duke-NUS Medical School, Lien Centre for Palliative Care**

**Total Value Awarded:** SGD \$40,000

***Preferences for End-of-life Care among End Stage Cancer Patients in Singapore***

Understanding preferences for care at the end-of-life (EOL) is important for planning and improving services that provide such care. Satisfying the needs of dying patients without unduly burdening the healthcare system is a public health priority; however preferences concerning care at EOL remain largely unknown. This project proposes to field a stated preference conjoint survey to 250 end-stage cancer patients and their caregivers in Singapore in order to understand their preferences for care at EOL.

Role: Principal Investigator

**2. Grant: U18DP003367-1,** (Hoelscher U. of Texas is lead) 01/09/2011 – 30/09/2015

**US Centers for Disease Control and Prevention (CDC)**

**Total Value Awarded:** Duke Direct Costs: USD \$93,990

***Texas Childhood Obesity Research Demonstration (CORD): Using a System-Level Approach to Prevent Child Obesity***

The goal of this demonstration project is to develop, implement and evaluate an integrated, systems-oriented obesity prevention and control program for underserved, ethnically diverse children age 2 to 12. The project will take place in Austin and Houston Texas.

Role: Co-I, Lead Economist

**3. Grant: 2R01AT004623-03,** (Pearlman; Duke U. is lead) 01/09/2011 – 30/06/2015

**US National Institute of Health (NIH)**

**Total Value Awarded:** Duke Direct Costs: USD \$1,831,525

***Multisite RCT Investigating the Efficacy of Massage in Osteoarthritis (EMBARK)***

To use a randomized trial to assess the effectiveness and cost-effectiveness of 8 weeks of Swedish massage relative to conventional treatment of knee osteoarthritis. Therapeutic effect will be measured by validated outcome measures (WOMAC, VAS, ROM, 50-ft walk) at the conclusion of therapy (8 weeks), as well as at 16, 24, 36, and 52 weeks post-baseline.

Role: Co-I, Lead Economist

**4. Grant: DPRT/AGE/2010/20** 04/04/2011 – 31/12/2014

**NUS-Virtual Institute for the Study of Ageing**

**Total Value Awarded:** SGD \$299,700

***A Blueprint for Identifying a Successful Walking Program Targeting Singaporeans 50+***

The goal of this proposal is to develop a physical activity program expected to have high uptake among older adults, partly through the use of modest financial incentives, in efforts to identify an effective long term strategy for increasing physical levels among older Singaporeans. The study aims to conduct an in-home nationally representative state preference conjoint survey aimed at identifying options for low cost, scalable, physical activity programs targeting older adults, and to conduct a 3 month pilot randomized control trial (RCT) of 100 older adults (aged 50+) to test the effectiveness of a model program in Singapore.

Role: Principal Investigator

**5. Grant: HSRG/0006/2010** (Koh; NUS is PI) 01/02/2011 – 31/01/2013

**Singapore Ministry of Health (MOH)**

**Total Value Awarded:** SGD \$987,000

***The health, social and financial effects of care-giving among primary caregivers of elderly stroke patients in the first post stroke year: a prospective cohort study***

The primary aim of the study is to prospectively assess the health, social and financial effects of care on a cohort of stroke patient-caregiver dyads from stroke onset to one year post stroke.

Role: Co-Investigator

**6. Grant: NHMRC APP1009844** (Lamoreaux; U. of Melbourne is PI) 01/01/2011 – 31/12/2016

**Australia National Health and Medical Research Council (NHMRC)**

**Total Value Awarded:** AUS \$614,240

***Comparing the Effectiveness of Selective Laser Trabeculoplasty with Tropical Medication For The Treatment of Primary Angle Closure Glaucoma: A Multicentred, Prospective, Randomized Controlled***

### ***Clinical Trial***

This research proposed a multicentre prospective randomized study, which will determine the optimum first line therapy for people with primary open angle glaucoma. This study will: evaluate treatment outcomes with respect to patient quality of life (QoL); provide a detailed economics effectiveness analysis; and compare the clinical effectiveness with respect to degree of IOP lowering and rates of treatment failure.

Role: Co-Investigator

**7. Grant: NMRC/NIG/1036/2010** (Malholtra; Duke-NUS is PI) 01/01/2011 – 31/01/2014

**Singapore National Medical Research Council (NMRC)**

**Total Value Awarded:** SGD \$165,000

#### ***Preferences for care at the end-of-life among middle-aged and older Singaporeans***

Understanding preferences for care at the end-of-life is important for planning and improving services that provide such care. However, the nature and extent of these preferences among Singaporeans remains unknown. This study aims to understand: 1) Preferences for care at the end-of-life among Singaporeans aged 50 years and over and 2) Whether preferences for care at the end-of-life vary by demographic and socio-economic characteristics.

Role: Co-Investigator

**8. Grant: EDG/NMRC/10May040** (Singapore – Saw; NUS is lead) 01/01/2011 – 30/12/2012

**Singapore National Medical Research Council (NMRC)**

**Total Value Awarded:** SGD \$199,179

#### ***An Exploratory Randomized Controlled Trial of a Novel Family-Based Intervention to Increase Outdoor Time for the Prevention of Myopia and Increase Physical Activity among Singapore Youth***

This study aims to develop, implement, and evaluate a novel incentive-based family intervention to increase time spent outdoors and increase physical activity among children aged 6 to 10 years in a 1-year exploratory randomized controlled trial.

Role: Co-Investigator

### **2010**

**1. Grant: ABC123** (Song; NUS is lead) 01/05/2010 – 30/04/2011

**National University of Singapore Medicine-Business Seed Grant**

**Total Value Awarded:** Direct Costs SGD \$50,000

#### ***Association Between Health Behaviors and Intra-Day Work Performance: A Mobile Survey Study of Nurses***

The goal of the proposed study is to examine the short-term relationship between health-related behaviours and job performance. Our proposed study population are nurses on shift work in a major tertiary hospital in Singapore. Behaviours, which will be measured several times per day over a 7-day interval, include sleep patterns, quantity and quality of food consumption, and leisure time physical activity.

Role: Co-Investigator

### **2009**

**1. Grant: RTI# 1-312-0212385** 01/11/2009 – 30/04/2011

**US Robert Wood Johnson Foundation (RWJF)**

**Total Value Awarded:** USD \$32,400

#### ***Studying the Effect of Beverage Taxes on Children's Energy Intake and Tax Revenue.***

The goal of this proposal is to use the Nielsen Company's Homescan longitudinal dataset of household weekly at-home food expenditures, which contains unparalleled information concerning the quantity and price of specific food purchases to address the following specific aims: 1. Compare differences in total household energy costs (cents per megajoule [MJ]) and energy costs for 43 common food categories between lower- and higher-income households. 2. For six obesity-promoting food items (pizza, French fries, salty snacks, cookies, sweetened breakfast cereals, and caloric carbonated beverages), conduct a detailed product-level analysis to determine differences in quantities purchased (by weight or by volume and by total calories) and differences in energy costs (cents/MJ) between lower- and higher-income households. 3. Use econometric models of household food purchases to conduct policy-relevant

simulations addressing the extent to which policy makers can encourage healthier food consumption via targeted taxes/subsidies on select food products (e.g., tax on caloric carbonated beverages).

Role: Principal Investigator

**2. Grant: RTI# 4-312-0211772**

01/08/2009 – 31/07/2011

**US Department of Homeland Security (DHS)**

**Total Value Awarded:** USD \$34,792

***Economic Analysis to support the Assessment of the Social Welfare Implications of US Counter-terrorism Policies.***

The purpose of this study is to explore individual's preferences concerning methods for reducing terrorist threats and the reductions in deaths on U.S. soil that would be required for individuals to willingly accept these measures. We will field a stated preference conjoint survey to a national sample of 1,000 adult living in the U.S. using the Knowledge Networks web-enabled panel. Survey respondents will complete a series of exercises in which they are asked to compare two potential options, described by the levels of the key attributes and the expected number of deaths from terrorism expected to occur over the next 5 years should that option be chosen. Individuals are expected to choose their preferred options. Using these results and discrete choice econometric methods, we will quantify average preferences over different program features and how these preferences vary by population subsets.

Role: Principal Investigator

**2008**

**1. Grant: RTI# 0280800.373.02 (Finkelstein)**

01/09/2008 – 30/09/2011

**US Robert Wood Johnson Foundation (RWJF)**

**Total Value Awarded:** Direct Costs USD \$268,147

The goal of this proposal is to use the Nielsen Company's Homescan longitudinal dataset of household weekly at-home food expenditures to determine differences in quantities purchased (by weight or by volume and by total calories) and differences in energy costs (cents/MJ) between lower- and higher-income households and to conduct policy-relevant simulations addressing the extent to which policy makers can encourage healthier food consumption via targeted taxes/subsidies on select food products (e.g., tax on caloric carbonated beverages).

Role: Principal Investigator

**2007**

**1. Grant: R01 HL084400-01 (Jakicic; U of Pitt is lead)**

01/09/2007 – 30/06/2012

**US National Heart, Lung and Blood Institute (NHLBI)**

**Total Value Awarded:** Duke-NUS Direct Costs USD \$123,383

***The Effect of a Stepped-Care Approach to Long Term Weight Loss***

The purpose of this project is to examine whether a chronic-care obesity intervention delivered in a "stepped-care" manner results in improved weight loss compared to a standard behavioral weight loss intervention (SBWP group).

Role: Co-Investigator

**2006**

**1. Grant: R01- 5-34396 (Linnan; UNC is lead)**

01/09/2006 – 31/05/2012

**US National Heart, Lung and Blood Institute (NHLBI)**

**Total Value Awarded:** Duke-NUS Direct Costs: USD \$101,829

***WAY to Health - Interventions to Control Obesity in North Carolina Colleges***

The purpose of this project is to test the effectiveness and cost-effectiveness of four interventions aimed at reducing weight among overweight employees in North Carolina colleges. The interventions are being fielded in 12 colleges. These interventions are an expansion of a prior study funded by the CDC that focused on reducing weight among employees of North Carolina Community Colleges. Two of the four Arms include incentive-based weight loss strategies first developed in the prior study. The study is being conducted over an 18 month time period.

Role: Co-Investigator



**Personal Information:**

1. Preferred email contact: [eric.finkelstein@duke-nus.edu.sg](mailto:eric.finkelstein@duke-nus.edu.sg)
2. Local work address:  
8 College Road, Level 4 LCPC  
Singapore 169857